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ABSTRACT 
Injecting drug use is a key risk factor, and injecting drug users (lDUs) are a core 
group for several blood-borne viruses (BBV) including hepatitis B (HBV) and 
hepatitis C (HCV). In 2003 the Unlinked Anonymous Prevalence Monitoring 
Programme reported that 62% of surveyed IDUs in England and Wales were found 
to ever having been imprisoned. Thus prison may provide a good opportunity to 
administer health interventions against BBVs to this hard to reach population. 
The aim of the thesis is to examine a number of alternative intervention measures 
that target IDUs in a prison setting against BBVs. Methods to inform as to the 
characteristics of the IOU population and its risk of infection from BBVs are also 
proposed. 
A method to determine the age specific rates at which individuals enter and leave the 
IOU population is presented. An age-specific dynamic model is developed that 
describes the flow of IDUs and non-IDUs through prison. This model is used to 
assess the potential impact of the HBV vaccination programme in England and 
Wales on the vaccination coverage of the IOU population showing that over 70% of 
IDUs may be captured with vaccination. Taking data that describes the prevalence of 
HBV and HCV in current IDUs in England and Wales, the injecting career length 
specific forces of infection for HBV and HCV in the IOU popUlation in England and 
Wales are estimated, these provide further evidence that new initiates to injecting 
may be at increased risk of infection compared to more experienced IDUs. 
Parameterised models are used to assess the impact that prison vaccination will have 
on HBV transmission within the IDU population with results showing that prison 
vaccination may result in a 75% reduction in acute infections in IDUs within 12 
years from the start of the programme. Finally the cost effectiveness of HCV case-
finding on prison reception is investigated showing the importance of encouraging 
current or former IDUs to accept ELISA testing on prison reception. 
The results provide further evidence that prison may be a good location in which to 
implement intervention measures against BBVs. The results also provide an 
increased understanding of the characteristics of IOU population in England and 
Wales and in particular its risk of infection from HBV and HCV. 
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CHAPTER 1 - INTRODUCTION AND BACKGROUND 
The thesis has two main aims. Firstly, to model the characteristics of the IOU 
population in England and Wales and in particular consider its risk of infection from 
HBV and HCV. Secondly to model the impact of a selection of intervention 
measures on reception into prison including vaccination and case-fmding that target 
IDUs and BBVs. 
Background information specifically associated with the IDU population, BBVs and 
the prison population are presented in this Chapter. In Chapter 2 the characteristics of 
the IDU population are examined, considering in particular the rates that IOUs start 
injecting illicit drugs and leave the IOU population. Also considered is the trend in 
the incidence of injecting drug use and how this may have evolved over time. The 
findings of this chapter are of importance as they contribute towards the 
parameterisation of a model of the flow of IDUs through prisons in England and 
Wales which is the subject of Chapter 3. Chapter 3 is of crucial importance as a 
model that describes the flow of IOUs through prisons can be applied to investigate 
many alternative prison based interventions that target IOUs in a prison setting. 
Using the model of the flow of IDUs through prisons, Chapter 4 considers the 
effectiveness of the HBV vaccination programme looking particularly at what 
proportion of the IOU population that may be captured with vaccination. In Chapter 
5 the forces of infection (FOI) (the per capita rate at which susceptibles acquire 
infection) are estimated for HBV and HCV including variation over time and 
injecting career length. Unlinked anonymous (UA) data on the prevalence of HBV 
and HCV within the IOU population in England and Wales is fitted to a model by 
maximum likelihood, with the individual heterogeneity of risk behaviour within the 
IOU population also being examined. In Chapter 6 the impact of HBV vaccination 
on prison reception on the transmission of HBV in the IDU population in England 
and Wales is considered. This chapter uses results from Chapter 4 that describe what 
proportion of the IOU population is captured by prison vaccination over time, and 
FOI estimates from Chapter S. The basis of this chapter is a dynamic mathematical 
model describing the natural history of HBV to estimate the impact of vaccination on 
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the prevalence and incidence of HBV within the IDU population in England and 
Wales. In Chapter 7 the cost effectiveness of a proposed HCV case-finding 
programme on reception into prisons in England and Wales is examined. Using the 
model of the flow of IDUs through prison described in Chapter 3 and the HCV FOI 
estimates in IDUs obtained in Chapter 5, this chapter considers the cost per new 
chronic HCV case detected on prison reception under a range of screening scenarios 
while extensive sensitivity analysis is undertaken. Finally, Chapter 8 is divided into 
two sections. Firstly, the main findings of the thesis are summarised, and then a 
discussion of the limitations of the studies and potential future work is undertaken. 
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1.1 Injecting Drug Users 
Due to their behaviour rous are at increased risk of incarceration when compared to 
non injectors (section 1.4). This may be due to criminal behaviour associated with 
trying to fund their illegal injecting or in some cases a criminal behaviour may itself 
have led to an injecting career. The injection of illicit drugs brings its own problems 
and if injectors share their injecting paraphernalia, as is often the case, then this leads 
to increased risk from BBYs (section 1.3.1). 
The rou population is a hard to reach population i.e. relatively little. is known both 
about the characteristics and dynamics of the rou population, and is a difficult 
population to target for intervention measures that may interrupt the transmission of 
BBVs. Since rous are more likely to go to prison than non-injecting drug users 
(non-rOUs), this setting may provide a good location in which to target rous for 
intervention measures (World Health Organisation, 2005; Weinbaum et al., 2005). 
A particular problem with studying IOUs is the selection of individuals into an 
analysis. While considering an IDU as being any individual that had used a syringe 
for taking drugs at least once in hislher life at the start of a survey (Broers et al., 
1998) may seem attractive for increasing the number of subjects in the analysis, this 
definition may include individuals who have long since left their drug using days 
behind them. Whereas including rous that have injected in the four weeks prior to 
being included in the survey may leave out those rous that inject less frequently. In 
this thesis it has been assumed that a current IOU is defined as a person that has 
injected in the previous 4 weeks. This was done for two reasons. First, many data 
sources used throughout this thesis collect data on IOUs that have injected in the 4 
weeks prior to having been surveyed. Second, IDUs that inject at least every four 
weeks are likely to be at greater risk from BBYs and other infections compared to 
injectors that inject less frequently (section 1.3.1). The success of intervention 
measures should therefore be judged on the impact they have on these high-risk 
IDUs. 
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1.1.1 The size and characteristics of the IOU population 
Various mathematical and statistical approaches have been made to gain information 
about the IOU population and its size (Frischer et 01., 2001; Godfrey et 01., 2002). 
Large surveys have also been undertaken (Frischer et 01.,2001; Johnson et 01.,2001; 
Johnson et 01., 1994) with the results extrapolated to draw conclusions about the 
wider drug using population (Johnson et 01., 2001). Many smaller surveys have also 
been undertaken, but frequently the size of these surveys limits the generalisability of 
the results between different populations and through time. 
It has been suggested that the IOU population in England and Wales has increased 
substantially in size since the 1980s. Using data on the number of deaths due to 
opiate overdose its has been estimated that the prevalence of opiate users / injecting 
drug users has increased from less than 20,000 in 1980 to between 100,000 and 
150,000 in 2000 in England and Wales (de Angelis et 01.,2004). However this work 
does assume that opiate overdose deaths have been recorded over the period of the 
analysis in a consistent manner. Alternative estimates of the prevalence of 
problematic drug use in the UK undertaken in 2001 have ranged from 161,000-
266,000 (Frischer et 01., 2001). The proportion of males that have ever injected in 
Britain has been estimated to be 2.0% in 2000, rising from 1.0% in 1990 (Johnson et 
01., 200 I) however this result must be approached with caution as the persons in the 
survey were selected from the small-user postcode address file for Britain, and as 
many current IOUs may be homeless a postcode is something that current IOUs are 
less likely to have compared to the general population. 
The incidence of new initiates to injecting that join the IOU population and how this 
varies over time is difficult to evaluate due to the delay that occurs from the time of 
injecting initiation until injectors report to services and can be surveyed. Using back-
calculation the incidence of opiate use / injecting drug use in England and Wales 
using data on the number of opiate overdose deaths by year has been estimated (de 
Angelis et 01., 2004). The authors suggest that the trend in the incidence of opiate use 
/ injecting drug use over time has shown a substantial increase in recent years. While 
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further evidence of the average age of first injection for an IOU suggests that this 
often occurs before the age of 20 (Goldberg et a/., 1998; Hutchinson et a/., 2000; 
Judd el aI., 1999; Muga et aI., 2000; Crofts & Aitken, 1997). 
A number of factors may lead to a cessation of injecting for an IDU. IOUs that are in 
contact with a drug network of other injectors have been shown to be significantly 
more likely to persist with their injecting behaviours. Whereas a decrease in 
addiction practices and unsafe sexual behaviours have been found to have a 
significant impact on injecting cessation (Bouhnik et a/., 2004). The treatment of 
IOUs and the kind of treatment that they receive can also have an impact on the rates 
that IOUs cease injecting. The rate that IOUs stop injecting drugs, the cessation rate, 
has been estimated in a number of studies. Law et a/., (2001) assumed a constant 
yearly cessation rate of 0.05 which would equate to an average injecting career 
length of 20 years, while Kaplan, (1989) estimated the cessation rate to be 
substantially higher at approximately 0.12 per year thereby giving a lower injecting 
career length of 8 years. Pollack, (2001) assumed that the true cessation rate lay 
somewhere between and adopted a value of 0.09 which gives an injecting career 
length of approximately II years, although in all these cases the variation of the 
cessation rate with age was not considered. It must be remembered however when 
considering the rates IOUs leave the IOU population that in many cases these rates 
are arbitrary and periods of relapse will often occur (Langendam et al., 2000). 
It has been shown that the mortality rate is higher in the IOU population compared to 
the general population (Ghodse et a/., 1998; Sorensen et a/., 2005) with estimates of 
the mortality rate among IOUs ranging from 0.54% (Frischer et a/., 1993) to 19/1000 
person years (Ghodse et a/., 1998). Within the IOU population it has been found that 
mortality is higher in older IOUs compared to the young (Sorensen et a/., 2005), 
which may be due to riskier injecting practices but may also be due to infection from 
BBVs such as HBV, HCV, or human immunodeficiency virus (HIV) (section 1.3.1). 
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1.2 Unlinked anonymous prevalence monitoring programme 
The most useful and 'representative' data from which inferences about transmission 
trends within an IOU population can be drawn, are probably those provided by large 
voluntary, UA cross-sectional surveys of injectors recruited concurrently from drug 
services and community sites (Hope et al., 2001). 
Since 1990, voluntary UA oral fluid samples have been collected from IOUs in 
contact with specialist drug agencies throughout England and Wales (Noone et ai., 
1993; Nicoll et al., 2000). These agencies provide services including needle 
exchange, methadone maintenance and outreach work. Behavioral information is 
collected through a brief anonymous questionnaire unlinked from client identifying 
information. This includes questions on previous HIV testing, characteristics of the 
IOU population, and the sharing of injecting equipment. Fluid samples can inform as 
to the prevalence of BBVs in the IOU population including HBV, HCV and HIV 
(section 1.3.1). These samples have been collected on an annual basis leading to the 
availability of 15 complete surveys (1990-2004), although they do not extend to 
Scotland or Northern Ireland where other methods of surveillance are used (Health 
Protection Agency et ai., 2005). As data from these surveys is used regularly 
throughout this thesis they are referred to as the UAPMP surveys from here on. 
While it is acknowledged that data such as this is representative of IOUs that are in 
contact with services (Hope et al., 2002), the IOUs recruited into the survey are self-
selected and may not be representative of the whole IOU population. Surveys of 
injectors that are in contact with services will inevitably lead to some bias, IOUs that 
have short careers will be under sampled whereas older injectors will be over 
represented and this can lead to a bias in the conclusions drawn from the data. 
Comparisons have been made between IOUs both in and out of drug treatment. IOUs 
that report to services are generally older (Cook et ai., 2001) and have a longer 
average injecting careers than those that do not (Godfrey et ai., 2002). Work has also 
been done to estimate the lag from the time of heroin use initiation until the time of 
first reporting (Hickman et al., 2001). It has been speculated that the average delay 
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from the time a person starts problematic drug use to receiving treatment is 5 years 
(Coid el al., 2000; Godfrey el al., 2002) or more. These caveats must all be 
remembered when drawing conclusions from UAPMP survey data. 
1.3 Injecting drug users and their risk from infection 
1.3.1 Blood-borne viruses 
A BBV is transmitted when blood from an infected person gets into the bloodstream 
of another (Health Protection Agency, 2006). It has been shown that IDUs are at 
increased risk from BBVs due to risky behaviour associated with their injecting 
behaviour (Hahne el al., 2004; Patrick el al., 200 I; Rhodes el al., 1996). Risk factors 
within the IDU population that have been identified as leading to increased 
prevalence and incidence of BBV infection include the sharing of needles and 
injecting paraphernalia, frequency of injection, repeated injecting with used needles, 
or the inadequate cleaning of injecting paraphernalia (Patrick el al., 2001). In the 
case of those BBVs that can also be transmitted via sexual contact, this can assist in 
the transmission of BBVs between IDUs and non-injecting populations. It is not 
unusual to find that IDUs with a specific ethnicity to be at greater risk from BBVs 
compared to the general IDU population. This was seen in IDUs with African-
American ethnicity in a study of IDUs recruited through street outreach in Baltimore, 
Maryland in 1988-1989 (Levine et al., 1995). This is likely to be due to increased 
sharing behaviour and perhaps increased prevalence within specific ethnic groups. 
While it is often not possible to prove conclusively that observed BBV infections 
over time are due to the sharing of injecting equipment, it is likely that most acquired 
their infection this way (Roy et al., 200 I). In many cases injecting drug use will be 
the only risk factor in those injectors that are found to be infected from BBVs. The 
attendance of 'shooting galleries', places where drug injection equipment is 
sequentially rented to users resulting in some users injecting with previously used 
equipment (Kaplan, (989) is also highly correlated with BBV incidence and 
prevalence (Patrick el al., 200 I). Providing further evidence of the risk that used 
injecting equipment poses to IDUs. 
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It is common amongst studies of the IOU population to find the prevalence of BBV s 
being associated with injecting career length, with those IOUs with longer injecting 
careers more likely to have evidence of past BBV infection compared to new initiates 
to injecting. This can also be said of older injectors compared to younger injectors 
although injecting career length and age are often found to be highly correlated 
(Rhodes el al., 1996). However the incidence of BBVs is often found to be higher 
amongst new initiates to injecting (van Beek et al., 1998). This is due to new initiates 
being more likely to share injecting paraphernalia in the early days of their injecting 
career before their injecting practices have been established (Rhodes el al., 1996). In 
the case of HeV in England and Wales (section 1.3.1.2) evidence has shown that 
HeV infection in IOUs is difficult to prevent and that infection is acquired rapidly 
after initiation into injecting (Hope et al., 2001). It has been suggested that younger 
IOUs could be at relatively higher risk of infection compared with uninfected older 
IOUs if being uninfected becomes a marker of well-established prevention practices 
with increasing duration of injection and age. Thus, increasingly lower risk cohorts 
of IOUs may be established with increasing age as those at higher risk are removed 
because of BBV seroconversions (van Beek et al., 1998). 
A major issue with BBVs is that many carriers may be unaware of their infection 
(Rhodes el al., 1996), particularly if there are no symptoms following infection as 
can be the case with HBV, HeV, and HIV. IOUs that are unaware of their infection 
can unknowingly contribute to transmission between the IOU population and non-
IOU populations if the infection is transmissible via sexual contact. It has been found 
in the UAPMP surveys (Health Protection Agency et al., 2005) that 49% of IOUs 
self reported that they were unaware of their Hey infection while an alternative 
study (Schlicting et al., 2003) found that in IOUs that tested positive for Hey only 
23% of them were aware of their positive status. This lack of awareness of their 
infection status imposes a considerable barrier to transmission prevention. 
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1.3.1.1 Hepatitis B 
HBV is transmitted by parenteral exposure to infected blood or body fluids, with 
transmission most frequently occurring either through sexual intercourse, as a result 
of blood-to-blood contact typically through the sharing of needles and other 
equipment by IOUs, or through perinatal transmission from mother to child. 
Transmission can also occur through transfusion-associated infection, although this 
is now rare in the UK as all blood donations are screened (Salisbury & Begg, 1996). 
It is estimated that 0.3% of the UK population is chronically infected with HBV 
which is equivalent to approximately 180,000 people. In 2003 there were 
approximately 1,300 cases of acute HBV in England and Wales reported to the 
Health Protection Agency (HPA) with the most common reported risk factor being 
injecting drug use (Health Protection Agency, 2006). The incidence of infection in 
the general population of England and Wales has been estimated at 7.4 per 100,000 
although this does not represent the huge heterogeneity of risk within the population 
with high risk groups being determined mainly by country of birth, ethnicity, and 
adult risk behaviours such as injecting drug use (Hahne et al., 2004). 
The average incubation period ranges from 40-160 days. Current infection can be 
detected by the presence of HBV surface antigen (HBsAg) in the serum. The risk of 
developing chronic HBV infection is heavily age dependent and is defined as 
persistence of HBsAg in the serum for six months or longer (occurring in 2-10% of 
those infected as adults rising to approximately 90% in those infected perinatally). 
Among carriers of the virus, those in whom HBV e-antigen (HBeAg) is detected are 
most infectious. Those with antibody to HBeAg (anti-HBe) are generally of low 
infectivity. This is summarized in Table 1.1. 
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Table 1.1 - Hepatitis B: diagnosis 
Status Detection of 
Anti- Anti-HBc HBsAg Anti- HBeAg Anti-
HBc IgM HBs HBe 
Acute + + + +/- +/-
(infectious ) 
Carrier + + + 
(low infectivity) 
Carrier + + + 
(high infectivity) 
Recovery + + +/-
(immune) 
Immunity + 
(after vaccination) 
Safe and effective vaccines to prevent HBY infection have been available since 
1992, with the World Health Organisation (WHO) having recommended that all 
countries adopt universal HBY vaccination by 1997. This has not been adopted in 
England and Wales where instead a policy of selectively immunizing key at risk 
groups from HBY infection has been implemented. This approach to vaccination in 
England and Wales has been justified by the low incidence of HBY infection within 
the general population (Hahne et al., 2004). A course of HBY vaccinations consists 
of three doses of vaccine with a booster dose typically administered 12 months after 
the lit dose. The timing of the first three doses is variable and is usually implemented 
at zero, one, and six months. For high risk groups faster schedules are implemented 
with an accelerated schedule being 0, I, and 2 months and a super accelerated 
schedule being 0, 7 and 21 days although the super-accelerated schedule is not 
licensed for those under 18 years of age. The improved compliance of these faster 
schedules is likely to offset any reduced immunogenicity when compared to the 0, 1, 
and 6 months schedule (Christensen el al., 2004; Bock et al., 1995). 
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The 10 pulali n in ngland and Wale i the largest at-risk group from HBV 
infection. ala r, m th' APMP urvey in 2003 ugge ted that amongst those cases 
f a ute HBV \\ ilh an identified ri k factor, 34% were attributable to injecting drug 
u e. The prop rti n flO in ngland and Wales ever infected by HBV (anti-HBc 
p iti e in 2004 w approximately 22% (Health Protection Agency el a/., 2005). 
The trend er time ha hown a decrea e overall since 1992 although since 1999 a 
light incr e h been n ted. Amongst new initiates to injecting (defrned as lDUs 
that tarted inje ting in the three years prior to participating in the survey) similar 
trend are cen (Figure 1.1). HBV vaccine uptake (receiving one or more vaccine 
do e )in the 10 population has hown a teady increase since 1998 up to over 50% 
in 2004 (Health Pr tecti n Agency et 0/.,2004) although the location of vaccination 
n t rep rted. H wever the overall HBV vaccination coverage in the lDU 
p pulati n i likely t be 1 wer as many IDUs are not in contact with drug agencies. 
Figure I. I - Trend in the HBV vaccine uptake and past HBV infection amongst 
10 in England and Wale (llcalth Protection Agency et aI., 2005). 
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1.3.1.2 Hepatitis C 
The WHO estimates that some 170 million people are chronically infected with HCV 
(World Health Organisation, 1999). On a global scale, the United Kingdom is 
considered to be a relatively low prevalence country. In 2002, the HPA estimated 
that the prevalence of HCV-specific antibodies (anti-HCV) in the general population 
is approximately 0.5%. While it has been estimated that there are approximately 
200,000 individuals chronically infected with HCV in England (Health Protection 
Agency Centre for Infections, 2005). 
The transmission of HCV predominantly occurs through blood-borne transmission 
such as injecting drug use and blood-transfusion although transmission can occur via 
routes such as mother to baby and sexual exposure although these are less efficient 
(Balogun et 01., 2002). As with HBV the transmission of HCV due to blood-
transfusion in England and Wales is rare due to the screening of all blood-donations. 
There are six major HCV genotypes (I to 6) with a variety of subtypes existing 
within each genotype. In the UK genotype I is the most common found in 40-50% of 
cases, genotypes 2 and 3 contribute another 40-50% while genotypes 4, 5, and 6 
constitute the remainder of about 5%. The genotype of the virus has been found to be 
the most important determinant of efficacy of treatment. Combination therapy with 
pegylated interferon alfa and ribavirin is recommended for the treatment of people 
aged 18 years and over with mild to severe chronic HCV. Overall, this treatment is 
successful in clearing the infection (leaving no detectable virus in the blood 6 months 
after treatment has ceased) in up to 55% of patients. The effectiveness of treatment 
varies according to the infecting genotype, from 45% in those infected with genotype 
I, up to 80% in those infected with genotypes 2 and 3. However, not everybody is 
suitable for treatment or can tolerate it. Factors such as age, sex, duration of 
infection. the strain of the virus, and the degree of existing liver damage determine 
the effectiveness of treatment (National Institute for Clinical Excellence Guidelines, 
2004). 
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After HCV infection hepatitis C ribonucleic acid (HCV-RNA) can be detected in 1-3 
weeks with the acute phase lasting 2-3 months. Of those infected 65-85% will 
develop chronic HCV and approximately 6.5% will develop cirrhosis within 20 years 
(Freeman el 01.. 200 I). Within 30 years 3-5% of those infected will develop liver 
failure associated with severe cirrhosis or may develop hepatocellular carcinoma 
(Hee). In many cases the infection will not be apparent for many years this is partly 
because the liver has the capacity to 'cope' with the infection. Symptoms do not often 
develop until the liver has been quite extensively damaged. Alcohol consumption, 
acquiring the infection at an older age, and being male, have all been shown to be 
associated with more progressive disease (Stein et 01.,2002). The natural progress of 
HeV is summarised in Figure 1.2. 
Figure 1.2 - Example of the natural progression of 100 people infected with Hey. 
100 people infected with HCV 
15-35 clear virus spontaneously within 
2-6 months 
(Stein et 01 .. 2002) 
65-85 go on to develop chronic 
HCV with 10 years. many 
asymptomatic 
Within 20 years, approx 6.5 wi\1 
develop cirrhosis (Freeman et 01., 
2001) 
Within 30 years, 3-5 will develop 
liver failure associated with severe 
cirrhosis or may develop HCC 
In England and Wales it has been suggested that Hey is currently the most 
significant infectious disease affecting those who inject drugs (Health Protection 
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Agency et al., 2005). Amongst the reported laboratory diagnoses ofHCV infection in 
England in 2004, 95% of those with exposure data were attributable to injecting drug 
use. UAPMP surveys have reported an increase in current IDUs (injected in the 
previous 4 weeks) that have antibodies to HCV (anti-HCY) in recent years up to 45% 
in 2004, while a similar increase has been seen in new initiates to injecting (started 
injecting within the three years prior to participating in the survey). This is shown in 
Figure 1.3: 
Figure 1.3 - The trend over time of past HCV infection in current rDUs and new 
initiates to injecting in England and Wales (Health Protection Agency et aI., 2005). 
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As many HCV infections are asymptomatic, it is of benefit if those individuals that 
have undiagnosed infection can be identified. Testing for anti-HCV antibody is now 
widely available sensitive (>95%) and relatively inexpensive, and case identification 
may be beneficial to patients, their families and to the general population. For 
patients that are found to be eligible treatment maybe offered (Gordon, 1999). 
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1.3.1.3 HIV 
In 2004 the number of prevalent HlV infections among adults aged 15-59 in the UK 
was estimated to be 58,300. However, unlike HBV and HCY, injecting drug use is 
not the biggest risk factor for HIV infection with only an estimated 2,000 cases being 
due to injecting drug use, the remainder being predominantly due to either sex 
between men or heterosexual sex. Overall HIY infection among IDUs in the UK 
remains relatively rare with around one in every 65 injectors infected (Health 
Protection Agency et al., 2005). UAPMP survey data show that the prevalence of 
HlV infection is very low compared to HBY and HCY even when individuals that 
have ever been injected are included in the data. Like HBV, H1V prevalence has 
shown a drop in early 1990s although an increase in recent years can be seen (Figure 
1.4). 
Figure 1.4 - The trend over time of past HIV infection in current and former IDUs in 
England and Wales (Health Protection Agency et al., 2005). 
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As the prevalence of H1V is low in the IOU population of England and Wales 
compared to HBV and Hey it has not been consid,ered in this thesi s. However it is 
acknowledged that a measure of the success of intervention mea ures that target 
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IDUs would be to consider their impact on the incidence and prevalence of HIV 
within the IOU population over time. 
1.3.1.4 The incidence of Blood-borne viruses 
As FOI of HBV and HCV will be considered in a later chapter (Chapter 5), a brief 
review of studies that consider the incidence of HBV, HCV, and HIV in England and 
Wales is included here. 
The incidence of infection is often used to gain some idea as to the FOI of a 
particular infectious disease where the FOI is defined as the per capita rate at which 
susceptible individuals acquire infection. Calculation of incidence is sometimes 
undertaken through the use of cohort studies in which IDUs are classified on the 
basis of the presence or absence of exposure to a particular factor and then followed 
for a specified period of time to determine the development of disease in each 
exposure group (Hennekens & Buring, 1987). This was the case in Judd et al.,(2005) 
where the incidences of HCV and HIV among new IDUs in London were found to be 
41.8 cases and 3.4 cases per 100 person years, respectively. 
Previous studies have considered the reports of acute HBV in England and Wales as 
reported to the HP A, Centre for Infections (Health Protection Agency, 2006). 
Considering reports from 1985-1996 a previous study (Balogun et al., 1999) 
calculated the average estimated annual rate of laboratory reported HBV infection in 
adults within each region of England and Wales varied from 1.27 to 2.81 per 100,000 
of the population, with the majority of reports being from symptomatic individuals. 
However this study considered the rate of reported acute HBV infection rather than a 
true HBV incidence that would include both asymptomatic and symptomatic 
individuals. Hahne et al., (2004) also considered data reported to the HPA, Centre for 
Infections of acute HBV infections in England and Wales from, lSI Janunary 1995 _ 
31st December 2000 (Health Protection Agency, 2006). However this study 
considered the impact of under reporting in the population where some persons 
infected by HBV for whatever reason would not necessarily report their infection. 
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Also considered in the incidence calculations was the proportion of infections that 
are asymptomatic which can also impact on incidence calculations. Taking these 
factors into account the authors found a higher HBV incidence estimate for England 
and Wales being 7.4 per 100,000, with injecting drug use being the most frequently 
reported route of transmission. 
An alternative proxy for incidence in the whole IOU population is to consider the 
prevalence of Bavs in new initiates to injecting as was seen in sections 1.3.1.1 and 
1.3.1.2. Assuming that these IOUs have only been exposed to BaVs during their 
injecting careers and were not at risk before the start of their injecting career then 
these individuals can provide a useful insight into the trend of recent infection over 
time within the IOU population. However it must be remembered when using this 
technique to make conclusions about the FOI in the overall IOU population that it 
has to be assumed that the at-risk behaviour of new initiates is the same for the rest 
of the IOU population. 
In an attempt to estimate the incidence of aBVs in the IOU population, studies have 
attempted to follow IOUs over time through the use of prospective cohort studies. 
However this approach may be biased as those IOUs that are not infected may not be 
highly street entrenched (i.e., are not involved in a chronic and intractable way with 
the street scene) and are therefore less likely to return for follow-up visits (Patrick et 
al., 200 I). In addition to this the number of person years injecting, often used to 
calculate the incidence of BaVs in the IOU population will often be over estimated 
since information may not be available on periods of injecting abstinence due to, for 
example, imprisonment, hospitalization or drug treatment (Roy et al., 2001). 
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1.3.2 Other infections 
The three main BBVs that occur in the IDU population are HBV, HeV, and HIV 
have been discussed. However these are not the only infections that IDUs are 
vulnerable to, and so for completeness a brief review of a selection of other 
infections is included here. 
Hepatitis A (HA V) infection may occur in the IOU population through person-to-
person contact with other infected individuals through poor-hygiene, via blood 
through sharing contaminated injecting equipment, through sexual activities that 
increase risk of oro-faecal contamination, or from drugs that have been contaminated 
with faeces during smuggling. An effective vaccination is available. In 2004 the 
number of laboratory reports of HA V in England and Wales was 627 compared with 
984 in 2003 and 1,352 in 2002. Only a small proportion of these reports in 2004 
contained information on risk factors with 73% reporting travel abroad as the main 
risk factor rather than injecting drug use (Health Protection Agency et aI., 2005). In 
the early part of the decade there had been a number of outbreaks of HA V that were 
associated with IDU and homelessness (Perrett et al., 2003). However 2004 data 
suggest that the outbreaks of HA V in IDUs have been waning. 
IDUs are also vulnerable to a range of bacterial infections as a result of non-sterile 
injecting or injecting contaminated drugs, a brief summary of which is given below 
(Health Protection Agency et al., 2005): 
Staphylococcus aureus is a common pathogen among IDUs, causing infections that 
vary in severity from minor skin and soft tissue infections through to life-threatening 
invasive disease such as bacteraemia and endocarditis. 
Group A Streptococci can cause skin sepsis, bacteraemia and necrotic infections 
among IDUs through infection of injecting sites. 
Clostridial infections; clostridia are a group of spore forming bacteria that are widely 
found in the environment. The spores produced by these bacteria may be found in 
drugs, such as heroin, through environmental contamination. They may cause wound 
infections among IDUs, particularly if they enter an intramuscular or subcutaneous 
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injection site, and can then produce toxins causing illness such as tetanus or 'gas 
gangrene' with a potentially fatal outcome. 
Botulism is an illness caused by botulinum toxin, a poison produced by the 
bacterium clostridium botulinum. Symptoms of botulism include blurred vision and 
difficulty in swallowing and speaking and may cause paralysis and death. However 
there is an effective antitoxin. When it infects wounds, including injecting sites, it 
causes wound botulism. Up until 2000 there had been no case of wound botulism 
reported among IDUs in the UK however by 2004 89 cases had been reported 
suggesting that this may be a growing problem. 
Neither HA V nor bacterial infections are given further consideration during this 
thesis although as with HIV, surveillance of these infections over time may provide a 
good measure of the success of future intervention measures that target the IOU 
population. 
1.4 Injecting drug users and crime 
Due to criminal behaviour associated with drug use, IDUs are at increased risk of 
becoming incarcerated compared to the non-drug using population. For example 
UAPMP surveys reported that 62% of surveyed IDUs in 2003 were found to have 
been in prison (Health Protection Agency et aJ., 2005). This is also verified in 
surveys undertaken in prisons that show the high proportion of prisoners that are 
found to have injected drugs (Gore et aJ., 1997; Weild et aI., 2000). 
It is accepted that illicit drug use and crime are associated and develop together, 
amongst illegal drug-using criminals the need for drugs may cause crime on a day-to-
day basis or both may tend to be determined by some other set of factors. A typical 
theory suggests that addiction causes crime. During periods of heavy drug use or 
'addiction', drug users commit more crimes to finance their expensive habits. This is 
in comparison to periods of treatment or abstention when users commit fewer crimes. 
Although alternatively it has been suggested drug use and crime co-occurs because 
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the people who become criminals are also likely to become drug abusers 
(Hammersley et al., 1989). 
It has been found that the offending characteristics of IDUs are significantly different 
when compared to non-IDUs. Due to their behaviour associated with injecting drug 
use, IDUs are more likely to go to prison than non-IDUs, and there is also evidence 
of IDUs being given shorter prison sentences than non-IDUs (Bird el al., 1995; 
Weild et al., 2000). This suggests that the turnover ofIDUs through prison is more 
rapid than non-IDUs as they pass through prison more rapidly and frequently. 
An important risk factor for BBV prevalence within the IDU population is a history 
of previous imprisonment (Patrick et al., 2001; van Beek et al., 1998). During any 
period of incarceration it has been shown that some IDUs will continue their 
injecting behaviour (Gore el al., 1995b; Gore & Bird, 1998; Covell et al., 1993; 
Allwright el al.. 2000), and while the prevalence of injection within prisons are 
probably much less frequent than outside (Hutchinson el al., 2000), those who 
continue to inject are highly likely to share needles when they are imprisoned, thus 
facilitating the spread of BBVs (Macalino et al., 2004; Covell et al., 1993). Evidence 
of a high risk needle sharing environment inside prisons has been seen in many 
previous studies (Gore et al., 1995b; Gore & Bird, 1998; Boys et al., 2002; Covell et 
al., 1993), and there is evidence of the rapid spread or outbreaks ofBBVs in prisons, 
this inevitably being due to a high level of circulating virus among inmates who 
practice needle sharing with ineffective cleaning and a limited number of needles 
(Taylor et a/., 1995; Hutchinson et al., 1998). 
Prison also poses an added risk to non-IDUs, it is common to find evidence of 
injectors that initiated their injecting career during a period of incarceration (Gore el 
al., 1997; Gore el al., 1995b; Boys el al., 2002; Gore el al., 1995a). It may be 
inferred from this that there are IDVs that wouldn't otherwise have initiated their 
injecting career except as a result of a spell in prison. However it has also been 
suggested that as some injectors discontinue their injecting while in prison, 
incarceration may have a protective effect on their health. Although the restricted 
access to drugs and injecting equipment does not prevent many from injecting in 
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prison for the first time and placing all those who do inject in prison at vastly 
increased risk of contacting infections (Taylor et al., 1995). 
1.5 Interventions targeting the IDU population 
It has been shown that IDUs are at increased risk from BBVs and other infections 
and it is therefore of public health importance if interventions that target this high 
risk group can be implemented. A number of interventions have been proposed that 
target individuals within the IDU population; these include vaccination, education, 
treatment, and needle exchange programmes (Francois et al., 2002). 
Where possible individuals at high risk from BBVs should be vaccinated (Salisbury 
& Begg, 1996). As has already been shown the prevalence of BBVs in the IDU 
population is much higher than in the general population (section 1.3.1). In the case 
of HBV, despite WHO recommendations the UK has not implemented a universal 
vaccination strategy and so in this case individuals at greatest risk particularly IDUs 
should be targeted for vaccination (Hahne et al., 2004; McGregor et 01.,2003). Data 
from the UAPMP surveys in 2003 (Health Protection Agency et al., 2005) showed 
that amongst current IDUs that report receiving HBV vaccination a reduced HBV 
prevalence can be seen (19% infected in the unvaccinated and 14% infected in the 
vaccinated). While this suggests that some IDUs are being infected prior to receiving 
vaccination, this does provide evidence that vaccination can impact on HBV 
transmission within the IOU population. From a previous study using semi-structured 
interviews with needle exchange staff (McGregor et al., 2003) it was found that the 
main barriers to vaccine uptake amongst IDUs include difficulties in contact tracing 
household contacts, IDUs chaotic lifestyles, and, the failure of services such as drug 
treatment, family doctors, and prison service to start or complete courses. Whereas 
enablers of vaccine uptake include administering vaccine in a variety of venues and 
settings, monitoring of vaccine courses, reminders in records to prompt next doses, 
and accelerated vaccine courses. Factors associated with vaccination may be 
applicable in settings where there are concerted campaigns to improve vaccine 
uptake in IDUs. 
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A needle exchange programme is defined as an organised service for the exchange of 
sterile needles and syringes used for injections as a potential means of reducing the 
transmission of infectious diseases (www.biology-online, 2006). Evidence of the 
impact that needle exchanges can have on the transmission ofBBVs was shown from 
IOUs in New York City, in which the incidence of HIV seroconversions was 
significantly lower among IOUs who were regular users of a syringe / needle 
exchanges than among non-users. Further analysis has shown that the mean annual 
HIV seroprevalence rate for 29 cities with exchange programs had fallen by 5.8%, 
whereas that for 52 cities without such programmes had increased by 5.9% (Mansson 
et aI., 2000). This finding has been echoed in Glasgow where sizeable reductions in 
anti-HCV prevalence among, newly initiated, injectors from Glasgow and Lothian 
from the early to mid 1990s support the hypothesis that harm reduction interventions, 
particularly needle exchanges may have played an important role in reducing the 
spread ofHCV (Hutchinson et al., 2002). 
Knowledge of infection may impact on injecting behaviour and may lead to a 
reduction in the behaviour that leads to further infection within the IOU popUlation. 
However this must be tempered against the possibility that identifying a positive 
individual with a BBV may impact on their quality of life (Forman et al., 2000; 
Rodger et al., 1999; Tompkins et al., 2005). Lifestyle modifications can be made to 
decrease the risk of further BBV transmission with education increasing overall 
public awareness of the disease and potentially improving prevention efforts 
(Gordon, 1999). In the case of patients that are HCV positive they can be counselled 
to avoid alcohol consumption and as these individuals typically share the same risk 
factors that lead to HA V and HBV infection, vaccination against these viruses may 
also be offered if appropriate (Salisbury & Begg, 1996). 
Measuring the impact of interventions that target the IOU population is hampered by 
the fact that IOUs, owing to the illegal nature of their drug use, are a 'hidden' 
population. In addition, the introduction of concurrent interventions makes it difficult 
to attribute positive changes within the population to anyone of them. Nevertheless, 
as has been shown studies evaluating BBV prevalence and incidence rates, as well as 
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risk-taking behaviour among IOUs, have been published. Most of them show a 
considerable reduction in risk behaviour after the introduction of prevention 
activities (such as methadone maintenance programmes and needles exchanges) as 
well as a decline in the incidence of BBY infection and a stabilization or reduction in 
BBY prevalence (Broers et al., 1998). 
1.5.1 Targeting the injecting drug user population in a prison setting 
Oue to the illegality of injecting drug use and the close association between crime 
and drug manufacture, trafficking, supply, and use, those involved with injecting 
illicit drugs frequently pass through prisons (Skipper et al., 2003). This suggests that 
prison may be a good location in which to administer intervention measures targeting 
the IOU population. These intervention measures may include but are not limited to 
vaccination, rehabilitation and treatment, and the exposure to screening programmes 
(McGregor el aI., 2003). Suggested recommendations that should form the basis for 
HBY prevention programmes within European prisons have included HBY 
vaccination for all inmates upon entry into prisons, the introduction of accelerated 
immunisation schedules with the aim of achieving higher vaccine uptake levels 
among prisoners, and being permitted access to drug rehabilitation programmes for 
inmates that inject drugs (Francois el al., 2002). 
In April 1999, the Scottish Prison Service implemented an initiative to offer HBY 
vaccination to all inmates. With the high rate of imprisonment (for short stays) 
among IOUs (section 1.4), it was concluded that any appreciable impact of this 
initiative should be evident in community-based IOU populations soon after its 
implementation. Four voluntary, anonymous cross-sectional surveys of Glasgow's 
IDUs were conducted in 1993, 1994, 1999 and 2001-2002. From these surveys it was 
observed that vaccine uptake increased significantly in all groups according to 
recruitment setting, gender, age, time since onset of injecting, having received 
treatment and imprisonment. But a much smaller rise in uptake was also observed 
among IOUs who had not been imprisoned since the onset of injecting. Observations 
in Glasgow showed that the uptake of at least one dose of HBV vaccine had more 
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than tripled (16% to 52%) among recent initiates to injecting drug use (i.e. those who 
had commenced injecting within the previous five years) in the two years since the 
introduction of universal HBV vaccination in prisons and young offender 
institutions. Since the introduction of vaccination in Scotland, no outbreaks of HBV 
among IDUs that had been witnessed prior to the introduction of vaccination have 
occurred (Hutchinson et al., 2004). Further evidence of the impact of HBV 
vaccination in prison settings has been seen in the low prevalence of HBV found in 
prisoners in the Republic of Ireland (Allwright et al., 2000) where there is a policy to 
offer vaccination to all prisoners with sentences of eight months or longer. 
As has already been discussed it is of advantage to identify those individuals that 
may have undiagnosed BBV infection (section 1.5), and that this may be undertaken 
in a prison setting. A previous study (Home et al., 2004) has suggested that offering 
case-finding to all prisoners is less effective than screening in specialist treatment 
services although this conclusion is largely based on the small numbers of eligible 
individuals that accepted Hev treatment. However the authors do argue that it may 
be possible to improve the effectiveness of HeV screening in the prison setting, with 
recommendations that include developing a standard HeV screening pathway across 
all prisons and focusing efforts to improve screening uptake among IDUs. An 
alternative study (Allen et al., 2003) argues that with its closely monitored 
environment, prison can provide a unique opportunity to identify and treat patients 
with HeV in a secure setting that may be a safer environment than other community 
settings. Additionally as most patients treated for HeV have drug dependence 
histories, prisons can provide an opportunity to treat during a period of forced 
sobriety. 
In many countries community drug treatment services have evolved considerably 
over the past decade with needle exchange and methadone maintenance becoming 
widely available (Allwright et al., 2000). However health care in prison settings 
often have not kept pace with these changes meaning that many IDUs that receive 
treatment for their drug abuse outside prison do not continue their treatment inside 
prison (Gore & Bird, 1998). An example of this is the case of the Irish prison 
healthcare system which has not kept pace with the treatment services available in 
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the community (Allwright et al., 2000). Evidence suggests that there is a need to 
consider increased provision of measures to reduce harm in Irish prisons and 
elsewhere. 
With evidence of their increased risk of infection (section 1.3.1) new initiates to 
injecting are ideal candidates to be targeted in an attempt to reduce the transmission 
of infection within IOU populations. The IOU population is a hard to reach 
population for intervention measures with new initiates in particular being hard to 
access, as is evidenced in the reduced number of new initiates to injecting that appear 
in the UAPMP surveys in England and Wales (Health Protection Agency et al., 
2005). However new initiates to injecting can still be imprisoned and prison may 
therefore provide a good location in which to capture this otherwise hard to reach 
population with drug related interventions. 
J. 5. J. J Hepatitis B vaccination programme in England and Wales 
The following description of the HBV vaccination programme in England and Wales 
has made use ofa previous study (Gilbert et al., 2004). 
A vaccination programme offering HBV vaccine at reception into prison began in 
England and Wales in June 2001. During 2002 it was estimated that approximately 
5% of all prisoners on reception into prisons in England and Wales were offered at 
least 1 dose of HBV vaccine, rising to approximately 15% in 2005. 
Prisoners are eligible for vaccination on each reception into pnsons that are 
participating in the vaccination programme. The current prison policy in England and 
Wales for adults is to use the super-accelerated programme with injections at 0, 7, 
and 21 days and a booster at the 12-month stage. This programme is not licensed for 
juveniles « 18 years), and so in their case an accelerated programme is administered 
at 0, 1, and 2 months with a booster again at the 12-month stage. A person who stays 
in prison for less than the time it takes to administer 3 doses will not complete the 
vaccination programme. 
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Ensuring that prisoners complete the full course of injections before they leave 
prison is an on-going problem particularly when prisoners may be imprisoned for 
less than 21 days. A further barrier to vaccination uptake within prisons is that 
prisoners are frequently moved between establishments often at short notice with 
vaccination being discontinued if the new prison is not participating in the 
programme. However over time, persistent offenders will begin returning to prison 
having already received vaccination in prison. As the recidivism rate is particularly 
high among IOUs this would indicate that this population group may be vaccinated 
effectively (receive a complete dose of vaccinations) over a series of custodial 
sentences rather than just one sentence. As more persons return to prison that have 
been previously vaccinated, less doses of vaccine will be required to maintain 
vaccination coverage. 
It has been found in prisons that are less efficient at delivering vaccination that 
valuable time is often lost between the prisoner being informed about the vaccination 
programme on reception and the first dose of vaccine being given. The logistical 
problems of locating prisoners and subsequently moving them to relevant treatment 
rooms are often blamed. However, several prisons have overcome this by introducing 
wing-based clinics situated closer to the prisoners. Problems are also associated with 
vaccinating prisoners who were reluctant to miss activities such as work, for which 
they are paid, and legal and domestic visits. Although funding is available for 
additional staff, prison healthcare centres frequently suffer understaffing issues 
because of recruitment and staff retention problems. 
1.6 Modelling the IDU population 
1.6.1 Injecting and sharing 
It has been shown that within the IOU population transmission of BBYs are most 
likely to occur when injectors share their needles and injecting paraphernalia with 
other injectors (section 1.3). Therefore models of the IOU population that describe 
the transmission of infections with emphasis on injecting and sharing practices are of 
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particular interest. The literature under review was identified through manual and 
computerised searches of the Pubmed and ScienceDirect databases using the subject 
headings of "modelling" and either "injecting" or "IOU". Additional papers were 
obtained by considering references in the papers as they were identified. Papers 
published from 1989-2006 were identified. 
In the past numerous intervention programmes have been carried out within various 
IOU populations around the world; these have included outreach education 
programmes, testing, counselling, bleach distribution, and access to clean needles 
and needle exchange programmes (section 1.5). However the impact of these and 
other prevention strategies can be difficult to measure due to the challenges of 
follow-up and confounding. Mathematical modelling can be used as an alternative 
means to overcome some of these problems. 
Murray et aJ., (2003) propose a simple deterministic model that describes the 
injecting behaviour of IOUs. Using this model it is possible to evaluate the effect on 
the prevalence and incidence of HeV and HIV within the IOU population of those 
invention measures that target a change in the injecting behaviour of IOUs. Typical 
intervention measures that can be examined include reduction in the frequency of 
injections, the cleaning of needles or a reduction of IDUs taking part in each 
injection event. However this model has a number of shortcomings, it relies heavily 
on the estimated size of the IOU across the years of interest as an input into the 
model, and is extremely sensitive to model parameters about which very little is 
known such as frequency of injection and number of IDUs present at each sharing 
event. 
Kretzschmar & Wiessing, (1998) describe a stochastic simulation model that models 
the spread of HIV in social networks of IDUs. The model distinguishes between 
stable 'buddy' relationships in which injecting equipment is shared on a regular basis 
and incidental risk contacts with strangers. The authors consider the effect of a 
reduction in sharing frequency or the effect of administering an Acquired Immune 
Deficiency Syndrome (AIDS) test to infected individuals on the incidence and 
prevalence of HIV over time the results from which are discussed below. 
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Peterson et al., (1990) use a stochastic micropopulation model implementing Monte 
Carlo techniques that describes a community of IOUs to demonstrate the effects of 
social networks on HIV transmission and the importance of prevalence levels in 
assessing the effectiveness of interventions in the IOU population. This complex 
model consists of three interacting models, a model of HIV disease progression 
within an infected individual, a model describing the heterogeneity of injecting drug 
use within the IOU community, and a model of the social networks describing the 
pattern of equipment sharing by IDUs. However a problem with this approach is the 
amount of data required to parameterise a complex model such as this, indeed 
authors themselves consider a 'generic' IOU population in which typical parameter 
values that are reported across the literature from many studies are applied rather 
than values estimated from one specific IOU population. 
A landmark paper by Kaplan, (1989) referred to from here on as 'Needles that kill' 
was one of the first papers to model the transmission of HIV via shared drug 
injecting equipment. This model describes the interaction between infected needles 
and infected IDUs. The author initially describes a homogenous model of an IOU 
population of constant size in which IOUs visit shooting galleries. The model 
considers how the probability of exposure to HIV and the prevalence of 
intravenously transmitted HIV within the IOU population may vary over time. The 
author then takes this model forward and introduces heterogeneity in the form of 
varying the rate that IOUs visit shooting galleries across the IOU popUlation. The 
model is extended to incorporate the cleansing or bleaching of injecting equipment 
showing the impact that this may have on HIV prevalence. The authors also propose 
a method of reformulating the model to account for the inactivation of HIV 
infectiousness on infected needles over time. An application of the 'Needles that kill' 
model was demonstrated by Kaplan & O'Keefe, (1993) to evaluate the impact of the 
New Haven needle exchange on the HIV infection rate. A syringe tracking and 
testing system that provided data for the 'Needles that kill' model was developed. 
Applying this data the model estimated that the needle exchange reduced the HIV 
infection rates among IOUs using the exchange by 33%. This result provides strong 
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evidence of the validity of a needle exchange as an intervention measure to target the 
IDU population and reduce the transmission ofBBVs. 
In many cases the modelling in this field has concentrated on the examination of the 
important parameters that make the greatest contribution towards the transmission of 
BBVs. This is often done out of necessity as the data describing a specific IDU 
population required to parameterise a model is often difficult to obtain. In the case of 
BBVs and the IDU population, one of the modelling objectives is always to help 
understand the basic dynamical epidemiological processes underlying the spread of 
BBVs amongst sharing IDUs (Greenhalgh & Hay, 1997). Using a simple model 
Mather & Crofts, (1999) show that the rate that HCV spreads through a population of 
IDUs is extremely sensitive to the interaction rate between IDUs and to the 
probability of infection through a single contact with an infective. Kretzschmar & 
Wiessing, (1998) show the importance of IDUs sharing injecting equipment with 
strangers on the prevalence of HIV while Atkinson, (1996) shows the importance of 
clean needles and frequency of injecting in the prevention of the transmission of 
HIV. These models are often used to inform as to the parameters that have the largest 
impact on BBV transmission (Mather & Crofts, 1999; Kretzschmar & Wiessing, 
1998; Atkinson, 1996; Peterson et af., 1990). 
There are some questions that often cannot be answered through the collection of 
data alone and in these circumstances modelling can playa useful role. For example 
Kaplan & Heimer, (1992) used the model described in 'Needles that Kill' in 
conjunction with data collected from the New Haven, Connecticut legal needle 
exchange programme to calculate the probability of HIV infection per injection with 
a contaminated syringe, estimating this to be approximately 0.067. Whereas 
Kretzschmar & Wiessing, (1998) were able to show through modelling that in 
populations where IDUs are part of a relatively stable social network, sustain steady 
partnerships and friendships, and confine their sharing of equipment to those persons 
they know well, HIV is given less of an opportunity to reach higher levels of 
prevalence. Modelling studies are a useful way of estimating the past and future 
trends of disease prevalence and incidence. An example of this can be seen with 
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Murray et al., (2003) who describes the past and future trends of the incidence and 
prevalence of HCV and HIV within the IOU population of Australia. 
A major problem with modelling the IOU population is that the data required to 
capture the true characteristics of the whole population is often difficult to obtain 
(Blower & Medley, 1992). The issues of data must be considered during model 
design, an overcomplicated model that considers too many subpopulations will result 
in a model that is impossible to parameterise. While models that consider the flows 
between subgroups of IOUs depending on their level of risk behaviour (Esposito & 
Rossi, 2004; Peterson et al., 1990) and their contact with services (Esposito & Rossi, 
2004) may seem attractive, to actually parameterise models such as this is often 
impossible. To avoid problems such as these, a generic IOU population describing a 
'typical' IOU population can be used with which to parameterise the model 
(Kretzschmar & Wiessing, 1998; Atkinson, 1996), leaving the possibility of 
modelling a true population aside until accurate data become available. Other typical 
solutions to the problem of hard to obtain data include assuming that IOU population 
is of constant size over time (Kretzschmar & Wiessing, 1998; Iannelli et al., 1992) or 
else assuming the IOU population is at steady state (Yakowitz, 1994). 
To remove some of the problems associated with data collection, it is possible to 
consider the IDU population as being homogenous meaning there is no core-group of 
high risk individuals. This has the advantage in that fewer data are required to 
parameterise the model, and results can be obtained more quickly from a relatively 
simple model. This is best emphasized by the model described by Murray et al., 
(2003), here the authors use a simple homogeneous model to make estimations in the 
trend of the HIV and HCV prevalence and incidence in the IDU population in 
Australia and their variation over time. While Kaplan & O'Keefe, (1993) use a 
homogeneous model to show the possible effects that a needle exchange has on the 
incidence of HIV. Kretzschmar & Wiessing, (1998) describe a homogeneous 
population regarding risk behaviour i.e. all individuals have the same propensity to 
borrow and share needles. The authors argue for this approach by pointing out that 
for any heterogeneity implemented into the model mixing rates between the different 
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subgroups must be defined and no information that could inform this was available to 
the authors in the population under consideration. 
The introduction of heterogeneity into a model enables a system to be more 
realistically modelled and allows for the effects of potential targeted intervention 
measures to be more closely examined. The most common way to introduce 
heterogeneity into transmission models is to consider the variation in the rates that 
persons make contacts where the contact can lead to the potential transmission of 
infection (Anderson & May, 1991). In this case the contact would involve the risky 
behaviour associated with the sharing of needles and injecting paraphernalia. This 
might take the form of considering whether an IOU shares at a high or low rate (Arca 
et al., 1992; Atkinson, 1996), whether an IOU shares with 'buddies' or strangers 
(Blower et al., 1991), whether an IOU uses shooting galleries or not (Peterson et al., 
1990), or whether syringes are shared among partners or not (Allard, 1990). 
Heterogeneous mixing by gender has also been considered (Vickerman & Watts, 
2002; Arca et al., 1992; Blower et al., 1991), and this is particularly useful when 
considering the additional effect of heterosexual transmission between the IOU and 
non-IOU populations. Mather & Crofts, (l999) describe heterogeneity in the IOU 
population by describing each sub-group in terms of its initial HCV prevalence and 
probability of infection through sharing needles. However the authors' approach is 
particularly unconvincing as they assume that there is no interaction between the 
different sub-groups of the population. Greenhalgh & Lewis, (2002) and Lewis & 
Greenhalgh, (2001) approach heterogeneity by considering the variable infectivity of 
HIV depending upon the time since infection, in both cases the authors expand on 
'Needles that Kill' and apply three-stage infectivity to both addicts and needles. To 
emphasise that over complicated models do not always have an advantage over 
simpler models, Iannelli et al., (1997) compared models of both homogeneous and 
heterogeneous contact within an IOU population finding that the model fit to the data 
for both models was similar. 
An individual based or micropopulation model is an alternative approach to the 
modelling of the IOU population (Mather & Crofts, 1999; Kretzschmar & Wiessing, 
1998; Atkinson, 1996; Peterson et al., 1990). Atkinson, (1996) describes an IOU 
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population of 100 users that interacts with a population of needles with each addict 
having a variable sharing and injecting rate. The model infonns as to the percentage 
of addicts that may become infected from HIV over time depending on their injecting 
frequency and their efforts at cleaning needles. The author's results show the 
importance of cleaning needles on the transmission of HIV. Peterson et al., (1990) 
uses a micropopulation model to describe HIV infection in an IOU population 
showing the importance of prevalence levels in assessing the effectiveness of 
interventions that target IOUs. As already discussed authors frequently use typical 
parameter values reported across the literature rather than values estimated from one 
specific population to describe a generic or general IOU population (Atkinson, 1996; 
Mather & Crofts, 1999), and this probably emphasizes most clearly the difficulties 
associated with a model of this type. To precisely parameterise an actual IOU 
population on an individual level, describing the characteristics of IOUs and their 
interaction with each other is obviously prohibitive and this is why authors will 
frequently describe a generic population in which parameter estimates reported 
across the literature are used to describe an IOU population rather than values 
estimated from one specific population. 
1.6.2 Modelling prison populations 
In various applications previous studies have attempted to model the prison 
population. Two previous studies that consider prison populations from the US are 
cost effectiveness studies examining the cost-effectiveness of HBV vaccination of 
prison inmates and combined HA V and HBV versus HBV vaccination for US prison 
inmates (Pisu et al., 2002; Jacobs et ai., 2004). Both of these models consider 
hypothetical cohorts of a fixed number of prisoners entering prison at age 25 years of 
age with the prison population being described in the context of imprisonment in a 
US setting. While this approach is useful for simplicity it prevents the option of 
considering age dependent health interventions. The authors acknowledge model 
limitations based on the data sources describing the prison costs, HBV incidences 
outside and inside prison, and the rates of release and recidivism. In both cases the 
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authors estimate that HBV vaccination and HA V IB versus HBV vaccination in 
prisons are generally cost-effective. 
A third study considers a model describing the HIV transmission in New South 
Wales (NSW) prisons (Dolan et al., 1998). This model takes the model proposed in 
'Needles that Kill' (Kaplan, 1989) and modifies it to incorporate flows of inmates 
into and out of prison. This deterministic model describes the interactions between 
inmates that are IDUs and needles circulating within prison with the HIV prevalence 
being considered in both populations. The author's assume that the rate that infected 
IDU inmates leave prison is equal to the overall inmate removal rate in other words 
IDUs and non-IDUs have the same imprisonment characteristics. Which given the 
mounting evidence that suggests that IDUs and non-IDUs have different offending 
characteristics (section 1.4 and Chapter 3) this is certainly a potential shortcoming of 
this approach. Using this model the authors are able to see the impact of cleaning 
needles in prisons, the infectivity of needles, and the HIV prevalence of IDUs 
entering prison on the number of IOU inmates infected per year. Although once 
again as this model is not age structured this prevents the examination of the impact 
of age dependent intervention measures. 
The Home Office which is a government department of England and Wales uses 
modelling techniques to estimate the size of the prison population into the future. 
This model uses as inputs views of future sentencing trends including changes in 
custody rates and average custodial sentence lengths, and the impact of government 
implemented legislation. Typically when reporting model results three alternative 
scenarios are investigated. These assume either that observed recent sentencing 
trends continue into the future or that there is an increase or decrease in custody rates 
and average custodial sentence lengths respectively (de Silva et al., 2006). The 
validity of the Home Office model is often vindicated by the closeness of the 
predicted prison population size to its actual size through time. 
Finally two complex theoretical studies propose alternative approaches to the 
modelling of prison populations (Yakowitz et al., 1996; Yablon, 1991). Yakowitz et 
al., ( 1996) describes a numerical technique for a compartmentalized Markov 
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population process while Yablon, (1991) describes various stochastic models to 
represent the input output dynamics of prison popUlations, although in both these 
cases results obtained from the models are not described. 
1.6.3 Modelling HBY transmission 
As the modelling of HBY transmission in the IOU population will be the subject of a 
later chapter (Chapter 6), a review of previous modelling studies that describe the 
transmission of HBY is considered here. 
The transmission ofHBY within countries of high HBY endemicity (where the HBY 
prevalence in the population is high) have been considered in many previous 
modelling studies (Edmunds et al., 1996b; Edmunds et al., 1996a; McLean & 
Blumberg, 1994; Edmunds et al., 1996c; Medley et al., 200 I; Zhao et al., 2000). Due 
to the increased likelihood of becoming an HBY carrier at lower ages of infection 
(Edmunds el al., 1993) models that consider populations with high HBY endemicity 
typically incorporate the transmission of HBY from mother to baby (Edmunds el al., 
I 996b; Edmunds et al., I 996a; McLean & Blumberg, 1994; Zhao et al., 2000; 
Anderson & May, 1991). Considering populations of high HBY endemicity Medley 
et al., (2001) examines the impact of a feedback mechanism where a higher 
prevalence of carriers leads to a lower average age of infection and this in tum leads 
to a high prevalence of carriers and so on. 
Many previous modelling studies that have considered the transmission of HBY have 
incorporated sexual transmission (Williams et al., 1996; Kretzschmar et al., 2002; 
Edmunds et al., 1996b; Edmunds et al., 1996a; McLean & Blumberg, 1994). A 
previous study by Kretzschmar et al., (2002) considers sexual behaviour and the 
transmission of HBY in the Netherlands focusing in particular on the impact of the 
immigration of HBY carriers from countries with higher prevalence, while Williams 
et al., (1996) considers the transmission dynamics of HBY in the UK. In both cases 
the Netherlands and the UK being countries oflow HBY endemicity. 
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Many studies have focused on the impact of various vaccination strategies on the 
transmission of HBV within the population under consideration (Kretzschmar et al., 
2002; Edmunds et al., 1996b; Edmunds et al., 1996a; Zhao et al., 2000; Williams et 
al., 1996). Zhao et al., (2000) found that the key to controlling and eliminating HBV 
transmission in China was to find ways to immunize all infants throughout the 
country, while Edmunds et al., (1996a) found that HBV eradication in the Gambia 
could be achieved by immunizing less than 70 per cent of infants. However in 
countries of low HBV endemicity mass vaccination was found to be a less attractive 
option. Examination of mass infant vaccination in the UK gave a poor effectiveness 
ratio (carriers prevented per cumulative dose of vaccine delivered) (Williams et al., 
1996). While in the Netherlands taking into account the prevalence of HBV carriage 
among immigrants and an age-dependent probability of becoming a carrier after 
infection, it was estimated that only a fraction of between 5% and 10% of carrier 
states could be prevented by universal vaccination (Kretzschmar et al., 2002). 
In previous models the impact of waning vaccine immunity has been considered 
(Edmunds et al., 1996b; McLean & Blumberg, 1994). Edmunds et al., (l996b) found 
that in a developing world setting providing that protection lasts in excess of 5-10 
years, waning immunity following vaccination is unlikely to alter substantially the 
outcome of a mass vaccination programme. 
In all cases the solution to the modelling of HBV transmission has been to use a 
detenninistic model (Anderson & May, 1991; Williams et aI., 1996; Kretzschmar et 
al., 2002; Edmunds et aI., 1996b; Edmunds et al., 1996a; Edmunds et al., 1996c; 
Medley et al., 2001; McLean & Blumberg, 1994; Zhao et al., 2000). This can be 
justified as the popUlations under consideration are usually large and do not have 
small numbers of susceptibles or infectives in which individual random events may 
affect the outcome. 
IOUs are at high risk from HBV infection although to the author's knowledge no 
previous modelling studies have modelled the transmission of HBV within the IOU 
population. However the previous examination of alternative approaches to the 
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modelling of sharing and transmission of other BBYs suggest many approaches that 
could easily be applied to HBY transmission in the IOU population. 
1. 7 Objectives 
The objective of this thesis is to gain a greater understanding of the characteristics of 
the IOU population and its risk of BBY infection. Beginning with the 
parameterisation of a model describing the flow of IOUs through prisons in England 
and Wales a number of modelling approaches will be applied to investigate the 
effectiveness of a range of intervention measures that target IOUs in a prison setting. 
As part of the parameterisation of a model of the flow of IOUs through prisons, the 
age-specific rates at which IOUs start and stop using drugs must be estimated. This is 
the subject of Chapter 2. 
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CHAPTER 2 - MODELLING THE CHARACTERISTICS OF THE MALE 
INJECTING DRUG USER POPULATION IN ENGLAND AND WALES 
2.1 Aims and introduction 
• To estimate the age specific rate that IDUs leave the IDU population and how 
these may have evolved over time. 
• To determine a distribution that describes the age that IDUs start injecting and 
investigate how this may have evolved over time. 
• To investigate the incidence of injecting drug use and how this may have 
evolved over time 
Understanding the characteristics of the IOU population is of major public health 
importance (Hutchinson et al., 2006). Information on, for instance, the age-specific 
rates at which individuals start and stop injecting drugs can inform policy-making, 
particularly strategies aimed at the prevention of drug misuse (Home Office, 2002b). 
The aim of this chapter is to propose a method in which key parameters that 
contribute towards the characteristics of the IOU population can be estimated from a 
data set such as the UAPMP surveys described in section 1.2. These key parameters 
can then be taken forward and applied in both modelling applications and to inform 
policy-making, as will be seen here where these results will be used during the 
parameterisation of a model describing the flow oflOUs through prisons (Chapter 3). 
Of particular interest are the age specific rates at which IOUs start and stop injecting 
drugs and how the incidence of injecting may have evolved over time. As the 
majority of IOUs are male (Hunter et al., 2000) and the characteristics of male and 
female IOUs may differ considerably, only the male IOU population will be 
analysed, however the techniques described here can also be applied to the female 
IOU population. 
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2.2 Methods 
2.2.1 Data 
Using data from the UAPMP surveys undertaken in England and Wales as described 
in section 1.2. A current IOU is defined as a person that injected non-prescribed 
drugs in the previous four weeks (Section 1.1), all participating persons that had not 
injected within four weeks of the survey were excluded from the present analysis. 
Surveys from 1990 and 1991 were considered to be too small and so were discarded 
leaving ten complete consecutive surveys 1992-2001 which were available at the 
time of the analysis. In each survey male current IDUs with data on their current age 
(at time of the survey) and the age of their first injection were considered. The data 
were further constrained by limiting the current age range to be from 16-49, and the 
age of first injection to be from 13-45. Data outside these ranges were sparse and 
deemed too unreliable to be used. 
2.2.2 Model 
Cijk is the number of current IDUs in year k, aged i who started injecting at age j. 
(E.g. C30.20.1992 would be the number of 30 year old current IDUs in 1992, who started 
injecting when they were 20 years old.) Where: 
2.1 
where: -
fjy is the proportion of those persons who started injecting in year y that were aged j 
gy is the number of persons that started injecting in year y 
Sijk is the proportion of those persons that started injecting at age j, who are still 
injecting at age i in year k. 
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Those persons (Sijk) continuing to inject one year later 
2.2 
where Aijk the removal probability, is the proportion of IDUs with current age i and 
start age j being pennanently removed from the surveyed injecting population in year 
k. This may be due to them stopping injecting for longer than 4 weeks, no longer 
reporting to services or because of deaths. 
To make the results here applicable to the later chapters in this thesis (Chapter 3) the 
removal probability Aijk is converted into a removal rate 'Yijk 
2.3 
The proportion of IDUs in contact with services may vary with injecting career 
length, for example it is known that IDUs with shorter injecting careers are likely to 
be underrepresented compared to more experienced users (Godfrey et al., 2002). A 
measure of this under representation across all career lengths is incorporated in the 
model: 
Pi-j is the proportion of persons with career length (i-j) captured by a survey relative 
to a baseline career length. 
The expected number of IDUs in survey year k of age i and start age j is 
Zijk is the probability than an IDU surveyed in year k, is of age i and start age j 
_ Mljl; 
Z/jl;-~~ 
£...J£...JM/jl; 
j I 
2.4 
2.5 
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2.2.3 Parameterisation 
It is assumed that both the proportion of persons starting injecting by age (fjy), the 
removal probability (Aijk ) and therefore the removal rate (Yijk) do not vary with time 
(fjy=fj, Aijk=Aij, and Yijk ="(ij). Both these assumptions will be examined during tests of 
sensitivity. It is also assumed that the removal probability (Aijk ) and therefore the 
removal rate (Yijk) do not vary with the age that IOUs start injecting drugs (Aij=Ai, and 
Yijk ="(i). 
The absolute size of the male IOU population is not known and so it is not possible 
to calculate the number of males starting injecting each year. Therefore gy is relative 
to some arbitrary fixed reference year detailed below. 
As a starting point for analysis, an initial model was proposed with which to fit the 
data and this is defined as: 
fj is described by a gamma distribution at age a with an offset ro,!(a-ro) 
=gamma(p, u) 
Pi-j is grouped into the following injecting career lengths; <I, 1-2, 3-4, 5-9 yrs, and 
calculated relative to a fixed injecting career length of 10+ years = 1. 
gy is grouped into eleven 2 year groups (1980-81, 1982-83 etc.) and is calculated 
relative to year group 1988-89 = 1000. 
Ai is grouped into four age groups; 13-19 years, 20-24 yrs, 25-29 yrs, 30+ yrs 
The initial model was fitted to the data as follows: 
Within each survey year k, the data, Dij, (count of the number of IOUs surveyed at 
age i, with starting age j) are assumed to follow a multinomial distribution. The log 
likelihood of the model given the data within year k is: 
loglik. = LDij. 10gZij. 
ij 
each survey is independent, therefore 
2.6 
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loglik = ~)oglikk 2.7 
k 
Then, maintaining the gamma distribution describing fj, backwards step-wise 
elimination was used to reduce the number of strata describing gy, Pi-j, and Ai. Nested 
models were compared by the difference in deviance and the degrees of freedom, 
which can be tested using a chi-squared test with degrees of freedom equal to the 
difference in degrees of freedom between models. For comparisons between non-
nested models, i.e. such as in a case where a function is changed from piece-wise 
constant to linear, a comparison between the resultant deviances was made. This 
process lead to a final parsimonious model containing less parameters than the initial 
model. 95% confidence intervals (CI) were calculated using the profile likelihood 
method (Armitage & Colton, 1998). 
A selection of the reduced models used during the step-wise elimination process is 
described below (only changes from the initial model are noted): 
1. The initial model 
2 A. is described by a linear function with age. l(a) = max(1/D + k,O). 
3 A. is described by a linear function with age up to a maximum and then 
constant thereafter. ,i(a) = min«max(1/D + k,O), v)). 
4 As model 3 above, except gy is grouped into five 4 year groups (1980-83, 
1984-1987, 1990-1993 etc.) and is calculated relative to the fixed year group 1988-
1989 = 1000. 
5 As model 3 above, except Pi-j is grouped into the following injecting career 
lengths; <1, 1-2, 3-9, and is calculated relative to a fixed injecting career length of 
10+ years. 
6 As model 3 above, except Pi-j is grouped into the following injecting career 
lengths; <I, 1-9, and is calculated relative to a fixed injecting career length of 10+ 
years. 
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2.2.4 Sensitivity Analysis 
Sensitivity analysis involves systematically examining the influence of uncertainties 
in the variables and assumptions employed in an evaluation on the estimated results. 
It encompasses at least three alternative approaches (Briggs & Gray, 1999): 
• One way sensitivity analysis systematically examines the impact of each 
variable in the study by varying it across a plausible range of values while 
holding all other variables in the analysis constant at their "best estimate" or 
baseline value. 
• Extreme scenario analysis involves setting each variable to simultaneously 
take the most optimistic (pessimistic) value from the point of view of the 
intervention under evaluation in order to generate a best (worst) case scenario. 
Frequently the components of an evaluation do not vary in isolation nor are they 
perfectly correlated, hence it is likely that one way sensitivity analysis will 
underestimate, and extreme scenario analysis will overestimate, the uncertainty 
associated with the results of an evaluation. 
• Probabilistic sensitivity analysis, which is based on a large number of Monte 
Carlo simulations, examines the effect on the results of an evaluation when the 
underlying variables are allowed to vary simultaneously across a plausible 
range according to predefined distributions. These probabilistic analyses are 
likely to produce results that lie between the ranges implied by one way 
sensitivity analysis and extreme scenario analysis and therefore may produce a 
more realistic estimate of uncertainty. 
The sensitivity analysis of the final model proposed here took three approaches. 
I. To test the assumption that the removal probability (Ai) is constant over time. 
The data from surveys 1992-1996 and 1997 -2001 were each modelled 
separately with the results compared to each other and that obtained from all 
surveys 1992-2001. 
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2. To test the assumption that the function describing the proportion of persons 
starting injecting by age (fj) is constant over time. Again the data from 
urveys 1992-1996 and 1997-200 I were each modelled separately with the 
re ults compared to each other and that obtained from all surveys 1992-2001. 
3. To te t the sensitivity of Pi-j and gy, 95% CIs were calculated for each of the 
parameters describing these functions. 
2.3 Results 
2.3 .1 Data 
Considering [DUs that started injecting from 1980 onwards, there were 
approximately 1,500 male current IOUs in each annual survey with an overall total 
of 13,536 records analysed (Figure 2.1). The mean age of an IDU surveyed across all 
year was 27.9 years old, the mean age of first injection was 21.2 years, with a mode 
of 18 years of age. Across surveys 1992-2001 the average injecting career of an IDU 
calculated using the total injecting years and the total number of records was found 
to be 5.82 years. Including the injectors that started prior to 1980, for surveys 1992-
200 I, the mean age of an IOU surveyed across all years was 29.3 years, the mean age 
of first injection was 20.8 years, and the average injecting career was 8.56 years. 
Figure 2.1 - Age breakdown of the current IDUs starting injecting from 1980 
onwards 
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2.3.2 Model Fit 
The calculated model parameters for the parsimonious model are shown in Table 2.1 
and Table 2.2 with CIs where appropriate. Table 2.3 shows the results of the fitting 
procedure. The deviance of the nth reduced model as described in the 
Parameterisation section is denoted On. Models I. 2, and 3 examined the removal 
probability with model 3 using a linear removal probability up to a maximum being 
selected. As none of these models were nested, only a direct comparison between 
each deviance could be made. Model 4 considers a reduction in the number of 
parameters describing the function gy however this was found to give a significantly 
less good fit than model 3 (04-03 = 112.9, 5 d.f., p<O.OOI). Model 5 considers a 
reduction in the number parameters describing Pi.j. this was found to give a 
significantly better fit than model 3 (05-03 = 1.9, 1 d.f., p = 0.165). A further 
reduction in the number of parameters describing Pi-j was also investigated (Model 
6), however this was found to give a significantly less good fit than model 5 (06 - Os 
= 19.0, I d.f., p <0.001). Model 5 was therefore taken to be the parsimonious model. 
Figure 2.2 shows for each survey the complete data set (bars) and the model fit 
(lines) for the parsimonious model, showing that the parsimonious model provides a 
good fit to the data. 
Table 2.1 - Parsimonious Model Parameters describing functions/(a-ro) and A.(a). 
Model 
Parameters 
ro 
a 
1t 
v 
1992-2001 1992-1996 1997-2001 
12.58 12.92 12.32 
3.61 3.58 3.57 
3.32 3.19 3.53 
0.020 0.027 0.016 
-0.353 -0.504 
-0.287 
0.310 0.332 0.319 
When considering data/rom 1992-2001. 1992-1996. and 1997-2001 
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Table 2.2 - Model parameters describing the parsimonious model for functions g and 
Pi-j. 
Best Fit 95% Confidence Interval 
gy 
1980-1981 3479 3008-3734 
1982-1983 2907 2696-3251 
1984-1985 2069 1882-2139 
1986-1987 1438 1326-1558 
1988-1989 1000 Fixed 
1990-1991 927 860-999 
1992-1993 743 683-812 
1994-1995 670 596-735 
1996-1997 622 551-709 
1998-1999 485 418-589 
2000-2001 334 272-413 
Po 0.733 0.660-0.794 
p •. 2 1.000 0.924-1.000 
P3.9 0.881 0.832-0.918 
P IO+ 1.00 Fixed 
For all data /992-200/ 
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Table 2.3 - Goodness of fit of initial and reduced models 
Model d.f.(n=3,051) Deviance 
(On) 
I (initial model) 3,032 5,553.2 
2 3,034 5,586.4 
3 3,033 5,514.9 
4 3,038 5,627.8 
5 3,034 5,516.8 
6 3,035 5,535.8 
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Figure 2.2 - Age specific data for each survey year 1992-2001 broken down by the 
age of first injection with model fit. 
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2.3.3 Under ascertainment (Pi-j) 
The values obtained for Pi-j (Table 2.2) suggest that there is evidence of under 
ascertainment particularly in the new initiates, i.e. those injectors whose injecting 
starting age (j) is the same as their current age (i). Although there was also some 
evidence of under ascertainment for those injectors with injecting career lengths of 
up to 9 years. 
2.3.4 Starting with age (fj) 
Over 50% of injectors are estimated to start injecting between 18 and 25 years of age 
and less than 15% start injecting over 30 years old (mean age of starting = 21 years) 
(Figure 2.3). Considering separately the data for 1992-1996 and then 1997-2001 
shows only a small difference in results and helps to confirm the validity of the 
assumption that the proportion of IDUs starting injecting by age does not change 
within this data set over time. 
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Figure 2.3 - Function ~: The proportion oflDUs starting injecting by age. 
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2.3.5 The relative number of male starting injecting over time (gy) 
The relative number of male tarting injecting each year, function gy, is shown in 
Figure 2.4. The graph compares the number of males starting injecting between each 
year as uming that 1,000 injectors started in 1990. If for example in a given year the 
number of male tarting injecting was 2000, this would mean that the model 
e timate that twice the number of males started injecting in that year compared to 
1990. The re ult pre ented here shows a peak of persons starting injecting in the 
early 19 0 . From then there was a drop in the number of males starting injecting 
until 1990 after which there has been a broad stabilization (or perhaps a small drop). 
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Figure 2.4 - Function g . The relative proportion of males starting injecting each 
year. 
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2.3.6 Removal Rate 
The removal rate for the parsimonious model were found to be linear with age up to 
a maximum and then con tant thereafter. The initial piece-wise constant distribution 
de cribed by the initial model was found to give a much inferior fit to the data. The 
re ult ugge t that the older an IOU is, the more likely it is he will be removed from 
the IDU population up to around 30-35 years of age, thereafter the removal rates 
appear to remain c n tant (Figure 2.5). Although the removal rates for male injectors 
under 19 years of age are estimated to be zero, it is acknowledged that there is a 
chance that a y unger IOU may leave the IOU population. For older data (1992-
1996) the rem val rate was found to be higher across all age groups aged 19 and 
above, thi ugge ts a potential change in injecting behaviour through the I 990s. If it 
i a umed that the removal rates accurately reflect the rate that IDUs either stop 
injecting r die, the re ult obtained from the removal probabilities (A.i) and the 
functi n de cribing the age of starting (fj) can be used to calculate the average 
injecting career of an IOU . From the parsimonious model the average injecting 
career w fi und t be 5.97 year (5.56 - 6.60 yrs; 95% CI). 
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Figure 2.5 - The age-specific rate that IOUs leave the IDU population per year (n). 
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2.4 Di cu ion 
The work propo es a method in which key parameters that contribute towards an 
increased understanding of the characteristics of the IOU population can be estimated 
from a data et consisting of a sequence of lDU surveys. In this case the data set was 
ten con ecutive UAPMP surveys (1992-2001) of current IDUs with infonnation on 
their current age, age at the time of the survey, and their age at fIrSt injection (section 
1.2). 
Many epidemiological surveys have sought to gain an insight into the characteristics 
of the ]0 populati n, and some estimates ofthe rates that IDUs start and stop using 
drugs have been made el ewhere (Murray et aI., 2003; Pollack, 2001; Law et aI., 
200 I; Kaplan, 1989) (section 1.1.1) however this work is novel in that it provides a 
method by which an age specific removal rate, a distribution for the age specific 
tarting age, and the trend in the injecting incidence of time can be estimated from 
data uch a the UAPMP surveys of 10Us in England and Wales (Health Protection 
Agency el 01., 2005). 
A a tarting point for analysis an initial model was proposed consisting of a number 
f paramete de cribing each model function. It is normal for a full model to be used 
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at this stage and it is acknowledged that the initial model could have been described 
by many more parameters however this was not done for two reasons. The 
computing power required to manipulate a model such as this would have been 
prohibitive and there is a danger that a 'many parameter' model may lead to 'over 
fitting' of the data. 
The model predicts the most likely starting age of a male IOU to be 21 years old 
(Figure 2.3) and this result compares well with the observed mean age of first 
injection of 21.2 years. It was also found that over 50% of injectors are estimated to 
start injecting between 18 and 25 years of age. It was assumed in the model structure 
that this function did not change over time. The similar results obtained when the 
model was fit to data from two separate time periods, i.e. 1992-1996 and 1997-2001 
gives confidence to the validity of this assumption. 
The removal rates obtained from the model (Figure 2.5) show that as an injector's 
age increases his chance of leaving the IOU population increases up to a plateau at 
around 30-35 years of age, after which the rate is constant. In the case of the data 
examined here, an IOU may leave the IOU population because he has died, stopped 
injecting, or stopped reporting to services. While it is impossible to know which, the 
results here do point to an increasing injecting cessation rate with age followed by 
constant cessation behaviour in older injectors. 
It is acknowledged that the natural death rate increases with age and the constant 
removal rate in the older age groups do seem to contradict this. However the small 
increase in the death rate for ages 35-49 is insignificant compared to the high 
constant removal rate across the same age group. 
Assuming the removal probability is a reasonable approximation of the probability 
that IOUs either stop injecting or die, the average expected injecting career length 
from the parsimonious model was found to be 5.97 years (5.56 - 6.60 yrs; 95% CI). 
This is similar to the average injecting career length obtained from the crude data of 
5.82 years. 
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The number of males starting injecting each year shows a high incidence of injecting 
in the early 1980s followed by a sharp decline (Figure 2.4). This fits well with the 
effects of individual and social concern following the sudden emergence of AIDS 
and HIV infection in IDUs. Throughout the 1990s there appears to have been a fairly 
stable incidence of new male injectors. This is also in agreement with other studies. 
For instance, Hickman et aI., (2001) estimated the incidence of heroin use from 
1991-1998, and found a stable incidence during this period. The slight reduction in 
the number of males starting injecting in 2000-200 I coupled with an increase in the 
average injecting career length of an IDU in more recent years (1997-200 I lower 
removal rate) may be indicative ofa change in the nature of the IDU population with 
more 'problem' rather than casual users. 
The methods described here provide a technique by which key parameters can be 
obtained that will contribute towards a greater understanding of the IDU population 
and its characteristics. As has been shown here, in each given moment the population 
of active IDUs is a mix of injectors who have been injecting for a different numbers 
of years and this range is very relevant in terms of the implementation of targeted 
prevention strategies. 
This chapter concludes analysis that has considered the characteristics of the IDU 
population. Having obtained age-specific rates that IDUs start using drugs and leave 
the IDU population this work can be taken forward and contribute to the 
parameterisation of a model describing the IDU population and its flow through 
prisons. This will be the major focus of Chapter 3. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A. J., Gay, N. 1., Edmunds, W. 1., Andrews, N. 1., Hope, V. D., & Gill, o. 
(2005). Modelling the Characteristics of the Male Injecting Drug User Population in 
England and Wales. International Journal of Drug Policy 16, 176-182 
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CHAPTER 3 - MODELLING THE FLOW OF INJECTING DRUG USERS 
THROUGH PRISONS IN ENGLAND AND WALES 
3.1 Aims and introduction 
• To parameterise a model describing the flow of IDUs and non-IDUs through 
prisons in England and Wales so that this can then be applied to investigate a 
variety of alternative intervention measures that target IOUs in a prison setting. 
• To provide a greater understanding of the offending characteristics of the IOU 
population and how this compares to non-IDUs. 
To estimate the impact of intervention measures that target the IDU population in a 
prison setting it is of importance to gain an understanding of the rate that IDUs flow 
through prisons. The number of IDUs that appear on reception into prison and their 
length of prison stay will have an impact on the success of any prison based 
intervention targeting the IDU population. To address questions such as this a model 
is required which describes the turnover of IDUs and non-IDUs through prison. This 
can inform as to the rates that IDUs and non-IDUs pass through prisons and provide 
a greater understanding of the offending characteristics of the IOU population. The 
chapter here describes the parameterisation of the model of the flow oflDUs through 
prisons in England and Wales. 
The estimation of the model parameters is described here and these are used in 
conjunction with the rates that IDUs start injecting and leave the IDU population 
estimated in Chapter 2 to fully parameterise the model. Sensitivity analysis of key 
model parameters is undertaken in the context of the HBV prison vaccination 
programme in England and Wales. This is shown in Chapter 4. 
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3.2 Methods 
3.2.1 Population 
The purpose of this model is not to make detailed projections regarding the prison 
population over time and so we assume that both the male prison population and the 
total male population (females are not considered) of England and Wales are stable. 
Mortality is assumed to be zero until 74 years and infinite thereafter producing a 
fixed Ii fe expectancy of 75 years. The model considers only males aged 15-74 years, 
stratified into 60 age cohorts. Persons enter the model at the start of the year into the 
first age cohort (at 15 years of age). Thereafter individuals change age cohorts at the 
beginning of each year. It is assumed that the total number of persons in each age 
group is the same and is constant over time. 
3.2.2 Model structure 
The model describes the flow of IDUs and non-IDUs through prison. It is an age-
structured deterministic model based on a set of ordinary differential equations 
illustrated in Figure 3.1 with parameter definitions described in Table 3.1. Each 
mutually exclusive compartment represents a different status of imprisonment and 
injecting, and the arrows represent the flow of individuals between them. A person 
can either have never been to prison, be currently in prison, or have been previously 
imprisoned, and, can never have injected drugs, be a current IOU, or have been an 
IOU in the past. Prisoners are considered to be IDUs if they were current IDUs 
(injected in the previous 4 weeks) on reception into prison. 
The rates of starting (fJ) or stopping (n injecting (as calculated in Chapter 2 in 
conjunction with an assumed IOU population size in the case of the start rates (fJ) 
are assumed to be independent of prison status (never, currently or previously 
imprisoned). The rates at which individuals go to prison for the first time (P), are 
discharged from prison (P), and return to prison (fJ) are assumed to be the same for 
non-IDUs and past-IDUs but may be different for current IDUs. 
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3.2.3 Mathematical Structure 
The differential equations for the detenninistic model are as follows: 
dX fJ, 
-' = -(II. + .)X dt r, , , 
d>: = XllJi + ZIB; - (PI + PI )>: 
dt 
dZ 0 a dt' = >:PI -( 1+ p;)Z; 
dXI; = PI(XP; + X;) - (lJol + rl)XII dt 
dY11 0 0 0 a ) 
-- = (XlljlJ 1+ ZIIjO I) - (p ; + rl)YII + PI(>: + YE: dt 
dZ11 0 0 
- = PI(Z; + ZP;) + YIIP I - Z11(0 1+ r i ) dt 
dXP; = Xllri - (Pi + IJI )XP; 
dt 
dYE: = (XE:IJI + ZP;B;) + Yllrl - (A + PI )Yp; 
dt 
dZP; = YP;PI + Zllrl -(01 + PI)ZP; dt 
3.1 
3.2 
3.3 
3.4 
3.5 
3.6 
3.7 
3.8 
3.9 
The number of individuals of age i who have never been imprisoned and are non-
lDUs (X), imprisoned non-IDUs (Y), previously imprisoned non-IDUs (Z), never 
been imprisoned lDUs (Xl), imprisoned IDUs (YI), previously imprisoned IDUs 
(ZI), never been imprisoned previous IDUs (XP), imprisoned previous IDUs (YP), 
previously imprisoned previous IDUs (ZP). The different parameters detennining the 
rates of flow between imprisonment states and IOU status are described in Table 3.1. 
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Figure 3.1 - Flow diagram of the age specific turnover of IOUs and non-IOUs in 
England and Wales repeated for each of the 60 age groups. 
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Table 3.1 - Baseline parameter estimates and definitions. 
Symbol Definition Baseline Value (01/ roles: / person / year) 
r The rate that current IDUs stop injecting Age specific 
p The rate that non-IDUs and past-IDUs start injecting Age specific 
p The rate that non-IDUs and past-IDUs go to prison for the first time Age specific 
pO The rate that IDUs go to prison for the first time Age specific 
p The rate that non-IDUs and past-IDUs are discharged from prison Age specific 
p The rate that IDUs are discharged from prison Age specific 
o The rate that non-IDUs and past-IDUs return to prison having been previously imprisoned Age specific 
O· The rate that IDUs return to prison having been previously imprisoned Age specific 
T Average injecting career length dependent on injecting starting age (Chapter 2) 5.97 years 
Size of the male IOU population 
Size of the male prison population 
Total male population 
120,000 (de Angelis el 01.,2004) 
61,775 
Variable with age, (Office of National 
Statistics, 2003) 
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3.3 Model parameterisation and key findings 
Where possible parameters were directly calculated from specific data sources 
(r,P,p) or were indirectly estimated by maximum likelihood from data on IDUs 
and prisons (O,,u) . Age specific rates at which IDUs start and stop using drugs (p(a) 
and r(a) respectively) were taken from analysis of the UAPMP surveys of current 
IDUs described in Chapter 2. 
3.3. J Prison discharge rates (p(a) and p,(a)) 
Data were taken from a survey of prisoners in 1997/8 (Weild el at., 2000) describing 
the sentence length, the age, and the IOU status of prisoners from a cross section of 
prisons in England and Wales (Table 3.2). There are two difficulties in calculating 
the average length of imprisonment per spell of imprisonment for IDUs and non-
IDUs from these data. The actual time served for a sentence will be less than the 
sentence length imposed, and a cross-sectional survey of prisoners' current sentence 
lengths is not representative of all admissions because the prisoners serving longer 
sentences will be over-represented. 
Prison statistics 2001 (Home Office, 2002a) provide data on the average time served 
by length of sentence, and so data were adjusted from length of sentence to average 
time served. To allow for the over-representation of longer sentences in the prison 
survey, the number of prisoners for each length of sentence was weighted by 
I/(average time served). The discharge rate for each age group was then calculated 
(Table 3.3). 
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Table 3.2 - Data (1997-1998) from a cross section of prisons in England and Wales. 
Non-Injecting Drug Users 
Young Offenders Sentence 
Age Remand <3months 3-12months 1-3years 3+years Total 
<16 49 14 26 49 20 158 
17 55 11 16 35 27 144 
18-19 138 22 26 52 39 277 
20-21 48 12 9 18 19 106 
Total 290 59 77 154 105 685 
Adult Prisoners 
Age Remand <3months 3-12months 1-3years 3+years Total 
<25 94 16 39 113 205 467 
26-30 59 9 47 114 266 495 
31-35 50 7 41 102 311 511 
36-40 11 3 14 70 146 244 
41+ 25 11 38 100 458 632 
Total 239 46 179 499 1386 2349 
Injecting Drug Users 
Young Offenders Sentence 
Age Remand <3months 3-12months 1-3years 3+years Total 
<16 1 1 0 0 0 2 
17 0 0 1 2 0 3 
18-19 3 0 0 0 1 4 
20-21 1 0 0 1 0 2 
Total 5 1 1 3 1 11 
Adult Prisoners 
Age Remand <3months 3-12months 1-3years 3+years Total 
<25 40 3 5 26 36 110 
26-30 39 3 15 29 63 149 
31-35 24 0 6 10 40 80 
36-40 4 0 1 6 12 23 
41+ 3 0 3 0 12 18 
Total 110 6 30 71 163 380 
(Weild et 01 .. 20(0) 
3.3.2 Imprisonment Rates (j.J(a), I1la), fJ(a), and fJla). 
The rate of first time imprisonment for IDUs and non-IDUs, and the rate of repeat 
imprisonment for IDUs and non-IDUs were estimated concurrently by fitting the 
model to data described in Figure 3.2 by maximum likelihood (section 3.3.3) keeping 
previously estimated parameters (discharge rates, IDU start and stop rates) at their 
basc-casc level. 
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Figure 3.2 - Model fit to age specific data. 
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(a) The percentage 0/ the male popUlation that has ever been imprisoned (Prime et 01 .• 
2001). (b) The percentage o/the male IDU population that has ever been imprisoned (2001. 
n=3.904 (Unlinked Anonymous Surveys Steering Group. 2002)). (c) The male prison 
population (Home Office. 20020). (2001. n=61.775). (d) The % o/prisoners that are current 
IDUs (Weild et 01 .. 2000) (n=3.425). 
Figure 3.2 (d) shows the proportion of the male prison population that are current 
IDUs (Weild et 01., 2000). The original data for age group 15-20 years was 1.6% 
(111708). From the UAPMP Survey 2001,35% of 15-17 year old IDUs had been to 
prison and for the 18-20 year group the figure was even higher at 44%. Coupled with 
the fact that the young offender data were only obtained from one institution, it may 
be that this figure is not a true reflection of the proportion of imprisoned young 
offenders that are IDUs. Additional data of arrestees aged between 17 and 24 that 
were interviewed and urine tested for drugs whilst on arrest in police custody suites 
showed that rates of last-year use of heroin, crack and cocaine all stood at around 
20% (Bennett, 2000). On the basis of these concerns an alternative arbitrary value of 
14.1 % was selected (1001708) as the base case however the effects of this selection 
are examined in the sensitivity analysis. 
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The full model was fitted using maximum likelihood applied to binomial data. The 
functions describing the first time and repeat reception rates were each examined 
separately to find an appropriate functional form. An iterative process in which 
various functional forms were applied and tested was used. Resultant deviances for 
each test were compared, with the functional form exhibiting the lowest deviance 
being selected. 
3.3.3 Maximum likelihood fitting to binomial data 
The model was fitted to the binomial data using maximum likelihood. The saturated 
likelihood (L·) and the model likelihood (L) are defined as: 
L· = ~:<a; In(p;) + b; 1n(1- P;» 
Where 
ai is the observed number of positives (data) in age group i 
bi is the observed number of negative (data) in age group i 
p = a; 
, a j +b; 
Mi is the modelled proportion positive in age group i 
Deviance for each data set (as shown in Figure 3.2) is: 
D=2(L· -L) 
3.10 
3.11 
3.12 
3.13 
The above is repeated for each independent data set, with the deviance for each data 
set being summed to provide an overall deviance 
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3.3.3.1 Over-dispersion 
Due to the size of the numerator in the prison population size, this dominates the 
binomial likelihood. The practical effect is that the model fit is also dominated by 
this part of the data. Despite this, no model gave a good fit to these data when using 
the binomial distribution. Therefore we introduced an over-dispersion parameter to 
this part of the data using the negative binomial distribution (McCullagh & Neider, 
1989). The over-dispersion parameter ~ was chosen to fix the deviance of that part of 
the data equal to its degrees of freedom. 
Negative Binomial Maximum Likelihood 
Yi = observed number of positives (data) for age group i 
Jli = expected number of positives (model) for age group i 
Saturated likelihood /-J;=Y; 
3.14 
3.15 
It was found as a consequence of applying the fitted model that the calculated values 
for the discharge rates for the IOU population resulted in lower repeat reception rates 
for IOUs compared to non-IDUs across all ages. IDUs are generally more likely to 
re-offend than non-IDUs (Seaman et at., 2000), and it was found by assuming that 
the discharge rate for IDUs was the same for all age groups (at the 15-19 age group 
rate) that a higher re-imprisonment rate for IDUs could be achieved. An argument for 
this can be made when considering data from different types of prison from the 
prison survey. Considering data from only local prisons the average time spent in 
prison for an IOU across all age groups is 3.8 months, this was comparable to the 
2.64 months for the 15-19 age group IDUs. The final fitted function for the first time 
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reception rate was found to follow a gamma function and an exponential function for 
the repeat reception rate as shown in Figure 3.3. It can be seen that the repeat 
reception rate was found to be constant for IDUs although the exponential function 
was used during sensitivity analysis (chapter 4). 
Figure 3.3 - The calculated rates of (a) first time imprisonment and (b) re-
imprisonment for IDUs and non-IDUs with variation in age 
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The complete age-specific parameter set that describes the model ofthe flow ofIDUs 
through prisons in England and Wales is shown in Table 3.3. 
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Table 3.3 - Baseline estimates for age specific parameters 
Age Group (years) 
Symbol Definition 15-19 20-24 25-29 30-34 35-39 40-49 50-59 60-69 70+ 
y(--) StopRales 0.0040(-) 0.0803 0.1807 0.2796 0.3\39 0.3139 0.3\39 0.3\39 0.3\39 
P(##) Start Rates 0.0030 0.0045 0.0029 0.0012 0.0005 0.0001 0.0 0.0 0.0 
p Discharge rates 4.3574 1.9180 1.4258 1.2294 1.0063 0.9604 0.9604 0.9604 0.9604 
. 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 P 
p(##) /st Time Imprisonment Rates 0.0042 0.0018 0.0011 0.0008 0.0006 0.0004 0.0002 0.0002 0.0001 
p.(##) 0.5274 0.3144 0.2605 0.2307 0.2108 0.1905 0.1718 0.1586 0.1508 
8(##) Repeal imprisonment rates 1.3405 0.5778 0.2497 0.1087 0.0480 0.0163 0.0048 0.0027 0.0023 
fI(##) 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 
(*) STOP RATE 0 UP TO AND INCLUDING 18 YEARS OF AGE 
(**) CONTINUOUS FUNCTIONS; PARAMETERS SHOWN ARE AVERAGED OVER EACH AGE GROUP 
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3.4 Discussion 
This chapter considers the structure, design, and parameterisation of a model 
describing the flow of IDUs through prisons in England and Wales. The 
parameterisation described here helps to inform as to the offending behaviour of 
IDUs when compared to non-IDUs and their flow through prison. This model can be 
taken forward and applied to a range of intervention measures that target IDUs in a 
prison setting as will be seen in later chapters. 
An alternative approach to the modelling here might be to apply a stochastic model 
instead of the deterministic model proposed. However the objections to this 
approach, are that the size of the populations under examination are quite large 
meaning that individual random events are unlikely to effect the model outcomes 
(Chapter 4, Chapter 6, and Chapter 7), while the re-parameterisation of the model 
that allows realistic variation in many age-specific parameters to represent the 
stochastic nature of the model may be problematic. 
The parameter values here provide further evidence that IDUs are at increased risk of 
imprisonment compared to non-IDUs. However of additional interest are the 
discharge rates for IDUs and non-IDUs which suggest that IDUs spend less time in 
prison during each spell of imprisonment compared to non-IDUs. IDUs frequently 
commit crimes to finance their drug using habits (section 1.4) although the evidence 
here suggests that these crimes would appear to be relatively minor as suggested by 
the short estimated time spent during each spell of imprisonment. 
The findings here suggest that the offending behaviour of IDUs that have previously 
been imprisoned is independent of age. For example the parameter estimates 
describing the discharge rates for IDUs suggest that IDUs are given similar length 
sentences independent of age, while the estimated re-imprisonment rates for IDUs 
are also constant across all age groups. This finding is not surprising. A current IDU 
here has been defined as an individual that has injected illicit drugs within the 
previous four weeks, and it would be expected that the criminal behaviour that these 
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individuals would undertake to finance their drug using habit would be independent 
of age. 
It has been assumed here that the rate that past-IDUs restart injecting is the same as 
those individuals that have never injected drugs. It is acknowledged that due to 
relapse individuals that have previously injected drugs are more likely to start an 
injecting career compared to individuals that have never injected (section 1.1.1). 
However this assumption was made due to the paucity of data describing the rates 
that individuals stop and restart injecting drugs over time. Similarly it has been 
assumed here that IDUs start and stop injecting drugs independently of prison status, 
which despite evidence that prison may lead to increased likelihood of cessation and 
initiation of an injecting career (section 1.4) has been implemented due to paucity of 
data. 
The model did not include the removal of individuals from each age group due to 
death but instead realistic age structuring was applied (Schenzle, 1984), in which all 
individuals within the model move up to the next age group at the end of every year 
and then die when reaching 75 years of age. While this solution is inevitably less 
realistic than applying age dependent death rates it has the advantage of maintaining 
an equal number of individuals within each age group, and should not impact on the 
results focusing on the IDU population as the majority of IDUs will have stopped 
injecting in the older age groups. 
The model here describing the flow of IDUs and non-IDUs through prisons in 
England and Wales used data collected from a survey of 10 prisons undertaken in 
1997 (Weild el al., 2000). From this it is therefore assumed the offending 
characteristics of IDUs have not changed since 1997. It is acknowledged that this 
data is old however no further surveys have been undertaken of sufficient size that 
would enable the model of the flow of IDUs through prison to be re-parameterised. 
The chapter here has described the parameterisation of the model describing the flow 
of IDUs through prisons in England and Wales. Chapter 4 takes this work forward 
and applies it to the HBV vaccination programme in England and Wales to show 
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firstly what proportion of the IOU population might be vaccinated under a range of 
hypothetical vaccination scenarios, and secondly to show the impact of key model 
parameters on model results. Chapter 7 describes an alternative application of this 
model considering the cost-effectiveness of HCV case-finding on reception into 
prisons in England and Wales. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A. J., Gay, N. 1., Edmunds, W. 1., Andrews, N. J., Hope, V. D., Gilbert, R. 
L., Piper, M., & Gill, O. N. (2006). Modelling the hepatitis B vaccination programme 
in prisons. Epidemio/ Infect. 134, 231-242. 
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CHAPTER 4 - MODELLING THE HEPATITIS B VACCINATION 
PROGRAMME IN PRISONS IN ENGLAND AND WALES 
4.1 Aims and introduction 
• Estimate the proportion of the IOU population in England and Wales that will 
become vaccinated over time under a range of realistic vaccination scenarios 
that describe the proportion of prisoners vaccinated on prison reception. 
• Using sensitivity analysis, identify the key parameters within the model of the 
flow of IOUs and non-IOUs through prison (Chapter 3) that have the largest 
impact on estimates of the proportion of the IOU population that may become 
vaccinated over time. 
As described in section 1. 5.1.1, since June 200 I vaccination has been offered to 
prisoners on reception into selected prisons in England and Wales with the 
programme expanding to incorporate a greater number of prisons in recent years. To 
judge the effectiveness of the HBV vaccination programme in prisons, it is important 
to estimate how quickly the IOU population (which is at significant risk from HBV 
infection, section 1.3.1.1) will be vaccinated and the maximum proportion of IOUs 
that can be captured by the programme over time under a range of alternative 
vaccination scenarios. To address these questions the model of the flow of the IDU 
population through prisons described in Chapter 3 is taken forward and applied to the 
HBV vaccination programme in prisons in England and Wales. 
The work here briefly describes how the model of the flow of IDUs through prisons 
is applied to the HBV vaccination programme in prisons in England and Wales. The 
model is then used to estimate what proportion of the total current IDU population in 
England and Wales will receive HBV vaccine from a range of alternative vaccination 
scenarios over time. Sensitivity analysis of key model parameters is also undertaken. 
Knowledge of what proportion of the IOU population may be vaccinated can then be 
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used to estimate the impact of prison vaccination on the transmission of HBV within 
the IDU population of England and Wales. This will be the focus of Chapter 6. 
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4.2 Methods 
4.2.1 Model structure 
The model describing the parameterisation of the flow of IDUs and non-IDUs 
through prisons in England and Wales has been described in Chapter 3. To apply this 
model to the HBV vaccination programme in prisons the vaccination status of 
individuals within the model must be introduced. The age-specific rates that non-
IDUs and IDUs pass through prisons are estimated in Chapter 3 however the set of 
ordinary differential equations that describe this model are modified to include 
vaccination. These are described below where i is age and j is the number of doses of 
HBV vaccine received. Parameter definitions are described in Chapter 3: 
4.1 
4.2 
4.3 
4.4 
4.5 
4.6 
4.7 
4.8 
4.9 
Vaccination is implemented in the model on reception into prison. A proportion art) 
of prisoners entering prison are included in the vaccination programme. The 
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proportions of those who receive I, 2, or 3 doses are denoted by a, b, and c 
respectively. The vaccination status transition matrix Jjk gives the proportion of 
persons that had received k doses before reception into prison and j doses following 
reception. Where: 
I-a 0 0 0 
aa I-a 0 0 
4.10 Vjk = ab aa I-a 0 
ac a(b + c) a 
4.2.2 Vaccination 
Throughout the model the vaccination status of each compartment is stratified by the 
number of doses received, 0, I, 2, or 3+. The prison vaccination programme is 
modelled by assuming 0, I, 2, or 3 doses are administered to prisoners at the 
beginning of their sentence. Prison vaccine coverage (any dose) is given by 
parameter a. and is defined as the proportion of prisoners that receive at least one 
dose of HBV vaccine on prison reception. The parameters a, b, and c represent the 
proportion of those vaccinated who receive one dose, two, or three doses of vaccine 
respectively (c = J -a-b). 
IDUs may be vaccinated outside prison in the community, implemented in the model 
as an annual event. It is assumed that a proportion A. of rous are given 3 doses and 
that this proportion is constant over time, with age, and with injecting career length. 
The model is run to steady state prior to the introduction of prison vaccination. 
4.2.3 Prison Vaccination 
Data was collected from the HBV vaccination programme in prisons from January to 
June 2003 (Table 4.1) on vaccination doses administered to prisoners on reception 
during this period. To reduce the effects of truncation only data from March and 
April was considered. Excluding the other and only 4 doses received, from this data, 
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38% of prisoners received one dose, 28% received two doses, and 34% received 
three doses. This is applied to the model representing vaccination parameters a, b, 
and c, respectively. 
Table 4.1 - Data on HeV vaccination doses received on reception into prison during 
2003 and month when first dose was administered 
Month First Dose Received 
Doses 
Received Jan Feb Mar Apr May Jun Total 
Other 81 39 64 55 31 1 271 
1&2 202 162 278 179 180 235 1236 
12&3 298 400 413 275 198 54 1638 
2&3 178 64 65 41 34 17 399 
only 1 221 219 258 235 197 396 1526 
only 2 147 53 68 74 59 101 502 
only 3 383 85 85 65 83 106 807 
only 4 58 105 70 76 56 74 439 
Total 1568 1127 1301 1000 838 984 6818 
Reference: (Gilbert et al., 2004) 
4.2.4 Community Vaccination 
Data was considered from the UAPMP surveys in 2001 (Unlinked Anonymous 
Surveys Steering Group, 2002) of male IOUs (who injected in the previous four 
weeks prior to the survey) reporting whether they have been vaccinated against HBV 
by career length. Assuming both that this data is representative of the IOU 
population in the community, and that all reported vaccinations were administered in 
the community, the model was fitted to the data (UAPMP survey 2001) using 
maximum likelihood (section 3.3.3) (Figure 4.1). The proportion of IDUs vaccinated 
in the community ( A. ) per year was estimated to be 0.106. 
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Running the model to teady state results in a fixed value of 38.4% for the proportion 
of 10 accinated in the community in 2001 prior to the introduction of the prison 
vaccinati n programme. This compares with the 39.6% of IDUs found in the 
UAPMP urvey 2001. 
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Table 4.2 - Baseline parameter estimates and definitions. 
Symbol Definition 
A. The rate lIlat IDUs are vaccinated in lIle conmnmily 
a The proportion of prisoners lIlat receive at least one dose of vaccine on prison reception 
a The proportion of those vaccinated lIlat receive one dose of vaccine 
b The proportion of lIlose vaccinated IIlat receive two doses of vaccine 
c The proportion of lIlose vaccinated lIlat receive IIlree doses of vaccine 
Baseline Value 
0.106 / IOU I year 
Variable see text. 
0.38 
0.28 
0.34 
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4.3 Sensitivity Analysis 
The sensitivity analysis presented here investigates how the following factors affect 
the final results from the model. In each case by substituting alternative values to the 
baseline (parameterised in Chapter 3) as follows: 
I. The total assumed size of the male IOU population inside and outside prison 
was chosen to be 80,000 and 160,000. 
2. The average injecting career of an IOU was assumed to be 5.56 years, 6.60 
years (by changing the age dependent injecting start and stop rates (Chapter 2 
95% Confidence intervals», and 20 years (assuming an age dependent start 
rate and constant stop rate across all ages) respectively. 
3. The percentage of imprisoned young offenders that are IDUs was assumed to 
be 1.6% (data, section 3.3.2), 4.9%, 10% and 20%. 
4. The average time an IOU spends in prison was assumed to be 2.0 months, 3.0 
months, 4.0 months, 5.0 months, and 6.0 months. 
5. The community vaccination rate (A.) was assumed to be 0.00, 0.05, 0.075, 
0.12, and 0.15 respectively. 
6. To simulate the effects of a growing prison population, the 151 time and repeat 
reception rates into prison for IOUs and non-IOUs across all ages are 
assumed to increase by 1%, 2.5%, and 5% per year. 
The first four factors that were tested during sensitivity analysis were used during the 
concurrent calculation of first time and repeat reception rates, these reception rates 
must be recalculated during each test of sensitivity. 
As (in the base-case) the prison population size is assumed to be constant over time, 
i.e. the total receptions is equal to the total discharges, it is important that any 
changes to the model maintains this equilibrium. Thus, if for instance the % of young 
offenders that are IDUs is altered, then the average sentence lengths (and therefore 
the discharge rates) of the non-IDUs must also be adjusted. 
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Alongside the vaccination parameters previously described (section 4.2), the baseline 
vaccination scenario (section 4.3.1 below) will be used as an input into the model 
when testing model sensitivity. 
4.3.1 Vaccination Scenarios 
To test the effectiveness of the HBV vaccination programme in prisons, a number of 
vaccination scenarios are proposed. The total proportion of prisoners on reception 
that participated in the HBV vaccination programme across all prisons in England 
and Wales during 2002 was 5%, in 2003 this figure is expected to rise to 10% and so 
these values are applied to all vaccination scenarios (Table 4.3). For each vaccination 
scenario: the parameters are at the baseline unless otherwise stated, the vaccination 
coverage on reception increases linearly between 2003 and 2006 where appropriate, 
and remains constant from 2006 onwards. In some cases the proposed vaccination 
scenarios are not achievable in reality (i.e. maximum scenario) however these have 
been selected to assist in drawing conclusions from the model. 
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Table 4.3 - Summary of vaccination scenarios investigated during sensitivity analysis. 
Strategy 2003 2006+ Notes Extra Strategy 
Baseline 10% 50% a = 38%, b = 28%, c = 34% 
Up to 33% 10% 33% 
Up to 66% 10% 66% 
No Expansion 10% 10010 
Targeting young offenders 100/0 100% Only young offenders are vaccinated from 2004 
onwards 
Baseline + vaccination 10% 50% Pulse: all prisoners given 3 
Campaign doses at the end of 2004 
Regular Campaign 10% 0% 0% vaccination on reception from 2004 onwards Pulse: (see above) at the 
end of 2004, 2007, and 2010 
Maximum 10% 100% c= 100% 
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4.4 Results 
The results presented here consider the implications of various tests of sensitivity on 
the results obtained from the model when the baseline vaccination scenario is 
applied. This is followed by an examination of the potential impact of the HBV 
vaccination programme in prisons depending on the vaccination scenario 
implemented. In both cases the key result is the proportion of the IDU population 
both inside and outside prison that has received two or more doses of vaccine, this is 
considered for a number ofreasons:-
I. There is some protection from infection when only one dose vaccine IS 
administered, while a small proportion of those that receive 3 doses of 
vaccine may not be protected (Bock et al., 1995). 
2. A previous study has suggested that the 3rd HBV dose of vaccine may not be 
necessary (Wilson & Nokes, 1999). 
For clarity of exposition in the sensitivity analysis (excluding that examining the 
community vaccination rate), it has been assumed the IDU population is initially 
completely unvaccinated. 
4.4.1 Results - Sensitivity Analysis 
It can be seen from the results of the sensitivity analysis presented in Figure 4.2 that 
the factors that are most important in evaluating the success of the HBV vaccination 
programme in prisons are the total IDU population size, the average time that an IDU 
spends in prison during each prison visit, the increasing reception rate into prison 
over time, and the rate that IDUs are vaccinated in the community. These are the 
factors that contribute towards the greatest variation in results obtained from the 
model. 
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Figure 4.2 - Re ult of the sensitivity analysis for the prison model. 
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4.4.2 Re ul - Vaccination cenarios 
The a cinati n enarios, Baseline (50% by 2006), Up to 33% by 2006, Up to 66% 
by 20 and N xpansion, all represent the potential future of the HBV vaccination 
p gramme in pri n . It can be een (Table 4.4) that greater vaccination coverage on 
pri n recepti n re ul in an increa e in the total proportion oflDUs vaccinated (2+ 
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2012 
= 
doses), an increase in the vaccination status of the prison population (2+ doses), and 
an increase in the number of IDUs appearing on prison reception that receive at least 
one dose of vaccine for the first time. However an increase in vaccination coverage 
on reception also requires a greater number of vaccine doses to administer the 
vaccination scenario. Figure 4.3 shows the vaccination status of the IDU population 
with variations in age when the baseline and 'up to 66% by 2006' scenarios have 
been applied. 
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Table 4.4 - Summary of results obtained from model with variations in the vaccination scenario applied. 
Vacdnation Scenario Total Proportion of male Total Proportion of male Total Doses TotallDUs vacdnated 
prison population vaccinated IDU population Vaccinated Administered for tbe J" time (*) 
By 1007 By 2011 By 1007 By 2011 By lOll By lOll 
Baseline 53.5% 66.1% 52.4% 57.2% 680,049 79,743 
No Expansion 26.0010 30.0010 42.2% 43.1% 204,403 26,008 
Up to 33% coverage by 2006 42.8% 53.9010 48.4% 52.1% 507,150 61,281 
Up to 66% coverage by 2006 63.0010 75.6% 56.0010 61.3% 759,140 86,618 
Targeting Young Offenders 33.8% 44.6% 44.6% 48.3% 298,713 24,714 
Baseline + Campaign 58.8% 67.7% 53.8% 57.4% 778,096 83,000 
Regular Campaign 100010 38.6% 45.6% 43.3% 425,086 17,184 
Up to 100010 + Campaign 99.0010 100.0010 69.4% 72.6% 1,231,559 120,392 
(*) The number of [DUs who are completely unvaccinated on prison reception and subsequently receive at least one dose of vaccine in prison. 
Vaccinated is assumed to be those persons receiving 2+ doses of vaccine 
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Figure 4.3 - The % of the IDU population that have received 2+ doses of vaccine by 
age. 
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Assuming pe simistically that the coverage on reception does not increase from 2004 
onwards, it is estimated that approximately 43% of the total IDU population will be 
vaccinated against HBV by 2012. This is only an additional 5% of the current IDU 
population being vaccinated by the prison vaccination programme, with the majority 
being captured by vaccination within the community. If the vaccination coverage can 
be increased to 66% by 2006 then this would result in an estimated 61 % of the total 
IOU population being vaccinated by 2012. An additional 23% of the current IOU 
population being vaccinated in prison compared to a scenario where coverage on 
reception does not increase from 2004 onwards. 
If from 2004 only young offenders are eligible for vaccine, and by 2006 100% of 
them are vaccinated on prison reception, then by 2012 approximately 48% of the 
10 p pulation are estimated to be vaccinated (2+ doses) and only approximately 
24,700 IOU would receive vaccine in prison for the first time during this period 
(Table 4.4). When compared to the baseline it can be seen that even if 100% of 
y ung tTenders are receiving vaccination on prison reception (as is the case here), 
thi i till Ie efTective than expanding the vaccination coverage including all 
indi idual (independently of age) on prison reception up to 50% by 2006. 
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While administering the Baseline vaccination scenario it can be seen (Table 4.4) that 
the introduction of an additional one-off vaccination campaign in 2004 has little 
long-term effect on the vaccinated IDU population. By 2012 only an additional 0.2% 
of IDUs would be vaccinated when compared to the Baseline scenario, this being due 
to the high-turnover rate of IDUs. The implementation of regular vaccination 
campaigns targeting the whole prison population (in this case every three years) 
results in a fluctuation in the proportion of IDUs and prison populations vaccinated 
with high values after the vaccination campaign followed by a steady decrease as 
vaccinated individuals leave the populations. This explains the estimated 43.3% of 
the IOU population and 38.6% of the prison population being captured by 
vaccination by 2012, a decrease from 45.6% and 100% respectively in 2007. 
Increasing the vaccination coverage of prisoners on reception into prisons up to 
100% by 2006, while at the same time administering a prison vaccination campaign 
at the end of 2004 results in 72.6% of the IDU population being vaccinated by 2012. 
An additional effect of this vaccination scenario is the 100% vaccinated status of the 
prison population. Having 100% vaccination coverage on prison reception will result 
in the prison population becoming completely vaccinated over time, the inclusion of 
the vaccination campaign results in this happening much sooner. 
96 
4.5 Discussion 
This chapter considers results obtained from a model of the flow of IDUs and non-
IOUs through prisons applied the HBV vaccination programme in prisons in England 
and Wales. Sensitivity analysis of key parameters is also undertaken. Over a range of 
vaccination scenarios the model informs as to the effectiveness of various levels of 
vaccination coverage on prison reception. The model describes what proportion of 
the IOU population will be vaccinated over time. 
Sensitivity analysis investigated the key parameters of the model of the flow of IDUs 
through prison that have the greatest impact on model results. The discharge rate of 
IOUs was found to be an important parameter that can have a significant impact on 
the estimated proportion of the IOU population captured by vaccine in prisons. A 
shorter discharge rate leads to IOUs spending less time in prisons, this means that 
IOUs will be released quicker and this increases the likelihood of re-imprisonment 
and then being re-exposed to vaccination on prison reception. The estimated size of 
the IOU population in England and Wales also has an impact on model results. If it is 
assumed that the data describing the % of the prison population that is a current IOU 
is correct and held constant, then a larger IOU population will result in a smaller 
proportion of IOUs going to prison and this leads to a reduction in the % of the IOU 
population that is vaccinated. 
A greater community vaccination rate results in more IOUs presenting themselves on 
prison reception having already being vaccinated. The community vaccination rate 
was calculated from UAPMP data of the vaccination status of current IOUs obtained 
in 200 I and then for clarity of exposition the base-case scenario assumed that the 
community vaccination rate was constant over time from 200 I onwards. One of the 
problems of drawing more up to date conclusions regarding the rate that IOUs are 
vaccinated in the community is that more recent surveys include IOUs that have been 
vaccinated in prisons. As the location of vaccination is not surveyed it is difficult to 
tease out what the current rate of community vaccination is. However if future 
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surveys give infonnation on the location of vaccination then the community 
vaccination rate applied here can be updated to reflect this new infonnation. 
The effectiveness of the vaccination scenario targeting only young offenders did not 
compare well with the vaccination scenarios advocating increased vaccination 
coverage of all prisoners on reception. This can be explained when considering the 
assumptions made during the model construction. It has been assumed due to the 
lack of data that persons start and stop using drugs at the same rates irrespective of 
prison status. Therefore persons that are currently imprisoned or have previously 
been imprisoned are assumed to start injecting at the same age-specific rate as those 
that are not. However in reality targeting young offenders for vaccination on 
reception into prison may lead to a greater proportion of IDUs vaccinated in the long 
tenn than has been presented here. This is because offenders, particularly young 
adults, are more likely to tum to drug use if they are currently in prison (Boys el al., 
2002) or have previously been to prison. 
The results here suggest that the effect of administering a vaccination campaign 
either as a 'one-oW or regularly in which all prisoners currently in prison are 
vaccinated over a short period of time has few long-tenn benefits, and the focus for 
vaccination should be towards capturing prisoners on reception into prison. This is 
because the majority of IOUs pass through prison quickly (short sentence lengths) 
and so at the time of the vaccination campaign, relatively few IOUs will be 
vaccinated. 
Monitoring the HBV vaccination coverage of IOUs in the community will infonn as 
to the impact of the prison vaccination programme. This can be compared to the 
results from the model to see whether the predicted vaccinated status of the IDU 
popUlation is comparable to actual data. 
This chapter has shown that the prison vaccination programme is an effective way of 
improving the HBV vaccination coverage of the IOU population. Increased 
vaccination coverage on prison reception is preferable to a vaccination campaign in 
which all prisoners are vaccinated as a 'one-off, as more IOUs with shorter sentence 
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lengths will be captured by vaccination. Applying FO! estimates that will be 
estimated in Chapter 5, the impact of prison vaccination on the transmission of HBV 
within the IDU population will be considered in Chapter 6. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A. J., Gay, N. J., Edmunds, W. l, Andrews, N. J., Hope, V. D., Gilbert, R. 
L., Piper, M., & Gill, O. N. (2006). Modelling the hepatitis B vaccination programme 
in prisons. Epidemiollnfect. 134, 231-242. 
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CHAPTER 5 - MODELLING THE FORCE OF INFECTION FOR 
HEPATITIS B AND HEPATITIS C IN INJECTING DRUG USERS IN 
ENGLAND AND WALES 
5.1 Aims and introduction 
• To estimate the FOI for HBV and HCV in IDUs in England and Wales and 
how this may vary over time and with injecting career length. 
• To investigate the presence of heterogeneity of risk behaviour within the IOU 
population 
A key measure of transmission within a given population is the FO!. This is defined 
as the instantaneous per capita rate at which susceptibles acquire infection and 
reflects the degree of contact with potential for transmission of infection between 
susceptibles and infecteds in the population (Farrington, 1990). 
The aim of this chapter is to estimate FOI for HBV and HCV in the IDU population 
in England and Wales and how this may have evolved, both over time and as IDUs' 
injecting careers progress. Analysis that includes only a single infection can estimate 
the mean FOI but not the variance. Therefore a model is proposed here that considers 
HBV and HCV simultaneously and fits to observed data on the prevalence of these 
infections from a survey of IDUs with markers of single and multiple infections. The 
effects of individual heterogeneity within the IDU population are investigated, while 
the proposed model also considers the transmission of HBV infection in IDUs from 
non-IDUs. Knowledge of the risk of infection allows opportunities to apply this to 
models that describe the transmission of infection within a population. This can be 
taken forward to estimate the impact of alternative interventions on the transmission 
of infection. In this case the results obtained in this chapter will contribute to models 
that consider the transmission of HBV and Hev in the IOU population and 
interventions that target these infections in a prison setting (Chapter 6 and Chapter 
7). 
tOO 
S.2 Methods 
5.2.1 Data 
Taking data on the IDU population of England and Wales from the UAPMP surveys 
as described in (section 1.2). The fields used in this analysis were: Year Surveyed, 
age at first injection, age when surveyed, injected in the last 4 weeks, ever vaccinated 
against HBY, and the number of doses of HBY vaccine received. Oral fluid samples 
were tested for antibody to HBY (anti-HBc) and from 1998 Hey (anti-He V) was 
also included. The sensitivity and specificity of the test for anti-HBc was 75% and 
100% respectively, and 83% and 100% respectively for anti-Hey (Judd et al., 2003). 
Throughout the thesis a current IDU is defined as having injected in the previous 4 
weeks prior to being surveyed, we continue to adopt this defmition here. Samples 
from 1990 to 1997 were not tested for Hey and so were excluded leaving six 
complete consecutive surveys 1998-2003 containing 12,826 records of current IDUs. 
Only IDUs with an unequivocal result for both tests were included in this analysis 
(leaving 12,814 records). The data were further constrained by limiting the current 
age range at the time of the survey to between 16-49 years, and the age of first 
injection to be from 13-45 years (12,031 records). As the FOI considers the rate that 
susceptibles acquire infection only those persons that were unvaccinated against 
HBY were considered in this analysis. (Unvaccinated IDUs were defined as those 
that answer no to the question of having been vaccinated against HBY and report 
having received no doses of HBY vaccine) (6,269 records). The percentage of the 
population with anti-HBc, anti-Hey, and dual infection with variation in injecting 
career length and over time is shown in Figure 5.1. The injecting career length for 
each IDU was calculated from this data by considering the difference between the 
current age and the age of first injecting. Due to paucity of data, those IDUs with an 
injecting career length of 20 years or more were omitted from this analysis, leaving 
5,682 reports from IDUs to be considered here. The impact of changing this cut-off 
was considered during sensitivity analysis. 
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Figure 5.1 - The surveyed IDU population by infection status over injecting career 
length and time. 
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The FO] (A.(t,t)) may vary with time (t) and injecting career length ( .. ). The 
prevalence P(t,t) quantifies the expected proportion of individuals with injecting 
career length T who were antibody positive at time t (Hennekens & Buring, 1987). 
Prevalence in year t for those who have injected for t years is: 
P(T,t) = J-e - A(T,/) 5.1 
where A(r, t) is the cumulative FO! in year t for those who have injected for t years 
and is given by: 
r 
A(r,/) = J..t(T' t -(r-r'))dr' 5.2 
o 
thi may be expre ed relative to a baseline year T 
r 
(T,/) = (ro,T)+ J.~(r',t -(r-r')dr' 5.3 
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Where To = max(O, T - (I - T» is the career length at time T. 
The cumulative FOI for each reported injecting career length is calculated by 
averaging over the range of possible career lengths. As previously discussed the 
reported injecting career length is calculated by considering the difference between an 
IOU's age at first injection and current age when surveyed. 
Therefore an IOU with a reported injecting career length = A years, may have been 
injecting from (A-I) years + I day to (A+ I) years - I day. 
For those IOUs that have been injecting from (A-I) years + 1 day to A years. 
The average cumulative FOI = Ao +.1. where Ao = cumulative FOI up to A-I years 
2 
and A, is the FOI from A-I to A years. 
For those IOUs that have been injecting from A years + 1 day to A+l years - 1 day the 
average cumulative FOI = Ao + A, + ~ where ~ is the FOI from A to A-I years. 
2 
Therefore the average cumulative FOI experienced by IOUs reporting an injecting career 
length of A is 
31 ,t, A +_"1_+_-
o 4 4 
5.2.3 Model 
5.4 
The status of each IOU is considered with respect to both infections. To introduce 
individual heterogeneity of at-risk behaviour into the model we introduce a frailty Z 
which represents an individual's relative rate of infection. An individual of frailty Z 
and career length 't at time t has the risk l_e-u,.(r.l) of previous HBV infection and 
1- e-lAc<fJ) of previous HeV infection. The frailty distribution is assumed gamma 
with shape 6 and scale parameter = 1. 
For infection acquired through injecting drug use only, let 1l'oo(T,I) , 1l'BO(T,t) 
,!rac(r,l) and !rBc(r,l) denote the proportion of IDUs in year t with an injecting 
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career length of t that are uninfected, infected by HBV not HCV, infected by HCV 
not HBV, and both HBV and HCV respectively. 
Beginning with the following equations proposed by (Farrington el al., 2001). 
5.5 
YcCr,/) 
{ }
-(J 
1fBO (r,t) = 1+ e - 1foo(r,t) 5.6 
YB(r,t) 
{ }
-(J 
1foc(r,t) = 1+ e -1foo (r,t) 5.7 
5.8 
The variables YB and Y c should not be interpreted as the cumulative FO! for HBV 
and HCV respectively because the total prevalence of each infection depends on e. 
We re-parameterize these equations so that the total prevalence of each infection is 
independent of e as shown below. 
We define 
and 
he = BLn{ 1 + ~ } 
These are then substituted into Farrington's equations above giving: 
A,lr,l) Adr,l) 
1f
oo
(r,t) = (e-tJ - + e-(J- _I)-II 
1f
BO
(T,t) = e-Aclr,l) -1foo (r,t) 
1foc(T,t) = e-A,(r,l) - 1foo(T,t) 
5.9 
5.10 
5.11 
5.12 
5.13 
104 
where: 
Total prevalence of HBV = 1r BO + 1r BC = 1-e-AB 
Total prevalence of Hev = 1r co + 1r BC = 1- e -Ae 
And therefore: 
5.14 
5.15 
5.16 
AB(r,/) and Ac(r,/) are the cumulative FOI for HBV and Hev respectively in year 
t for injecting career length 'to 
5.2.4 HBV Background Prevalence and Test Sensitivity 
Background HBV prevalence is included in the model and reflects the possibility of 
transmission of HBV from outside the IDU population. As 95% of reports with 
exposure data to HeV indicate injecting drug use (Health Protection Agency et al., 
2005), it has been assumed here that there was no non-injecting related transmission 
of HeV. To incorporate HBV background prevalence and the sensitivity of the HBV 
and Hev tests into this model the equations describing the prevalence of the two 
viruses 1r.ry(r,/) have been modified to both reflect the possibility that HBV 
infection can occur for reasons other than injecting and that the tests for HBV and 
HeV have a sensitivity and specificity that is less than 100%. It is assumed in this 
model that the risk of background HBV infection is constant through time and 
injecting career length. 
and 
v 00 = Poo + (l-sB )PBO + (1- Sc )Poc + (1- s B )(1- sc)PBC 
VBO = PBOSB +SB(1-SC)PBC 
5.17 
5.18 
5.19 
5.20 
lOS 
where 
b = background prevalence of infection of HBV. 
S8 = sensitivity of the HBV test 
Sc = sensitivity of the HCV test 
5.21 
5.22 
P"y = proportion of IDUs in year t with an injecting career length of't with status xy 
allowing for the background prevalence of infection of HBV . 
V"y = proportion of IDUs in year t with an injecting career length of't who have test 
status xy (allowing for the sensitivity of the HBV and HCV tests) 
5.2.5 Parameterisation 
The cumulative FOI in 1998 (the first year of data considered here for each virus) by 
injecting career length, A(1998, r) is described by the functionf(r). This is described 
by a four parameter logistic function. 
(u -z) fe r) - z + ----:~---=,-­
- 1+ (e(r.,.,>)" 5.23 
The cumulative FOI in 1998 describes all infection in previous years and is estimated 
with the FOI for the more recent years (1999-2003). No attempt has been made to 
reduce the parameters describing this function with the priority being to ensure 
sufficient flexibility and a good fit to the data. 
The FOI from 1999 onwards is modelled as the product of a function describing its 
trend over time get) and a function describing its trend with injecting career length 
her) (Ades & Nokes, 1993): 
A(t, r) = g(t)h(r) 5.24 
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To standardize results for each virus, h(O) is fixed equal to 1. Both g(t) and h(r) are 
parameterized on piecewise constant functions 
The initial model used at the start of the analysis is defined as describing function 
/(r) for each virus with a four parameter logistic function (8 parameters), and 
functions g(l) and h( r) for each virus are described by an individual value for each 
year 1999-2003 (10 parameters) and injecting career length 1-19 years respectively 
(38 parameters). Along with the parameters frailty 0 and HBV background 
prevalence h. this leads to the initial model being described by 58 parameters. 
It is assumed that IOUs who report an injecting career length of 0 years have been 
injecting for an average of 6 months (section 5.2.2). IOUs who appear in the UAPMP 
surveys such as those considered here, are recruited from those in contact with 
services. The probability of being in contact with services increases with injecting 
career length (Chapter 2) and therefore the average career length of surveyed new 
initiates may be higher than the 6 months assumed. Because the estimated FOI in 
new initiates will be correlated with the duration of exposure (injecting career length) 
we investigate the sensitivity of our estimates to the career length assumed. As an 
extreme case, it is assumed that IDUs with a reported injecting career length of 0 
years have been injecting for 12 months, while applying the injecting career length of 
the remaining (DUs at reported levels. 
5.2.6 Model Fitting 
If nr,(r,tJ denotes the number of individuals in year t with injecting career length t 
with test results coded xy as above, the log-likelihood (L) is the product multinomial. 
I 
L = LL Ln~(r./)log{V~.(r,t)} 5.25 
f I .... ~o 
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Beginning with an initial model and then maintaining the four parameter logistic 
function for j(r). backwards-stepwise elimination was used to reduce the number of 
parameters describing g(l) and h(r). Models were compared using the analysis of 
deviance with the Chi-squared test, the criteria for dropping parameters being that p 
> 0.05. When the parsimonious model (the best fitting model with the fewest 
parameters) had been identified. Cis were calculated using profile likelihood. For 
both functions g(t) and h(r) a range of alternative reduced models were considered 
including alternative values for the fixed category of h(O) e.g. 0 years 0-1 years, 0-2 
years etc. A selection of the reduced models examined during the backwards-
stepwise elimination process is described in the following (only changes from the 
initial model arc noted): 
I. Initial model 
2 h( r) for each virus is grouped into 4 injecting career length groups (1-2 yrs, 3-
4yrs. 5-9yrs. 10+yrs. Oyrs is fixed) 
3 As model 2 above. except h( r) is the same for each virus. 
4 As model 3 above. except h( r) is described by 1 injecting career length group 
( I + years. Oyrs is fixed) 
S As model 4 above. except g(t) for each virus is a single parameter (1999-
2(03). 
6 As model 5 above. except function h(r) =1. 
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~.3 Rnulh 
The calculated model parameters for the parsimonious model are shown in Table 5.2 
with 95% Cis. The results from the model suggest that HBV background prevalence 
is low (=0.00. 95% CI: 0-0.0161). 
Table 5.1 shows a summary of the results of the fitting procedure. The initial model 
gave a good fit to the data and successive reducing in the number of parameters in 
models 2-5 did not significantly worsen the fit. Model 6 considered the impact of 
removing the function h( r), however this provided a significantly less good fit than 
Model 5 (p<0.00 I). Model 5, therefore, was taken to be the parsimonious model. 
Table 5.1 - Goodness of fit for initial and reduced models 
Model d.f·ln .... '1l Deviance e value 
I (Initial Model) 413 392.2 
2 443 413.6 0.87 
) 447 415.6 0.73 
4 450 417.9 0.52 
S 458 428.8 0.21 
6 459 469.6 <0.0001 
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Table 5.2 - Parameter values describing the parsimonious model 
P .... meter HBV 95·/. CI HCV 9S·/. CI Global 9Se;. CI 
g(t) trend in the FOI by year 1999-2003 0.1079 (0.0840-0.1327) 0.1608 (0.1314-0.1942) 
h(t) trend in the FOI by injecting career length 
<I Fixed Same as HBV 
I .... 0.3272 (0.2359-0.4443) Same as HBV 
HBV background prevalence 0 (0.0-0.0161 ) 
Frailty 9 0.6566 (0.5305-0.8224) 
u -0.132 -2.524 
v 0.117 0.026 
w 63.99 77.52 
z 295.5 19.49 
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Figure 5.2 shows the estimated FO! by injecting career length for HBV and HeV, 
while the model fit to data for each survey is shown in Figure 5.3. Across similar 
injecting career lengths the FOI was found to be higher for Hev than HBV. For both 
HBV and HeV the FO! is higher for new initiates to injecting (injecting career 
length <1 year) (Figure 5.2) compared to experienced IDUs. 
Figure 5.2 - The FO} for HBV and HeV with variation in injecting career length for 
1999-2003. 
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Figure 5.3 - Model fit to data for each survey] 998-2003 
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The model fit to data for HCY and HBY in 1998 is shown in Figure 5.4. The close fit 
of the model to the data provides additional confidence in the selection of the four 
parameter logistic function to describe functionf(T}. 
Figure 5.4 - The model to data fit for 1998 survey data describing the prevalence of 
HBY and HCY infection. 
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The estimated frailty distribution for the IOU population is shown in Figure 5.5. It 
can be seen that there is strong evidence of individual heterogeneity, with the 
majority of IDUs (64%) having a FOI less than the average (relative risk (RR)<l), 
and a small proportion (15%) having a FOI much higher than average (RR >2). 
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Figure 5.5 - The estimated frailty distribution and a cumulative density function 
describing the frailty for HBV and HCV. 
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To investigate the impact of excluding those IDUs with an injecting career length of 
20 years or greater, a further reduction was made with IDUs with an injecting career 
length of greater than 10 years being excluded from the analysis. However model 
results were found to be similar (Table 5.3) thereby suggesting no good reason to 
further reduce the number oflDUs included in this analysis. 
Table 5.3 - FOI estimates for HBV and HCV with variations in injecting career 
length. 
Injecting career <1 years 1+ Years 
length 
HBV 0-10 years 0.1079 (95% CI: 0.0805-0.1347) 0.0349 (0.0185-0.0586) 
<20 years 0.1079 (0.0840-0.1327) 0.0353 (0.0198-0.0590) 
HCV 0-10 years 0.1644 (0.1339-0.1989) 0.0531 (0.0307-0.0865) 
<20 years 0.1608 (0.1314-0.1942) 0.0526 (0.0310-0.0863) 
When IDUs with an injecting career length of greater than 10 years are excluded from the 
analysis compared to the baseline that includes IDUs with an injecting career length less 
than 20 years. 
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The importance of considering the test sensitivity for HBV and Hev in the model 
was shown when these are excluded from the model. The resultant FOI estimates for 
both HBV and HeV were found to be lower than when test sensitivity is included in 
the model (Table 5.4). 
Table 5.4 - The impact of the exclusion of the test sensitivities on the FOI estimates 
for HBV and HeV. 
Test Sensitivity <1 years 1+ Years 
HBV Excluded 0.0807 (95% CI: 0.0640-0.0992) 0.0253 (0.0147-0.0383) 
Included 0.1079 (0.0840-0.1327) 0.0353 (0.0198-0.0590) 
HCV Excluded 0.1313 (0.1082-0.1582) 0.0411 (0.0247-0.0611) 
Included 0.1608 (0.1314-0.1942) 0.0526 (0.0310-0.0863) 
It has been assumed that all new initiates to injecting (injecting career length=Oyrs) 
have been injecting for an average six months. However if instead it is assumed that 
all IDUs in the surveys have been injecting for at least 1 year, then this lessens (but 
does not remove) some of the injecting career length effect on the FOI 
(h(l+)=0.5704, 95% CI: 0.4471-0.7801) although as before the strong evidence of 
individual heterogeneity remains (9 = 0.6547, 95% CI: 0.5301-0.8208). 
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S.4 Discussion 
UAPMP data collected from IOUs in England and Wales (section 1.2) was analysed 
to estimate the trend in the FOI for HBV and HeV in IDUs over time and career 
length. By considering both viruses together we assessed the heterogeneity of risk 
within the IOU population and the effect of background HBV transmission due to 
transmission between IOUs and non-IOUs. 
As has been discussed in section 1.1 IOUs recruited into surveys such as the UAPMP 
surveys considered here may not be representative of the whole IOU population. For 
example if there is a greater difference in Hev prevalence among new initiates 
contacting and not contacting services than among experienced IOUs, then this will 
influence the estimated difference in FOI between new and experienced IDUs 
compared to the actual FOI in the overall IOU population. It has been assumed that 
the risk behaviour in the surveyed IOU population considered here is the same as the 
IOU population in England and Wales and additionally it is assumed there is the 
same likelihood of a positive or negative IOU being surveyed as there would be in 
the IOU population in England and Wales. These assumptions are typically difficult 
to corroborate as it is hard to imagine future surveys of IDUs that are not biased 
towards more experienced IOUs, as new initiates will always be more difficult to 
recruit into surveys of current IOUs (section 1.2). 
The model suggests that the FOI of HBV and Hev is up to four times higher among 
new initiates (injecting career length <1 year) than for IOUs with longer injecting 
careers, a finding which is supported by previous studies (Kretzschmar & Wiessing, 
2004; Rothenberg et al., 1998). In all cases it was found that there is increased risk of 
infection in new initiates compared to experienced IOUs. The scale of these findings 
must be approached with caution as they are sensitive and dependent on information 
about and from a small sub-group of IOUs (those with injecting career lengths of less 
than I year). It has been assumed that IOUs reporting an injecting career length of 0 
years (i.e. start age = current age), have an even chance of their exact injecting career 
length being anything from 0 days to I year. However this does not allow for the 
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delay from the initiation of injecting until coming into contact with services. If it is 
assumed instead that all current IOUs (including new initiates) in the surveys have 
been injecting for at least one year, the injecting career length effects are lessened 
with new initiates only having FOl estimates for HBV and Hev up to twice as high 
as experienced IOUs. 
The model indicates considerable heterogeneity in the FOI among the sample 
suggesting some (OUs are at significantly greater risk from infection from BBVs 
within the larger IOU population. Analysis that considers only a single infection 
cannot address the issue of individual heterogeneity, or its effect on other estimates. 
In such analysis the presence of high risk individuals within the IOU population 
would cause an apparently higher FOI in IOUs with short injecting career lengths. 
However such a career length effect is found here after allowing for individual 
heterogeneity. These results demonstrate the added value of this combined analysis. 
From this data alone it is impossible to draw any conclusions about the reasons for 
this individual heterogeneity, although it could be due to certain groups within the 
overall IOU population stratified by ethnicity, socioeconomic status, sex, or other 
demographic variables. 
It is acknowledged that the prevalence of each virus within the IOU population may 
be due to infection from outside the IOU population particularly for HBV. However 
the low prevalence of background HBV infection suggests that the infection in the 
IOU population is primarily due to contact between IDUs (needle sharing or sexual 
contact). 
One of the key assumptions in the proposed model is how long a new initiate to 
injecting (injecting career length =0 years) has actually been injecting. It has been 
assumed at baseline that a new initiate has been injecting for six months which is half 
way between the possible injecting career lengths (Odays - 364days) of an IDU that 
reports an injecting career length of 0 years. The impact of varying this assumption is 
that the assumed time that a new initiate is at risk from injecting related infection will 
either be increased or decreased. This has a significant impact on model results, with 
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variation in the trend in the FOI over injecting career length being dependent on this 
assumption. 
During this analysis we excluded those IDUs that reported being vaccinated against 
HBV. This was done as their inclusion would result in an underestimation in the FOI 
estimates obtained for HBV. When individuals are diagnosed with HCV infection, 
due to complications associated with dual infection they should be vaccinated against 
HBV (Salisbury & Begg, 1996). A consequence of this is that some individuals that 
are HCV positive and vaccinated against HBV were excluded from this analysis. As 
the prevalence of HCV is higher in those IDUs that are excluded from this analysis 
(vaccinated against HBV) compared to those included (RR=1.15, 95% CI: 1.09-1.21 
adjusting for injecting career length), the results here may underestimate the FOI in 
IOUs for HCV. To overcome this and to allow a greater number of IDUs to be 
included in the analysis, future models should incorporate an HBV vaccination rate 
that varies based on IDUs' HCV status, this wil11ead to a greater number of IDUs 
being included in this analysis (vaccinated and unvaccinated) and may help to 
remove any bias in the FOI estimates obtained here. An additional advantage of this 
is that an increase in the number of HCV positive individuals included in this 
analysis may also increase power to detect any changes in the FOI over time. 
The estimation of the FOI from serial prevalence data provides added 
epidemiological value. Previous authors have studied the incidence of infection in a 
cohort of IOUs (Judd et al., 2005) although to the authors' knowledge no previous 
studies have used this method of modelling to estimate the FOI for HBV and HCV in 
the IOU population. The models highlight the need to increase interventions that 
target new initiates to injecting to reduce the transmission of BBVs. Although from 
the evidence here, identification of those individuals that engage in heightened at-
risk behaviour should be undertaken. The data and methods described here may 
provide a baseline for monitoring the success of public health interventions. 
This chapter concludes work examining the rate that susceptible IDUs acquire 
infection from HBV and HCV. This work is taken forward and used to parameterise 
a model describing the transmission of HBV within the IOU popUlation and the cost-
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effectiveness of HCV case-finding on prison reception. This will be the focus of 
Chapter 6 and Chapter 7 respectively. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A. J., Gay, N. J., Edmunds, W. 1., Hope, V. D., Gill, O. N., & Hickman, M. 
(2006). Modelling the force of infection for hepatitis B and hepatitis C in injecting 
drug users in England and Wales. BMC Infect.Dis. 6,93. 
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CHAPTER 6 - MODELLING THE IMPACT OF THE HEPATITIS B PRISON 
V ACCINATION PROGRAMME ON HEPATIITIS B TRANSMISSION 
WITHIN THE INJECTING DRUG USER POPULATION OF ENGLAND 
AND WALES 
6.1 Aims and introduction 
• To parameterise a model describing the transmission of HBV within the IDU 
population of England and Wales. 
• To investigate the impact of HBV vaccination on reception into prisons in 
England and Wales on the incidence and prevalence of HBV within the IDU 
population of England and Wales. 
• To conduct sensitivity analysis of key parameters within the proposed 
transmission model. 
Chapter 3 describes a model of the flow ofIOUs and non-IOUs as they pass through 
prisons in England and Wales. In Chapter 4 this model is applied to show the 
potential coverage of the HBV vaccination programme in prisons in England and 
Wales. This work demonstrated that over a range of vaccination scenarios, 57% of 
the IOU population might be vaccinated by 2012 if coverage of 50% or more on 
prison reception could be achieved across all prisons in England and Wales. 
However this model does not show the impact that this vaccination programme may 
have on the transmission ofHBV within the IOU population in England and Wales. 
The model proposed here describes the dynamics of HBV transmission in the IOU 
population of England and Wales. The work here takes estimates of the proportion of 
the IOU population vaccinated from the model of the HBV vaccination programme 
in prisons (Chapter 4) under a range of vaccination scenarios and considers the effect 
of this programme on the incidence and prevalence of HBV in the IOU population in 
England and Wales. Sensitivity analysis of the key model assumptions and 
parameters is undertaken. 
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6.2 Methods 
The model presented here considers the transmission of HBY due to contact between 
IDUs. This represents the sharing of injecting paraphernalia and other at-risk 
practices that may lead to the transmission of BBYs; this may also include the 
potential for transmission via sexual contact between IDUs. 
6.2.1 Model Structure 
Only the IDU population of England and Wales is considered with non-IDUs being 
excluded from this analysis, and it is assumed that the IDU population is of fixed size 
and equal to 160,000 (Frischer et al., 2001) (section 1.1.1). The results from the 
model of the HBY vaccination programme in prisons in England and Wales have 
been used here (Chapter 4), and as this model considers only males, it has been 
assumed here that female IDUs have the same offending characteristics as males. 
Using a mathematical model of HBV natural history and transmission dynamics 
(Medley et al., 2001; Edmunds et al., 1 996a; Williams et al., 1996), the IDU 
population is stratified into six epidemiological groups: those who are susceptible to 
infection, denoted S; those who have been infected but are not yet infectious, L; 
acute infections, A, who are in the initial highly infectious stage of infection; those 
who are carriers, C; vaccinated, V, those that have been vaccinated and are immune 
from infection; and those with protective immunity, R, due to recovery from either 
carrier or acute stages of infection. As the model includes an injecting career length 
dependent FOI the IDU population is stratified by injecting career length. 
IDUs enter the model at the start of the year into the first injecting career length 
cohort. Thereafter individuals change cohorts at the beginning of each year. The 
rates, with respect to both injecting career length and time, at which individuals flow 
from one epidemiological state to another, are described by a system of differential 
equations. 
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The differential equations for the deterministic model are as follows: 
dSo 
- = a - PoSo - ,1.0 (t)SO - VO(t)SO 
dt 
dSj = -pjSj -A.j(/)Sj -vj(/)Sj where i = 1,2,3 etc. 
dt 
d£. 
-' = A.-(t)S - II.£. - oL-dt ' ,r" , 
dA· 
-' =oL- -II·A· -rIA. dt ,r" , 
dV. 
-' = v.(t)S. - II.V. dl ' ,r" 
6.1 
6.2 
6.3 
6.4 
6.5 
6.6 
6.7 
where i represents the injecting career length class, a represents the rate at which the 
latently infected become infectious, and YI and Y2 are the recovery rates of acute 
infections and carriers, respectively. (Note that 1/a, 1/YI and 1/Y2 are, respectively, 
the average duration of the latent, acute and carrier states.) The number of new IDUs 
that start injecting each year is represented by a. The probability that an individual 
fails to clear an acute infection and develops the carrier state is represented by p. 
The rate at which individuals with injecting career length i leave the IDU population 
is denoted pj (dependent of injecting career length and time). The vaccination rate is 
denoted as v;{I}. The FOI A.;{I). also depends on injecting career length and time. The 
FOI acting on susceptibles with an injecting career length of i at time t is assumed to 
be 
A.j(t) = fPij[A(/)j +£5L'(t)j] 
j=O 
6.8 
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where f3;j describes the transmission coefficient between susceptibles of injecting 
career length i and infectious individuals (both carriers and acute infections) of 
injecting career length j, and <5 represents the relative infectiousness of carriers 
compared with acute infections (Edmunds et al., 1996a) and p is the number of 
injecting career length classes. The initial conditions X(), L(), A(), C(), ~(), 
and V() are the numbers of IOUs of injecting career length i, in each state at time=O 
and are taken to be the equilibrium number of susceptibles, latents, acutes, carriers, 
immunes, and vaccinated prior to the introduction of prison vaccination (but with 
community vaccination). This was found by setting the time derivatives to zero and 
solving the resulting set of simultaneous equations to yield the equilibrium numbers 
of susceptibles, latents and so 00. 
6.2.2 Parameterisation 
6.2.2. J IDU Population Data 
It has been assumed that an IOU has an average injecting career length of 5.97 years. 
This estimate is taken from Chapter 2 coupled with the fixed IOU population size of 
160,000 this leads to a=26,80 I IOUs starting injecting each year. The removal rates 
are defined as the rates that IOUs leave the IOU population due to either the 
cessation of injecting or death. Assuming that the age dependent removal rates 
provided in Chapter 2 are a reasonable approximation of the rate at which IOUs 
leave the IOU population, to be compatible with the model presented here, these 
removal rates are converted to be injecting career length dependent. 
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6.2.2.1.1 Removal Rates 
The age-specific removal rates are converted to be injecting career length specific via 
the following method: 
nkj is defined as the total number of IDUs with injecting career length i of age k and 
is equal to 
j=;-I 
nkj = afk-; n (1- (i)k_ j) 6.9 
j=O 
where fi is the proportion of IDUs starting injecting at age k, and OJ" is the age 
dependent stop rate 
The total number of IDUs with an injecting career length i, Ni is 
k=7S 
N; = Lnkj 
k=IS 
and 
6.2.2.2 Theforce of infection and transmission coefficients 
6.10 
6.11 
The FOI estimates presented here are taken from Chapter 5 which considered the 
IOU population as being divided into two groups which have been adopted here; new 
initiates, i.e. those injectors with an injecting career length of less than I year, and 
experienced IDUs, i.e. those injectors with an injecting career length of greater than 
1 year. It was found that the FOI for HBV had not changed from 1999-2003 and so it 
is assumed here that the FOI is constant within both of the discrete injecting career 
length groups prior to the introduction of prison vaccination. 
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As the FOI is different for new initiates to injecting (injecting career length <lyear) 
and experienced IOUs (injecting career length 1+ years), the FOI within each of 
these discrete injecting career length groups is described by the following 2 
equations: 
;=1 ;=ao 
A.I = fill L (A; + cSt';) + fil2 L (A; + cSt';) 
;=0 ;=1 
;=1 j=ao 
A.2 =fi2IL(A j + cSt';) +P22L(A; +cSt'j) 
;=0 ;=1 
where 
AI is the FOI for those IOUs with an injecting career length of <1 years. 
A2 is the FOI for those IOUs with an injecting career length of 1 + years. 
6.12 
6.13 
The transmission coefficients, fJ",n, are the per capita rate of effective contact 
between two IOUs of career length m and n (where an index = 1 represents those 
with an injecting career length of less than 1 year, and 2 those with a career length of 
more than 1 year). They were calculated from the equilibrium values of An the FOI 
for individuals in group n and the number of carriers and acutes in the population at 
steady state assuming proportional mixing. This type of mixing arises when 
individuals make contacts with other people in their own or other groups in 
proportion to the number of contacts that are supplied from each group (Garnett et 
al., 1992). 
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6.2.2.2.1 Proportional Mixing 
For proportional mixing Pij is defined as: 
6.14 
Where d i is the effective contact rate for individuals in group i, and Ni is the number 
of individuals in group i. 
The estimates of the transmission coefficients for the 'Who acquires infection from 
whom' (WAIFM) matrix are shown in Table 6.1: 
Table 6.1 - The structure of the WAIFM matrix (f3ij) with values at baseline. 
j=1 2 
i=1 1.69*10 5.53*10' 
2 5.53*10.5 1.81*10.5 
The injecting career length groups (numbered 1 to 2) refer to <1 years, and 1+ years 
respectively. 
A summary of parameters is given in Table 6.2 along with a reference to the data 
source as appropriate. 
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Table 6.2 - Baseline parameter estimates used in numerical simulations 
Parameter Symbol Value Data Sources 
FOI in new initiates prior to the introduction of prison vaccination AI 0.1079 per year, Chapter 5 
FOI in experienced IDUs prior to the introduction of prison A2 0.0353 per year, Chapter 5 
vaccination 
IDU population size 160,000 Frischer et al., (200 1) 
Rate of lose of latency 0- 6 per year Edmunds et aI., (1996a) 
Recovery rate (acutes) 11 4 per year Edmunds et aI., (1996a) 
Recovery rate (carriers) 12 0.025 per year Edmunds et al., (1996a) 
The proportion of those with acute infection that become a carrier p 0.05 Edmunds et al., (1996a) 
Relative infectiousness of carriers b 0.16 Edmunds et al., (1996a) 
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6.2.3 Sensitivity Analysis 
To test the effect of the model assumptions on the results obtained from the model a 
number of different tests of sensitivity were undertaken, these are listed below: 
1. Alternative values for the FOI in new initiates and experienced IDUs were 
applied. These estimates taken from Chapter 5 are the values of the upper and 
lower 95% CIs of the baseline values, and an estimate of the FOI that is equal 
for both new initiates and experienced IDUs (Upper, Lower, and Equal). 
These are shown in Table 6.3: 
Table 6.3 - FOI estimates (lpersonlyr) used during sensitivity analysis 
FO! 
Upper 
Lower 
Equal 
0.1327 
0.0840 
0.0476 
0.0590 
0.0198 
0.0476 
2. To test the assumption of proportional mixing, the effects of alternative 
values of the transmission coefficients on model results were investigated. 
The first set of values assume that new initiates and experienced IDUs mix at 
the same rate as experienced IDUs mix amongst themselves (Mixing One), 
and the second set of values assumes that there is no mixing between new 
initiates and experienced IDUs (Mixing Two). The mixing matrices for each 
of these mixing assumptions (using the baseline FOI) is summarised in Table 
6.4: 
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Table 6.4 - Values of the transmission coefficients (/yr) used during sensitivity 
analysis for: a) Mixing One and b) Mixing Two. 
a) Mixing one i=1 i=2 b) Mixing Two i=l i=2 
i=l 2.83*10 i=1 2.20*10 
i=2 4.49*10.5 4.49*10.5 i=2 3.02*10'5 
6.2.4 Vaccination Scenarios 
Three vaccination scenarios describing the potential future of the HBV vaccination 
programme in prisons in England and Wales are taken forward from Chapter 4 and 
applied here. Further scenarios are also examined here with a summary of the 
vaccination scenarios implemented provided in Table 6.5. The vaccination rates for 
the vaccination scenarios are calculated from the results obtained from the model of 
the prison vaccination programme (Chapter 4). They are for those IDUs that receive 
2 or more doses of HBV vaccine and incorporate the possibility that an IDU may be 
vaccinated either in the community or in prison. It is assumed that an IDU is 
protected from HBV if they have received 2+ doses of vaccine. The rates for a 
selection of the scenarios stratified by year and injecting career length are shown in 
Table 6.6 and Table 6,7. Experienced IDUs are more likely to have been incarcerated 
in the past than new initiates, and as recidivists are more likely to go to prison than 
first time offenders, this explains the higher vaccination rates for experienced IDUs 
compared to new initiates which can be seen for all scenarios (Table 6.6 and Table 
6.7). As the focus of this study is the impact of prison vaccination, the vaccination 
rate for IDUs in the community is taken at a constant value for all vaccination 
scenarios estimated to be O.106/IDU/year as calculated in Chapter 4. For all 
vaccination scenarios where vaccination is administered on prison reception, at each 
vaccination event 38% receive 1 dose of vaccine, 28% receive 2 doses of vaccine, 
and 34% receive 3 doses of vaccine (Chapter 4). 
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Table 6.5 - Summary of vaccination scenarios 
Vaccination Scenario Description 
England and Wales (Scenarios Taking the vaccination scenarios first described in Chapter 4, vaccination coverage IS 
A, B, and C) administered to prisoners on reception into prison. Coverage is 5% in 2002, 10% in 2003 and then 
a linear increase up to 33% for scenario A, 50% for scenario B (baseline scenario), and 66% for 
scenario C in 2006. Coverage is constant thereafter (Table 6.6). 
Age Specific 
Equilibrium 
Campaign 
Vaccination coverage is administered from 2002 on reception into prison targeting specific age 
groups. The age groups independently targeted are 15-17 years, 18-29 years or 30+ years with 
coverage that is constant over time of 30%, 70% or 100%. 
Vaccination coverage is administered on reception into prison from 2002 onwards at a constant 
rate until equilibrium has been reached. A number of alternative levels of vaccination coverage 
are examined to see which would result in the HBV prevalence (IDUs ever infected) reaching zero 
(Table 6.7). 
90% of prisoners receive 3 doses of vaccine in 2003, and then from this point on vaccination on 
reception into prison is introduced at 80% coverage. This represents a possible scenario where a 
strong commitment to vaccinate all prison inmates is introduced as was the case recently in 
Scotland (Hutchinson et al., 2004). An alternative to this scenario sees 90% of prisoners receive 3 
doses of vaccine in 2003,2006, and 2009 with no further vaccination administered in prison. 
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Table 6.6 - Vaccination rates / IOU / year for scenarios A, B, and C for England and 
Wales applied to new initiates and experienced IOUs. 
New Initiates Experienced IDUs 
Scenario: 
Year A B C A B C 
2002 0.01 0.01 0.01 0.13 0.13 0.13 
2003 0.02 0.02 0.02 0.13 0.13 0.13 
2004 0.04 0.04 0.04 0.13 0.13 0.13 
2005 0.06 0.07 0.09 0.14 0.14 0.14 
2006 0.08 0.11 0.14 0.15 0.15 0.15 
2007 0.11 0.15 0.20 0.16 0.17 0.18 
2008 0.11 0.16 0.21 0.17 0.19 0.22 
2009 0.11 0.16 0.21 0.19 0.21 0.24 
2010 0.12 0.17 0.22 0.19 0.23 0.26 
2011 0.12 0.17 0.22 0.20 0.24 0.28 
2012 0.12 0.17 0.22 0.21 0.24 0.28 
2013 0.12 0.18 0.23 0.21 0.25 0.29 
2014 0.13 0.18 0.23 0.21 0.25 0.29 
2015 0.13 0.18 0.23 0.21 0.25 0.29 
Where each scenario assumes a vaccination coverage of 5% on prison reception in 2002, 
10% in 2003 and then a linear increase o/up to constant 33% in 2006/or Scenario A, 50% 
for Scenario B, and 66%for Scenario C (Chapter 4). 
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Table 6.7 - Vaccination rates / IOU / year for the equilibrium scenarios applied to 
new initiates and experienced IDUs. 
Vaccination coverage on prison reception New Experienced 
Initiates IDUs 
5% 0.03 0.14 
10% 0.05 0.15 
15% 0.07 0.17 
20% 0.09 0.18 
25% 0.11 0.19 
6.3 Results 
The results for each of the vaccination scenarios described in the methods are shown 
below. In all cases HBV prevalence is defined as the proportion of IOUs in the 
overall population that have ever been infected by HBY i.e. have antibodies to HBY 
(anti-HBc), while the acute infections here may be symptomatic or asymptomatic. 
6.3.1 England and Wales Scenarios 
Prior to the introduction of the prison vaccination programme it is estimated that 
despite the presence of community vaccination there were over 350 new initiates and 
over 1000 experienced IOUs acutely infected from HBV in England and Wales in 
2002. The overall HBY prevalence in the IOU population in 2002 was estimated to 
be approximately 15% with the HBV prevalence in new initiates and experienced 
IDUs being 9% and 17% respectively. 
If there had been no community vaccination prior to 2002, then it is estimated that 
the prevalence of HBV in 2002 in the IOU population would be over 18% 
(approximately 9% and 20% in new initiates and experienced IOUs respectively). No 
community vaccination would lead to the annual number of acute infections in new 
initiates and experienced IOUs being estimated at 400 and 900 respectively. The 
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reduction in the number of acute infections in experienced IDUs in the no 
community vaccination scenario compared to the community vaccination scenario 
being due to many more IDUs being infected as new initiates. 
The impact of prison vaccination on the incidence of HBY in new initiates and 
experienced IOUs within the overall IOU population of England and Wales is shown 
in Figure 6.1. The results show that as the vaccination rate increases over time the 
incidence of HBY in both new initiates and experienced IOUs decreases over time. A 
high proportion of the total number of acute infections of HBY in new initiates can 
be seen with over 30% occurring in the new initiates across all years. 
Figure 6.1 - The estimated annual number of acute infections of HBY in the IDU 
population and new initiates. 
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The implementation of the baseline vaccination scenario (scenario B) results in the 
total number of acute cases of HBY being reduced by approximately 35% by 2008 
and then by approximately 75% in 2014. If vaccination coverage can reach 66% of 
all prison receptions by 2006 (scenario C) then the total acute cases within the IOU 
population can be reduced by approximately 45% in 2008 and 85% by 2014. 
However even if the vaccination coverage on prison reception only reaches 33% of 
all prison receptions by 2006 (scenario A) then the total acute cases within the IOU 
population will still be reduced by approximately 30% in 2008 and 60% by 2014. 
The impact of the England and Wales scenarios on HBY prevalence in England and 
Wales in 2015 is shown in Figure 6.2. It can be seen that assuming that the 
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characteristics of the IOU population do not change over this period and there is no 
vaccination either in prison or the community, the HBY prevalence in 2015 will be 
approximately 18%. If vaccination is implemented on reception into prison and 
coupled with community vaccination (scenarios A, B, and C), it is estimated that 
HBY prevalence in the IOU population can be reduced to fewer than 10% by 2015. 
Figure 6.2 - The estimated HBY prevalence in IDUs in 2015 with variations in the 
vaccination scenario implemented. 
20%, 
i 
~ I j 15% I j ! 
~ i ! 10% i 
i ! 
~ 5% I ~J 
No Comn.Inity 
Veccnation Vecclnetton 
Only 
6.3.2 Age Specific Scenarios 
A B c 
Vaccinallon Scenario 
The impact of applying alternative age specific vaccination scenarios on the HBY 
prevalence in the IOU population in 2015 is shown in Table 6.8. It can be seen that a 
targeted vaccination strategy targeting 18-29 years which represents 49% of the 
prison population at 30% coverage has a substantial effect on HBY prevalence 
reducing it by almost 50%. In the case of the 15-17 year olds, it is unsurprising to 
find that targeting this age group was the least effective vaccination strategy given 
that this age group represents only 4% of the prison population. However despite 
approximately 47% of the prison population being represented by over 30 year olds 
(Home Office, 2003), targeting this age group for prison vaccination was still found 
to be largely ineffective. 
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Table 6.8 - The impact of alternative age specific vaccination scenarios on the HBV 
prevalence in the IOU population in 2015 
Age Group Vaccinated 
Coverage 15-17 18-29 30+ All 
0.0 15.3% 15.3% 15.3% 15.3% 
0.3 13.9% 8.8% 13.7% 7.3% 
0.7 12.4% 4.9% 12.9% 3.6% 
1.0 11.5% 3.5% 11.5% 2.6% 
6.3.3 Equilibrium Scenario Results 
It can be seen from Figure 6.3 that the HBV prevalence within the IOU population 
may reach zero when the vaccination coverage on prison reception is between 0.2 
and 0.25 I prisoner I year. While this result is subject to a number of caveats and may 
not occur for many years (OOOs) it does show the potential long term impact of the 
HBV vaccination programme on prison reception on HBV transmission within the 
IOU population. 
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Figur 6.3 - Th r lation hip between the vaccination coverage on prison reception 
and th p ination quilibrium 
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populati n dropping to Ie than 2% within 15 years. The impact of administering a 
accinati n campaign every three years from 2003 until 2009 is shown in Figure 6.4. 
It can n that whil this trategy does have a positive effect on HBV prevalence, 
if thi not u tain d then 9 years after the final pulse vaccination the HBV 
pre al n on again b gin to risco 
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Figure 6.4 - The impact of alternative campaign vaccination scenarios on the 
prevalence ofHBV within the IDU population over time. 
0.20 
~ 
u 
(1) 
£ 0.15 
L.. 
(1) 
> ~ 
(1) 0.10 u 
c 
(1) 
"ffi 
> ~ 0.05 G.. 
> ~ Campaign+Routine co 
-..- Pulse Campaign until 2009 I 
0.00 
2002 2006 2010 2014 2018 
Year 
6.3 .5 en itivity Analysis 
The effect on the ba cline vaccination scenario of varying the estimated FOI in new 
initiate and experienced IDUs is shown in Figure 6.5. It ean be seen that alternative 
values of the FOl have the potential to have a substantial effect on the HBV 
incidence estimates obtained from the model. 
Figure 6.5 - The estimated annual number of acute infections of HBV in the IDU 
population with variation in the estimated FO!. 
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Figure 6.6 - Th e timated annual number of acute cases in the IDU population with 
variation in estimations of the transmission coefficients. 
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The impact of varying the proportional mixing assumption is shown in Figure 6.6. It 
can be een that either assuming that the rates of mixing are dominated by 
experienced IDU (Mixing 1) or assuming that there is no mixing between new 
initiates and experienced IDUs (Mixing 2) has very little impact on the estimated 
number of acute ca es ofHBV in the IOU population. 
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6.4 Discussion 
Using a detenninistic model to describe the epidemiology of HBV within the IDU 
population and HBV FOI estimates calculated in Chapter 5, the work here shows the 
potential impact of the HBV vaccination programme in prisons on the incidence and 
prevalence of HBV in the IDU population in England and Wales. Over a range of 
vaccination scenarios the model shows that increased coverage of HBV vaccination 
on prison reception can have a substantial effect on the incidence of HBV within the 
IDU population over time. Indeed, the base case model (that assumes that the 
vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then 
increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts 
that the incidence of HBV in IDUs might be reduced by approximately 75% in 12 
years from over 1,000 acute cases down to less than 300. 
It has been assumed that the IOU population can be divided into two groups, those 
new initiates with an injecting career length of less than 1 year, and experienced 
IOUs with an injecting career length of greater than 1 year. This finding can be 
justified when considering the FOI estimates obtained in Chapter 5 which are 
substantially higher in new initiates compared to more experienced IDUs. While it is 
acknowledged that this is almost certainly an over simplification of the process by 
which IOUs interact, its simplicity makes model parameterisation easier based on 
data currently available. 
Chapter 5 showed that no statistically significant variation in the FOI over time in 
IOUs was detected from 1999-2003. It has therefore been assumed that there is no 
variation in the FOI through time prior to the introduction of prison vaccination. 
Although as has been shown here the impact of using a dynamic model in which the 
FOI is not fixed inevitably results in a decrease in the FO! over time when 
vaccination is introduced. 
Over a range of vaccination scenarios the results from this model have shown that an 
increase in the vaccination coverage on prison reception results in a reduction in the 
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number of acute cases of HBV in both new initiates to injecting and in experienced 
IOUs over time. Allowing for community vaccination the total number of acute HBV 
infections in 2002 in the IOU population in England and Wales was estimated from 
the model to be approximately 1,000 this includes all acute cases of HBV both 
asymptomatic and symptomatic. To verify this result it can be compared to the 
number of acute cases of HBV in England and Wales with a risk factor associated 
with injecting drug use as reported to the HPA in 2002 (Health Protection Agency, 
2006), this was found to be 193. However after adjusting for under-reporting 
(Ramsay et al., 1998) and asymptomatic infection (Hahne et al., 2004), the annual 
number of acute infections is estimated at 1,100 cases, suggesting that the model is 
providing a reasonable estimation of the number of acute HBV infections in the IOU 
population in England and Wales. 
The impact on the HBY prevalence within the IOU population over a range of 
hypothetical vaccination scenarios was also investigated. It was found that targeting 
the 18-29 age group had the greatest impact on HBV prevalence, compared to the 15-
17 age group and 30+ age groups. Although targeting age groups of different sizes 
will inevitably favour the larger age groups it is likely that this result is due to the 
majority of current IOUs being aged from 18-29. However the model of the HBV 
vaccination programme in prisons assumes that the likelihood of starting injecting is 
the same irrespective of imprisonment status, whereas it is likely that persons that 
have previously been imprisoned are more likely to start injecting than those that 
have not. This suggests that the impact on HBY prevalence of vaccinating young 
prisoners may be underrepresented here. 
The equilibrium scenarios were examined to see what levels of constant vaccination 
coverage on prison reception would result in the HBY prevalence reducing to zero. It 
was found that under base case assumptions a vaccination rate of between 20-25% 
would ultimately result in the HBV prevalence in the IDU popUlation reducing to 
zero. While this result is interesting it is subject to a number of caveats. It is assumed 
both that the characteristics of the IDU population both inside and outside prison and 
the characteristics of the prison population are reasonably approximated here and 
remain constant over the same time period, which is unlikely particularly given that 
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equilibrium is not reached for thousands of years. While these are important caveats 
and should not be overlooked it does show that prison vaccination on reception has 
the potential to impact upon HBY prevalence within the IOU population in a 
substantial way. 
The assumption that there is proportional mixing between new initiates and 
experienced IOUs was tested during the sensitivity analysis. It was assumed that the 
rate that the two groups interact was dominated by experienced IDUs, and 
alternatively it was assumed that there was no mixing between the groups. In each 
case it was found that the model results are not sensitive to these changes. 
As has already been discussed the FOI estimates were taken from a previous analysis 
of IDUs in contact with services (Chapter 5), to test their impact on model results 
alternative plausible FOI estimates were substituted (Chapter 5). It was found that the 
FOI estimates have a major impact on the results obtained from the model 
particularly when the FOI is estimated to be the same in both groups suggesting that 
future work should be aimed at verifying these parameter values. It was assumed that 
the FOI estimates applied here were the same both inside and outside prison, while 
this is a bold assumption, obtaining data from which prison and community specific 
FOI estimates can be estimated will always prove problematic. As better FOI 
estimates become available that can distinguish the risk of infection both inside and 
outside prison, these can be incorporated into the model. 
To verify whether the results obtained from this model are a reasonable estimation of 
the impact of the HBY vaccination programme in prisons on the transmission of 
HBY in the IOU population, reports of acute cases of HBY that are reported to the 
HP A in future years can be compared to the results presented here. Allowing for 
asymptomatic infection and underreporting, it will then be possible to verify whether 
the estimated impact of the HBY vaccination programme in prisons on HBY 
transmission in the IOU popUlation in England and Wales is correct. 
An important caveat within this work is that HBY transmission by non-IDUs has not 
been explored within this model. While it is likely that HBY will never be eradicated 
141 
In the IOU population due to transmission from non-IDUs to IOUs, prison 
vaccination will inevitably capture many non-IDUs that have increased risk factors 
from HBV infection e.g. sex workers and this will have a positive impact on HBV 
transmission within the overall population of England and Wales. 
This chapter concludes the research investigating the impact of the HBV vaccination 
programme in prisons in England and Wales on the IOU population. However as has 
already been discussed IOUs are also at increased risk of infection from HeV and 
prison may also be a good location in which to target IOUs against this BBV. This 
will be the subject of Chapter 7. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A. J., Gay, N. J., & Edmunds, W. J. (2006). Modelling the impact of prison 
vaccination on hepatitis B transmission within the injecting drug user population of 
England and Wales. Vaccine 24,2377-2386. 
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CHAPTER 7 - ESTIMATING THE COST-EFFECTIVENESS OF 
DETECTING CASES OF CHRONIC HEPATITIS C INFECTION ON 
RECEPTION INTO PRISONS 
7.1 Aims and introduction 
• To estimate the cost per HCV case detected under a range of screening 
scenarios implemented on reception into prisons in England and Wales. 
• To estimate the proportion of the IDU population that is HCV -RNA positive 
that might be screened on reception into prisons in England and Wales. 
• Using sensitivity analysis, identify the parameters that have the greatest impact 
on the estimated cost per HCY case detected. 
Previous chapters have shown that prison may be a good location in which to 
vaccinate IDUs against HBV and that this intervention may have a significant impact 
on the transmission of HBV within the IOU population of England and Wales. It has 
also been shown amongst the reported laboratory diagnoses of HCV infection in 
England in 2004, 95% of those with exposure data were attributable to injecting drug 
use (Health Protection Agency et al., 2005). The advantages of identifying 
individuals with undiagnosed HCY infection have already been discussed in section 
1.3.1.2. By applying the model of the flow ofIDUs through prisons in England and 
Wales (Chapter 3) in a different setting, in this chapter the effectiveness of HCV 
case-finding on prison reception is examined. 
An analyses in which costs are related to a single, common effect which may differ 
in magnitude between the alternative programmes, is usually referred to as cost-
effectiveness analyses (Drummond et ai., 1997). In this case the cost effectiveness of 
a range of alternative HCV case-finding scenarios implemented on reception into 
prisons in England and Wales to identify persons infected by chronic HCV (HCV-
RNA positive) is investigated. Each scenario is compared by considering the 
cumulative cost of identifying a new case of HCV (HCV-RNA positive) and how 
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this cost changes over time as previously tested individuals return to prison. 
Incremental cost-effectiveness analysis is also undertaken. 
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7.2 Methods 
7.2.1 Model Structure 
The model here is adapted from the model of the flow of IDUs and non-IDUs 
through prisons described in Chapter 3. The current IDU population described here 
has been subdivided into new initiates to injecting and experienced IDUs. New 
initiates to injecting are defined as those IDUs with an injecting career length of less 
than a year, and experienced IDUs are those individuals with an injecting career 
length of greater than one year. The FOI estimates for both new initiates and 
experienced IDUs are taken from Chapter 5. It is assumed that the FOI rates are 
constant over time and independent of prison status. While it is acknowledged that 
the risk of BBV infection amongst IDUs inside prison may be significantly higher 
than in the community (Macalino et al., 2004), reliable FOI estimates that distinguish 
between prison status have not been obtained. Due to the small proportion of HCV 
infections that have an identified risk factor other than injecting drug use in England 
and Wales (Health Protection Agency Centre for Infections, 2005), it is anticipated 
that the FOI in non-IDUs will be extremely low, and so for this reason it is assumed 
that only IDUs can become infected by HCV with the incidence of new infections in 
the general population (non-IDUs) assumed to be zero. For those persons that are 
infected by HCV it is assumed at the time of infection that 80% (Health Protection 
Agency, 2006) become HCV RNA positive, although this assumption will be tested 
during sensitivity analysis. 
7.2.2 HCV Case-finding Coverage 
Currently there is no significant ongoing HCV case-finding on reception into prisons 
across England and Wales. It is assumed therefore that HCV case-finding coverage 
on prison reception is expanded over time to reflect the rolling out of an HeV case-
finding programme across prisons in England and Wales. Figure 7.1 shows the 
percentage of prison receptions in England and Wales where case-finding is 
undertaken over time assumed in this analysis. 
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Figure 7.1 - As umed proportion of prison receptions covered by HCY case-finding 
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7.2.3 a e-finding Pathway on Prison Reception 
The ca e-finding pathway through prison reception proposed here is taken directly 
from a previou study using publicly available information describing the 
implementation of screening and treatment of HCY in the Isle of Wight prison 
c1u ter (Skipper et al., 2003) although treatment is excluded from the pathway 
con idered here. The study of the Isle of Wight Prison Cluster considers prisoners as 
they fir t attend a one hour health awareness lecture during which they are alerted to 
the ri k factor for BBY and are then invited to the Healthwatch clinic which was 
et up in 1997 to provide coun elling on BBYs for all new receptions to the Isle of 
Wight pri on . Testing and counselling undertaken in the Healthwatch clinic on 
reception a de cribcd in the Isle of Wight Study are applied here and described 
below (Figure 7.3 and Figure 7.4). In addition verbal tests are introduced along the 
screening pathway to investigate whether alternative HCY case-finding strategies 
may be more co t effective than offering testing to all individuals . Prisoners are 
giv n verbal te t regarding their previous injecting behaviour and results of previous 
H te ting, with the answers to these questions used to judge whether the prisoners 
are eligible t receive serological HCY tests to establish their HCY status. 
The ca e-finding pathway i described in Figure 7.3 and Figure 7.4 and applies to all 
pri oner that are amongst the proportion on reception that are covered by the HCY 
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case-finding programme (Figure 7.l). Initially all prisoners on reception into prison 
attend a one hour health awareness lecture alerting them to the risk factors of BBYs. 
During each lecture it is assumed that 10 prisoners are present. Following this, 
prisoners are submitted to verbal tests to determine their eligibility to receive 
antibody tests. The verbal tests are a combination of the following, and represent the 
alternative case-finding scenarios considered here: 
I. Have you received a positive Hey test previously? 
2. Have you ever injected illicit drugs? 
The first question is asked to establish whether the prisoner has been previously 
diagnosed with Hey. This question specifically asks about a previous positive test 
rather than simply a previous test, as a previous negative test is of limited interest as 
the prisoner may have been exposed to Hey in the mean time. The 2nd question is 
used to establish whether the person has ever injected illicit drugs. Where verbal 
questioning is administered (scenarios one to three, see below), the time taken to 
question the prisoners is assumed to be independent of the number of questions asked 
and is assumed to take 5 minutes, although this will be examined during sensitivity 
analysis. Previous studies (Schlicting et al., 2003; Best et al., 1999; Darke, 1998) 
have considered the sensitivity and specificity of IDUs responses to questions related 
to Hey positivity and the self-reporting of their illicit behaviours. The values taken 
at baseline and applied during sensitivity analysis are described in Table 7.2. 
Following the verbal tests those prisoners that have been identified as being eligible 
to receive serological testing are assumed to be offered pre-test counselling. For 
those prisoners that are willing to accept serological testing an enzyme linked 
immunosorbant assay (ELISA) antibody test is assumed to be administered. 
Prisoners identified as having a positive antibody test are assumed to be informed 
that they have evidence of contact with Hey and are then offered a polymerase 
chain amplification (peR) test for the presence of Hey viral RNA as a marker of 
ongoing infection. Those who are positive for Hey by antibody testing but negative 
on a single peR test are assumed to be offered two further peR tests as was adopted 
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in the Isle of Wight Study (Skipper et al., 2003), the costs of which are incorporated 
in the analysis. 
Post-test counselling is administered to all prisoners on receipt of the results from the 
ELISA and PCR tests. Those with positive tests are assumed to be counselled on 
harm reduction and harm minimisation. Assumed time and staff allocations for each 
task on the case-finding pathway are shown in Table 7.2, where no reference was 
available to inform these values, reasonable assumptions were made with the impact 
of these being examined during sensitivity analysis. 
7.2.4 Community HCY Testing and Diagnosis 
As a result of drug treatment and prevention services in the community, it is possible 
for some HCY positive IDUs to become aware of their positive status as a result of 
testing in the community. Further to this, HCY positive individuals that develop 
symptoms associated with their infection may also have their HCY infection 
diagnosed in the community. 
Data was considered from the UAPMP survey 2003-2004 of IOUs (who injected in 
the previous four weeks prior to the survey) reporting whether they had ever received 
a test for HCY by career length. Assuming that this data is representative of the IOU 
population in the community and that no HCY testing had been undertaken in prison, 
a model was fitted to the data using maximum likelihood fitting to binomial data 
(section 3.3.3). Amongst IOUs that are infected but undiagnosed the rate that IOUs 
in the community are tested and diagnosed for HCY was estimated to be 0.15 IIOUI 
year, and while it is acknowledged that this model does not provide a good fit to the 
data (Figure 7.2) the impact of this parameter on model results will be investigated 
during sensitivity analysis. 
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Figure 7.2 - Model fit to UAPMP survey data 2003-2004 describing the % of current 
IDUs reporting receiving a previous HCV test 
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7.2.5 Case-finding Scenarios 
20 
Varying the verbal questions asked on prison reception allows us to compare five 
alternative case-finding scenarios used to identify individuals that are eligible to 
receive an offer of serological testing for HCV (the ELISA and peR tests offered 
being the same for scenarios one-four, see above). A negative answer to the question 
of previous injecting and a positive answer to the question of a past positive HCV 
test would indicate that the person is ineligible for HCV serological testing. The 
verbal screening that distinguishes each scenario is described in Table 7.1: 
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Table 7.1 - Summary of case-finding scenarios 
Scenario Description 
One Verbally screen for ever having received a past positive HCV test, and 
for ever having injected illicit drugs. 
Two 
Three 
Four 
Five 
Verbally screen for a past positive HCV test only. 
Verbally screening for ever injecting illicit drugs only 
No verbal screening 
No verbal screening and no testing (do nothing scenario) 
Comparisons are made between each case-finding scenario by considering the 
cumulative cost per chronic Hev case (RNA positive) detected and how this varies 
over time. The complete parameter set describing the case-finding scenarios at 
baseline are shown in Table 7.2. The implication of these parameter selections on the 
model results are examined during sensitivity analysis with the values taken during 
sensitivity analysis also shown in Table 7.2. All costs are presented in year 2004 with 
discounting rates for both costs and benefits taken at 3.5% as recommended by the 
HM Treasury (HM Treasury, 2003) although the impact of these are varied during 
sensitivity analysis (Table 7.2). The analysis here is considered from the perspective 
of the health care provider. 
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Figure 7.3 - Schematic diagram of the case-finding scenarios used in this analysis 
General lecture delivered during the 
Induction programme 
ReceIVed put POlitlve HCV list? 
Received past POSItive HCV test? 
SeI.ct 1e.".lIo 
Ever injected Mllcit drugs? 
No question just t •• t. Gato Figure 7.4 
Do nothing scenario 
No E_ ~d *'<:It drug.? 
151 
Figure 7.4 - Pathway describing the administering of Hey serological tests 
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Table 7.2 - Model parameters and values used during sensitivity analysis 
Parameter Baseline Sensitivity Source (where available) 
value 
..10 = FOI for new initiates 0.1608 0.1314-0.1942 Chapter S 
~ = FOI for experienced IOUs 0.OS26 0.0310-0.0863 Chapter S 
Cost of Doctor £3.49/min GP: Ihome visit / min 
(£209.40 With Qualification costs 
Ihr) With direct care staff 
costs(Curtis & Netten, 
2004) 
Cost of Nurse £S4/hour District Nurse (midpoint 
grade G) Ihr with patient 
+ extra costs (Curtis & 
Netten, 2004) 
Time Taken/or BBV lecture / 10 patients / I patient Ihr - (Skipper et al., 2003) 
prisoner hr 20 patients / hr 
% Nurse time SO% 0-100% 
% Doctor time SOOIo 0-100% 
Time taken to verbal test on Smin l-ISmin (Stein et al., 2002) 
reception into prison 
% Nurse time SO% 0-100% (Stein et al., 2002) 
% Doctor time SO% 0-100% (Stein et al., 2002) 
% who are HCY positive and say so SS% 23%-83% 23% (Schlicting et al., 
(midpoint) 2003),83% (Best et aI., 
1999), 
% never received a positive HCY 1% 0%-10% 
test but say they are HCY positive 
% IOUs that report IOU use (current 7S% 30-90% Darke, (1998) reports that 
or ever) IOUs give reasonably 
reliable answers to 
questions about drug use. 
% non-IOUs that report IOU use 0% 0-20% 
(current or ever) 
Time Taken to Counsel prior to an 2Smin 10-6Omin 2Smin (Leal et al., 1999) 
ELISA test 10-60min (Stein et al., 
2002) 
% Nurse time SO% 0-100% (Stein el al., 2002) 
% Doctor time SO% 0-100% (Stein et al., 2002) 
Time taken to Administer ELISA test Smin 1-IOmin 
% Nurse time SO% 0-100% 
% Doctor time SO% 0-100% 
Cost of ELISA test £12 £S-20 Virus reference 
department, HPA, 
Colindale (200S) 
% of those offered who accept 8S% 10-100% (Stein et al., 2002) 
ELISA testing 
ELISA Sensitivity 97% 90-100% (Stein et al., 2002) 
ELISA Specificity 99% 90-100% (Stein et al., 2002) 
Time taken to administer peR test 5min 1-IOmin 
% Nurse Time 50% 0-100% 
% Doctor Time 50% 0-100% 
153 
% of those offered who accept PCR 100% SO% Assuming that those that 
testing accept an ELISA test will 
PCR Sensitivity 100% 
then accept a PCR 
99%·100% (Stein et al., 2002) 
PCR specificity 100% 99·100% (Stein et al., 2002) 
Cost of PCR test £57 £50-80 Virus reference 
department, HPA, 
Colindale (2005) 
Time taJcen to counsel the result of Smin S-ISmin 
negative ELISA or PCR test 
% Nurse time SO% 0·100% 
% Doctor time SO% 0·100% 
Time taken to counsel the result of a 2Smin 15-7Smin 25min (Stein et al., 2002) 
positive ELISA test 15· 75min (Stein et al., 
2(02) 
% Nurse time SO% 0-100% 
% Doctor time SO% 0-100% 
Time taken to counsel the result of a 2Smin IS-7Smin 2Smin (Stein et al., 2002) 
positive PCR test IS· 7Smin (Stein et al., 
2002) 
% Nurse time 50010 0·100% 
% Doctor time 50% 0-100% 
Proportion infected with HCV that 80% S4%·86% (Seeff, 2002;Health 
become HCV·RNA positive Protection Agency, 2006) 
Rate of HCV testing and diagnosis O.IS 0.1·0.3 See text 
in the community 
Discount rate for costs 3.S% 0%·6% (HM Treasury, 2003) 
Discount rate for benefits 3.S% 0%·6% (HM Treasury, 2003} 
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7.3 Results 
It can be seen (Figure 7.5c) that scenario one: identifying those individuals that have 
not received a past positive Hey test, and have ever injected illicit drugs is the most 
cost effective scenario over time. This shows the importance of identifying those 
individuals with a history of injecting drug use, which is the biggest risk factor for 
Hey infection. Least cost effective is scenario two: only identifying those 
individuals that have not received a past positive Hey test. For all scenarios the cost 
per new Hey case detected rises over time indicating that they become less cost 
effective as time passes. This is due to IDUs returning to prison that are already 
aware of their Hey infection, leaving a smaller proportion of individuals on 
reception into prison that have undiagnosed infection. 
The undiscounted cost of implementing each case-finding scenario is shown in 
Figure 7.5a. For each case-finding scenario the cost increases up to a plateau in 2010 
and then is broadly constant from then on. The initial increase and then plateau can 
be explained by the assumed expanding coverage of Hey case-finding on prison 
reception over time up to a constant coverage from 2010 onwards (Figure 7.1). It can 
be seen that scenarios two and four are far more costly than the remaining scenarios, 
however neither of these scenarios screen prisoners on prison reception for any 
previous injecting drug use, and as a consequence many more ELISA and peR tests 
are administered for scenarios two and four than are necessary. A slight reduction in 
the cost was observed in scenarios one and two from 20 I 0 onwards, this is due to 
persons having been diagnosed with Hev infection returning to prison and then 
being verbally screened for a past positive Hey test, hence reducing the costs further 
along each of the case-finding pathways. 
From Figure 7.5d it can be seen that scenarios two and four identify the greatest 
proportion of individuals that are HeY-RNA positive over time, however these 
scenarios are not very cost effective due to the high costs required to administer 
them. 
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R ult fr m th incr mental analy is are reported in Table 7.3, where the alternative 
b en ranked according to their cumulative discounted cost in 2017 
and th t-effe tiveness ratios have been calculated. This highlights 
that nan tw i the rna t co t-effective option and has the smallest budget impact 
t). 
iguIc 7.5 - The rc ult for thc first four case-finding scenarios compared with the 
CUff nt d n thing (no H V case-finding in prisons) strategy 
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Table 7.3 - Incremental cost effectiveness analysis of each case-finding scenario 
Case-finding Cumulative Cumulative Incremental 
Scenario discounted cost in discounted no. of Cost 
2017 (I,OOOs) casesofHCV Effectiveness 
identified in 2017 
Five (Do Nothing) £0 0 
One £28,192 13413 £2,102 
Three £30,444 13548 £16,681 
Four £53,123 17098 £6,388 
Two £54,670 16927 dominated 
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7.3.l ensitivity Analysis 
Figure 7.6 - The impact on the cumulative average cost effectiveness of scenario one 
in 2017 compared to the current no case-finding strategy when applying one-way 
sensitivity analysis (section 2.2.4). 
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Figure 7.6 shows the impact of one-way sensitivity analysis on the cumulative 
average cost per case detected in 2017 for case-finding scenario one compared with 
the current do nothing policy. In each case only those parameters that impact on the 
baseline value by greater than 10% are shown. It can be seen that in many cases the 
parameter values have little impact on the cost effectiveness of this scenario and in 
all cases this scenario was found to be the most cost-effective. 
The parameters that have the largest impact on cost-effectiveness were found to be 
the number of prisoners that attend the BBV lecture on reception into prison, and the 
proportion of prisoners that accept an ELISA test. Also noted is the impact of non-
IDUs reporting previous injecting drug use, however there was no evidence of this 
occurring during previous screening programmes (Home et al., 2004; Skipper et al., 
2003). It can be seen that the rate of HeV testing and diagnosis in the community 
and the FOI estimates in the experienced IDUs also have an impact on the cost 
effectiveness estimates of scenario one. An increase in the rate of testing and 
diagnosis in the community and a reduction in the FOI in experienced IDUs both 
result in the prison case-finding programme becoming less cost effective. 
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7.4 Discussion 
Using a Markov decision analysis model, a model of the flow of IDUs through 
prisons in England and Wales (Chapter 3), and estimates of the FOI for HCV in the 
IDU population (Chapter 5) the chapter here investigates the cost effectiveness of a 
number of alternative HCV case-finding strategies including verbal screening for 
ever injecting drug use and for previous HCV testing. Results indicate that verbally 
screening for ever injecting illicit drugs and for ever having received a past positive 
HCV test is the most cost effective approach to establishing prisoners eligible for 
serological testing, while sensitivity analysis found that the proportion of eligible 
prisoners that accept ELISA testing has a significant impact on the cost-effectiveness 
of the case-finding scenarios. 
A typical approach to a cost-effectiveness analysis such as this would be to adopt a 
simple spreadsheet model in which a hypothetical cohort of individuals (usually 
modelled as being at the same age) would be modelled flowing into prison, however 
this approach would not allow the impact of previously screened individuals 
returning to prison to be investigated. This is of particular significance here as it has 
been found that the case-finding scenarios described here all become less cost-
effective over time, this being due to previously screened individuals returning to 
prison that do not need re-screening and the time taken to identify these prisoners. 
Although a reduction in annual costs were noted over time in some of the case-
finding scenarios due to prisoners that had already received a positive serological test 
being identified on prison reception. For each scenario when the proportion of prison 
receptions covered by HCV case-finding had been assumed to have reached a 
constant the costs and benefits over time display only relatively small variation. 
It is possible for an individual to become HCV -RNA positive during a spell of 
imprisonment, this may occur for two reasons, either the individual was infected 
while in prison or the individual was infected outside prison but due to the natural 
history of HCV, HCV-RNA was not detectable on reception into prison. HCV-RNA 
can be detected within I to 2 weeks after exposure to the virus although HeV -RNA 
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positivity may appear much later at 30 to 40 days (World Health Organisation, 1999; 
Mortimer, 2000). As two further peR tests are administered to those individuals that 
are anti-HCV positive but negative for HeV-RNA it is unlikely that individuals 
infected just prior to reception will remain undetected. If however it is felt that there 
is a significant risk of some prisoners becoming HeV -RNA positive while in prison, 
then to allow these individuals to be offered treatment or counselling it may be 
necessary to administer some HCV testing during an individuals prison sentence or 
perhaps on discharge from prison. 
Results from sensitivity analysis showed the importance of encouraging eligible 
prisoners to accept the offer of an ELISA test, with a reduction in uptake having a 
large impact on cost-effectiveness. Intervention measures outside prison such as 
testing and diagnosis in the community or those that target IOUs aimed at reducing 
their at risk behaviour (and therefore the FOI) can have a negative impact on the 
cost-effectiveness of a prison based case-finding programme even, though a prison 
based programme may well be more cost-effective than a programme based in the 
community. This shows the importance of coordinating intervention measures inside 
and outside prison to ensure the maximum effectiveness of both. 
The work here has focused on identifying those individuals that may be at risk from 
Hev infection and then offering them an HeV test as appropriate, however it is 
possible that an individual may encounter further problems if they admit to injecting 
drug use, this in many instances may take the form of the social stigma associated 
with injecting drug use. It is hoped that admitting to previous injecting drug use will 
be seen in a positive light as individuals can then be targeted for drug related 
intervention measures or HCV treatment if necessary. To allow for the possibility 
that individuals may not give reliable answers to questions regarding injecting drug 
use or HeV status a range of values describing the sensitivity and specificity to 
individuals answers related to previous HCV testing and injecting drug use were 
considered. It was found that of importance to model results were the answers that 
individuals gave to the issue of previous injecting behaviour. However it is hoped 
that the one hour health awareness lecture described at the start of the screening 
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pathway will provide a good opportunity in which to address individuals concerns 
regarding the revealing of potentially sensitive information. 
A further account of screening for Hey in the prison population in England and 
Wales is described in a previous study considering the experience of screening in the 
Dartmoor prison (Home et al., 2004). In this study the authors describe data 
collected from a cohort of prisoners screened from 1 January 1998 to 30 June 2001 
describing progress from test result to treatment. A key difference between the 
screening pathway described in Dartmoor compared to the Isle of Wight appears to 
be the additional two peR tests administered at the Isle of Wight for those 
individuals that test anti-Hey positive but HeY-RNA negative after a first peR test. 
This means that the costs of the scenarios reported here may be less cost-effective 
than if the requirement to implement these two additional PCR tests was removed. 
The approach to staff costs in this work has considered only the role of a doctor and 
nurse in implementing the alternative case-finding scenarios, while the estimates of 
the length of time taken to undertake the individual tasks along the case-finding 
pathways are inevitably subject to much variation. Considering only doctors and 
nurses is an obvious over simplification, with other members of staff such as prison 
chaplains and guards playing a role in the implementation of a prison based case-
finding programme. However in mitigation the results from the sensitivity analysis 
have shown that staff costs and length of time required to accomplish each task play 
only a small part in variation in the estimates of the cost-effectiveness of the case-
finding scenarios. 
While treatment has not been considered here, there are still advantages in 
identifying those individuals that are HCY-RNA positive. Any individual that is 
HCV-RNA positive obviously has the potential to transmit infection particularly if 
the person is an IDU and continues to inject illicit drugs. An awareness of the 
infected status of these individuals is useful to services as they can then be targeted 
for intervention measures aimed at reducing the behaviour that leads to further HCY 
transmission. This may take the form of encouraging injecting cessation or the 
supplying of clean needles to reduce the risk of transmission due to the sharing of 
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syringes. While identified HCV positive individuals themselves may choose to 
modify their own behaviour to prevent further transmission. A further advantage of 
HCV case-finding is that positive individuals can be monitored so that they can be 
treated when treatment criteria have been met, which in the case of IDUs will be 
when the individual has ended their injecting career (National Institute for Clinical 
Excellence Guidelines, 2004). Identification of HCV positive individuals on prison 
reception may also assist in identifying further positive individuals in the community 
through contact tracing exercises. However it is of some importance that those 
individuals that are identified with HCV infection are given post test support to come 
to terms with their infection. Previous studies have shown that knowledge of a past 
positive HCV test can have a negative impact on an individual's quality of life 
(Forman et ai., 2000; Rodger et ai., 1999; Chong et ai., 2003; Tompkins et ai., 2005) 
particularly when post-test support is not offered. This should be considered when 
weighing the pros and cons of adopting a case-finding programme such as this. 
In summary, prison provides a good location in which to identify individuals 
previously infected by HCV. Verbally screening for individuals that have previously 
received a positive HCV test and for ever having injected drugs was found to be the 
most cost effective scenario. However it is expected that the cost-effectiveness of 
HeV case-finding will decrease over time as HCV infected individuals that have 
already been identified previously return to prison. 
The research in this chapter has been published in full in the following peer 
reviewed article: 
Sutton, A.J., Edmunds, W.J., & Gill, O.N.(2006). Estimating the cost-effectiveness 
of detecting cases of chronic hepatitis C infection on reception into prison. BMC 
Public Health 6, 170. 
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CHAPTER 8 - DISCUSSION 
8.1 Introduction 
A variety of methods have been considered in this thesis that has helped to further 
knowledge about the characteristics of the IOU population and in particular its risk of 
infection from BB V s. The potential impact of a number of prison based intervention 
measures that target the IDU population in a prison setting has also been considered. 
These methods have included statistical and mathematical modelling techniques and 
also some economic evaluation. Statistical techniques have been used to obtain 
parameter estimates that have helped to understand the characteristics of the IOU 
population and its flow through prison. The impact of prison based intervention 
measures have been investigated through mathematical modelling. Moreover, an 
economic evaluation has been utilised to assess the cost-effectiveness of alternative 
HCV case-finding strategies on reception into prison. 
8.2 Summary of main findings 
Younger IDUs are less likely to stop injecting than older IDUs suggesting that those 
individuals that embark on an injecting career at a younger age will inject for far 
longer than those that start injecting at an older age. The trend in the incidence of 
injecting in the male IDU population in England and Wales was estimated to peak in 
the early 1980s followed by a steep reduction down to a constant throughout the 
1990s with a slight reduction in 2000-2001. This slight reduction in the number of 
males starting injecting coupled with an increase in the average injecting career 
length of an IOU in more recent years (1997-2001) may be indicative of a change in 
the nature of the IOU population with more 'problem' rather than casual users. This 
may have had an impact on the spread of BBVs within the IOU population of 
England and Wales in recent years and help to explain the rise of HBV and HCV 
prevalence since 2000 (sections 1.3.1.1 and 1.3.1.2). 
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To estimate the impact of a series of alternative intervention measures that target 
IDUs against BBVs in a prison setting a model of the flow ofIDUs through prisons 
in England and Wales was designed and parameterised. This model provides 
estimates of the rate that IDUs and non-IOUs pass through prison, and then return to 
prison due to recidivist behaviour. Using this model it is then possible to estimate 
what proportion of the IOU population might be captured by prison based 
intervention measures particularly those aimed at BBVs, as is the focus of this thesis. 
The parameterisation of the flow of IOUs through prisons in England and Wales 
provided further evidence that IOUs are at increased risk of imprisonment compared 
to non-IDUs. A comparison of the discharge rates for IDUs and non-IOUs show that 
IDUs spend less time in prison per spell of imprisonment compared to non-IOUs. For 
IDUs that have been imprisoned parameter values for the discharge rates and re-
imprisonment rates were found to be constant across all age-groups, suggesting that 
much of the IDUs offending behaviour may be independent of age. 
Under a range of vaccination scenarios applied to the model of the flow ofIOUs and 
non-IDUs through prisons in England and Wales, the impact of the HBV vaccination 
programme in prisons on the vaccination status of current IOUs was estimated. 
Results showed that with increasing coverage on reception into prisons a greater 
proportion of the IOU population may be vaccinated against HBV. However, even 
with 100% vaccination coverage on reception a proportion of the IOU popUlation 
will not be vaccinated as some IOUs will never go to prison. This shows the 
importance of ensuring that vaccination is also administered in the community, a 
finding that was verified during the sensitivity analysis that showed the importance 
of the community vaccination rate on estimates of the proportion of the IDU 
population captured by vaccination. Sensitivity analysis also showed the importance 
of the estimated discharge rate of IDUs from prisons and the estimated IDU 
population size on model results. A higher discharge rate will result in IDUs flowing 
through prisons faster and lead to a greater proportion of the IOU population being 
exposed to prison vaccination as individual IOUs return to prison. As it has been 
estimated from data what proportion of the prison popUlation is defined as being a 
current IOU (Weild et al., 2000) smaller estimates of the size of the IOU population 
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will result in a greater proportion of IDUs being vaccinated in prisons, as shown in 
the sensitivity analysis. 
In order to inform the models that appear later in the thesis that describe the 
transmission of HBV in the IOU population and the cost-effectiveness of HCV case-
finding in the IOU population, estimates of the FOI for HBV and HCV must be 
made. Using data from the UAPMP surveys of current IDUs in England and Wales 
the FOI for HBV and HCV and how this has varied over time and with injecting 
career length was estimated. The issue of individual heterogeneity within the IOU 
population was also addressed to determine whether certain individuals are at greater 
risk from infection than others independently of injecting career length or time. 
Model estimates found that new initiates to injecting are at increased risk from BBVs 
compared to more experienced injectors, and that there is evidence of individual 
heterogeneity of risk behaviour where independently of the injecting career length 
effects, some IDUs are at increased risk of infection compared to others. A key 
question from this work is why the prevalence ofBBVs is so high in the new initiates 
to injecting, which in turn leads to the high FOI estimates reported here? Is the 
infection due solely to injecting behaviour, or is it due to infection for some other 
reason? Background HBV infection where transmission occurs between IDUs and 
non-IOUs was incorporated in the FOI model and was found to be at very low levels, 
this suggests that the major cause of HBV infection in new initiates is due to their 
injecting behaviour. 
A simple heterogeneous model describing the mlxmg of new initiates and 
experienced IOUs was applied to estimate the impact of HBV vaccination in prisons 
on transmission of HBV in the IOU population of England and Wales. Estimates of 
the vaccination coverage of the IOU population from the model of the HBV 
vaccination programme in prisons were applied along with the FOI estimated in 
Chapter 5. The base case model (that assumes that the vaccination coverage on 
prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% in 
2006) predicts that the incidence of HBV in IDUs might be reduced by almost 75% 
in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced 
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from approximately 15% in 2002 to 6% in 2015. Sensitivity analysis demonstrated 
that the FOI estimates had a significant impact on the results obtained from the 
model. This emphasised the importance of obtaining reliable FOI estimates for 
application in this setting. Further sensitivity analysis examining the proportional 
mixing assumption found that alternative assumptions describing the contact between 
new initiates and experienced IDUs had very little impact on the estimated number of 
acute cases of HBY in the IOU population. 
The cost-effectiveness of a number of alternative Hey case-finding scenarios on 
reception into prisons in England and Wales was examined. It was found that 
identifying those individuals that have not received a past positive Hey test, and 
have ever injected illicit drugs is the most cost effective approach to case-finding on 
prison reception. This shows the importance of identifying those individuals with a 
history of injecting drug use, which is the biggest risk factor for Hey infection. Over 
time it was found that the case-finding scenarios all become less cost-effective this 
being due to the impact of previously screened individuals returning to prison that do 
not need re-screening and the time taken to identify these prisoners. Sensitivity 
analysis showed the importance of encouraging eligible prisoners to accept the offer 
of an ELISA test, with a reduction in uptake having a large impact on cost-
effectiveness. This work is novel in that rather than applying a hypothetical model in 
which a set number of individuals are exposed to screening as a 'one-off, the impact 
of previously screened individuals returning to prison on the cost-effectiveness was 
considered. 
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8.3 Limitations of study and future research 
At the time when analysis of the characteristics of the IDU population was 
undertaken the UAPMP (section 1.2) had collected surveys on the IDU population up 
till 200 I and as such surveys up to this time were used in this analysis. Data from 
these surveys has continued to be collected and therefore the findings here, 
particularly the rates that IDUs start injecting drugs and leave the IDU population 
can be updated to represent more up to date information. This would then allow the 
model describing the flow of IDUs through prisons to be re-parameterised. Future 
work could apply this method of estimating the characteristics of the IDU population 
to other surveys as they become available particularly those that survey IDU 
populations outside England and Wales. This will provide further insight into the 
usefulness of this method of analysis, and will allow comparisons between 
alternative IDU populations to take place. However it is acknowledged that 
collecting annual surveys from current IDUs that is suitable for analysis such as this 
is a considerable undertaking. 
During calculation of the rates that IDUs leave the IDU population it was not 
possible to distinguish the reason that injectors leave the IDU population although it 
is likely that this is due to a combination of cessation and perhaps death due to the 
chaotic life style associated with drug use e.g. overdose or bad health due to injecting 
related infection. For the calculation of the average injecting career length of IDUs 
and parameterisation of the flow of IDUs through prisons it was therefore assumed 
that the removal rate is the same as the stop rate, however by considering death rates 
obtained from other sources (Darke & Zador, 1996; Ghodse et al., 1998; Hulse et al., 
1999; Law et al., 2001), future work could consider what impact death has on the 
removal rates estimated here. 
Throughout this thesis a current IDU has been defined as an individual that has 
injected in the previous 4 weeks or in the case of the flow of IDUs through prison 
defined as injecting within 4 weeks prior to reception into prison. However this 
simplistic approach to the complex behaviour of IDUs does not acknowledge that 
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many IOUs may stop drug using for extended periods of time before relapsing into 
their previous drug using behaviour. Cohort studies that follow IOUs and ex-IDUs 
for an extended period could provide a greater understanding of the rates that IDUs 
start and stop using drugs whether this be temporary or on a more permanent basis, 
although studies such as these would certainly be expensive and time consuming to 
implement. 
Data from a survey of prisoners in 10 prisons was used to parameterise the model of 
the flow of IDUs and non-IOUs through prisons in England and Wales (Weild et 01., 
2000), however only one of the surveyed prisons included females. As this was felt 
to be insufficient to extrapolate to represent the whole of the female prison 
population in England and Wales only males were considered in the analysis. For 
consistency the parameters describing the rates that IDUs start injecting and leave the 
IOU population were also parameterised from male IDUs. Data on the time spent in 
prison for each spell of imprisonment for males and females shows that females 
spend less time in prisons than males (Home Office, 2003). The faster that IDUs pass 
through prisons the quicker they will reappear on prison reception and this will 
increase the chance that they will participate in a prison reception based intervention. 
Therefore by only considering male IDUs in this analysis a conservative view of the 
potential of the prison interventions has been considered. However if data becomes 
available that can be extrapolated to represent the whole of the female prison 
population then the models here can be re-parameterised to reflect this. 
The prison survey (Weild et 01., 2000) informed as to the proportion of the prison 
population that were current IDUs and the average length of time that IOUs spend 
incarcerated during a spell of imprisonment. However by using these data it must be 
assumed that the offending characteristics of IDUs have not changed since 1997. 
And while it is acknowledged that these data are old, no further surveys have been 
undertaken of sufficient size that would enable the model of the flow of IDUs 
through prison to be re-parameterised. However as more up to date data becomes 
available of sufficient quality to inform as to the current offending and re-offending 
characteristics of IDUs and non-IDUs within prison, then this model may be re-
parameterised to reflect this. A further advantage of collecting more prison based 
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data is that multiple prison surveys would also allow time trends in the offending 
characteristics of IDUs to be investigated. 
The model of the flow of IDUs through prisons in England and Wales describes a 
simplistic approach to the workings of the prison population as individuals enter, 
stay, and then exit prisons. The prison population in England and Wales is housed in 
138 prisons of varying type, housing different types of prisoner depending on the 
prisoner's sex, length of sentence, or type of offence. During their time in prison, 
prisoners may be transferred between prisons for numerous reasons. The model of 
the flow of IOUs through prisons has not considered different types of prison, but 
instead models the whole of the prison population in England and Wales with 
variation in age and injecting status. One obstacle to incorporating prison transfers 
into a prison based model is that data on the rates that prisoners are transferred 
between prisons is very sparse and further to this if transfers between prisons are to 
be incorporated in the model then the issue of previously imprisoned individuals 
returning to prison by type and perhaps location would need to be considered. 
The model of the flow of IDUs through prisons assumes that the IOU population of 
England and Wales is a closed population in that the migration of injectors into the 
population from other countries is not considered. These individuals could 
potentially bring infection into the population which is in addition to the transmission 
that is already occurring. If the rate at which infected injectors from other locations 
flow into the IDU population in England and Wales can be evaluated along with the 
prevalence of infection within this group, then the impact of this on the effectiveness 
of the HBV prison vaccination programme both on vaccination coverage and HBV 
transmission could be considered. 
Apart from Chapter 7 that considered the cost-effectiveness of Hev case-finding on 
reception into prison, there has been very little consideration regarding costs in this 
thesis. The effectiveness of the HBV vaccination programme in prisons has been 
considered here in terms of the proportion of the IDU population that may be 
captured by vaccination, and its impact of prison vaccination on HBV transmission 
within the IOU population of England and Wales. A further measure of effectiveness 
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would be to estimate the cost-effectiveness of administering HBY vaccination in 
prisons. This would consider the cost of administering the programme and the 
potential benefits to the health care provider that would be made due to a reduction in 
the transmission of HBY and an increase in the quality of life of individuals that 
would otherwise have had HBY. Previous studies have considered the cost-
effectiveness of HBV vaccination in a prison setting (Jacobs et al., 2004; Pisu et al., 
2002) although this proposed future work would be novel as by applying models 
described here, this would allow the use of dynamic modelling with the FOI 
changing over time to be undertaken. 
The HBV vaccination programme in prisons continues to expand in prisons across 
England and Wales and as of July 2006 111 out of the 143 prisons in England and 
Wales reported to the Prison HBV Vaccination Monitoring Programme at the HPA 
that they were offering vaccine to prisoners on reception into prison. At the time 
when this research was undertaken, the most up to date data informing the current 
state of the prison vaccination programme was used to inform the vaccination 
scenarios, e.g. data collected in 2003 described the proportion of individuals on 
reception into prisons receiving 1, 2, or 3 doses of vaccine. However it is 
acknowledged that the results here can certainly be updated to reflect new 
information as it becomes available, although a range of alternative vaccination 
scenarios have been considered here and new data is unlikely to change the 
conclusion that prison is a good place in which to vaccinate IDUs against HBV. 
The FOI model proposed here relies heavily on data describing the injecting career 
length of current IDUs as this informs as to the length of time that an IOU is exposed 
to BBY infection. The injecting career length has been calculated for each IOU by 
considering the reported difference between IDUs current age and age at first 
injection. A possible improvement to this and to get an additional insight into the 
injecting career length of IDUs might be to actually ask how long an IDU has been 
injecting. To validate IDUs responses to surveyed questions, both this question and 
the questions relating to age at first injection and start age could be asked. The model 
has estimated that new initiates to injecting are at increased risk of BBY infection 
compared to more experienced IOUs although additional data on new initiates would 
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be beneficial to confirm the findings here. However as has been previously discussed 
the IOU population a hard-to-reach population, and finding new initiates to survey is 
inevitably problematic. 
Although the model structure described here has allowed for the possibility of trends 
in the FOI over time no significant trends were detected by the model. However it 
has been shown in analysis from data from these UAPMP surveys that the prevalence 
of HCV in the IDU population of England and Wales has increased in recent years 
(section 1.3.1.2). As the data used in the FOI analysis only considered susceptibles to 
infection and FOI estimates were obtained simultaneously for both HBV and HCV 
infections, those IDUs that were vaccinated against HBV were excluded from the 
analysis. The impact of this is that many of the IDUs in the survey that are diagnosed 
as being HCV positive, will receive HBV vaccination and therefore be excluded 
from this analysis. Future work may consider each virus separately in an attempt to 
identify trends over time, although individual heterogeneity of risk behaviour could 
not then be considered. 
The FOI for BBVs amongst IDUs is inevitably a product of many components that 
describe the injecting behaviour of IOUs. These components include but are not 
limited to the number of injections per unit time, the number of instances of sharing 
per unit time, and the proportion of reused needles that are adequately cleaned. It 
would be both informative and useful for future modelling work if the FOI estimates 
described here could be described in terms of the injecting behaviour of IDUs in 
England and Wales. This would be of particular benefit for future work that 
considers the impact of intervention measures that target IDUs behaviour on the 
prevalence and incidence of HCV or HBV within the IOU population of England and 
Wales. 
As has been shown during the sensitivity analysis of the model of the HBV 
vaccination programme in prisons (Chapter 4) the estimated size of the IOU 
population has a large impact on the model results describing the proportion of the 
IDU population that may be vaccinated over time on reception into prisons in 
England and Wales. Data from a previous study has been used to estimate the 
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proportion of the prison population that is a current IOU (Weild et al., 2000), 
therefore a larger estimated IOU population results in a smaller proportion of IOUs 
being exposed to vaccination on prison reception and this will inevitably have less of 
an impact on HBY transmission within the IOU population. Results obtained here 
based on an assumed IOU population size of 160,000 provide estimates of the 
number of acute cases and HBY prevalence within the IOU population that have 
been broadly validated by data which help to give confidence to the validity of the 
assumptions made here, however further work that can provide estimates of the size 
of this hard to reach population will always be of benefit. 
The models proposed here have not considered BBV transmission in non-IOUs, 
whether this is transmission between IOUs and non-IOUs or in non-IOUs alone due 
to risk factors other than injecting (e.g. transfusion, blood product recipient, or sexual 
exposure as appropriate) to fully measure the impact of intervention measures that 
target BBVs in the IOU population the transmission of infection in non-IOUs should 
be incorporated. A reduction in the prevalence of BBVs within the IOU population 
may have an impact of reducing the prevalence in the non-IOU population. Although 
it is likely that due to the migration of individuals from countries of high BBY 
endemicity (HBY, HCY, or HIV) into England and Wales, the impact of prison 
interventions on the prevalence within non-IOUs will be reduced. 
As discussed in the introduction (section 1.6) previous studies have considered the 
possibility of adopting an individual based model to describe the IOU population and 
the transmission of infection within it (Peterson et al., 1990; Mather & Crofts, 1999; 
Kretzschmar & Wiessing, 1998; Atkinson, 1996). The HBY transmission model 
proposed here has considered a relatively simple model structure in which the 
contact between new initiates and experienced IOUs is described. A more 
complicated individual based model could perhaps be considered although due to the 
data requirements associated with a model of this type the parameterisation of the 
model may prove difficult. Assumptions regarding the transmission of HBV between 
individuals, how the individuals flow through prison, and their exposure to the prison 
vaccination programme on an individual basis would have to be made. It has been 
shown in Chapter 5 that there may be individual heterogeneity of risk behaviour 
173 
within the IOU population that is independent of injecting career length, although the 
model structure proposed here does not allow for this possibility. Future work may 
involve the modification of the model structure by assigning IOUs based on their 
injecting behaviour to be either high-risk or low-risk from BBYs that better 
represents the characteristics of the IOU population. This could include the number 
of injections, the number of partners, and may include the possibility of interaction 
between buddy and stranger users (Kretzschmar & Wiessing, 1998). However more 
complex models will rely on detailed data with which to parameterise them and this 
may not be readily available. 
A consequence of taking the vaccination rates from the HBY vaccination programme 
in prisons and applying them to the HBY transmission model is that FOI is assumed 
to be constant both inside and outside prison. As has already been discussed (section 
1.4) IDUs may be at increased risk of BBY infection in a prison setting due to the 
lack of availability of clean needles, although it is increasingly difficult to get an 
informed estimate of the FOI for BBVs that are dependent on location. If this were to 
be done it is proposed that a cohort study would have to be initiated that follow IDUs 
for a period of time which would involve frequent BBY testing as their imprisonment 
status changes. However it is likely that due to the length of time a study such as this 
would need to be implemented, the cost of following IDUs as they change location 
and the number of IDUs that would be required to get informed FOI estimates, this 
approach would be problematic, while there would also be ethical issues of having to 
monitor individuals as they become infected from BBYs without offering any 
intervention. Future work could consider assumptions regarding the increased risk of 
infection inside prisons and how these would impact on the transmission results 
estimated here, although offering vaccination on reception into prisons must have a 
positive impact on the FOI in the prison setting. 
Only the cost-effectiveness of Hey case-finding in a prison setting has been 
considered here although it is acknowledged that the inclusion of the costs and 
benefits associated with treating individuals that have been identified with HeV in 
prison will play an important role in judging whether to implement an HeV case-
finding programme on reception into prison. Previous studies have considered the 
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cost effectiveness of HCY treatment (Wright et a/., 2006; Stein et a/., 2002; Stein et 
a/., 2004) although there are issues regarding the treatment of individuals that are 
specific to a prison setting, e.g. the possibility that some individuals will follow a 
treatment pathway that involves continued treatment in the community following 
discharge from prison. The work here examines the best approach to identifying 
individuals that may be eligible for treatment and future work will consider the cost 
effectiveness ofHCY treatment in a prison setting in England and Wales. 
BBY infection is not the only problem that faces IOUs. It has been shown in 
previous studies that IOUs are at increased risk of mortality immediately following 
spell of imprisonment (Seaman et a/., 1998; Bird & Hutchinson, 2003), this 
frequently being due to increased drug taking following a period of abstinence. 
Future work could consider this problem by modifying the model of the flow of 
IOUs through prison as described in Chapter 3 to reflect this increased risk to IDUs. 
Following this a cost-effectiveness study could be undertaken to compare the cost of 
targeting IOUs on discharge from prison to reduce the mortality risk versus a do 
nothing scenario. 
Issues that are of interest to the population outside prison do not stop being a 
problem once individuals enter prison. Over the last few years much research has 
been undertaken into severe acute respiratory syndrome (SARS) and pandemic flu in 
the general population both in England and Wales and around the world. The 
potential impact of these infections within the prison population could be 
investigated, although it is acknowledged that it would not be necessary to use a 
model stratified by IOU status in this case. 
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8.4 Concluding remarks 
This thesis has estimated the characteristics of the IOU population and its risk of 
infection from HBV and HeV and following this a range of alternative prison based 
intervention measures that target IOUs and their infection from BBVs have been 
considered. It has been shown that IOUs that start injecting at a younger age are 
likely to inject for longer than those individuals that start injecting later in life, while 
it has been shown that new initiates to injecting are at increased risk of HBV and 
Hev compared to more experienced IOUs. This is of importance as it provides 
strong evidence that younger IOUs with shorter injecting careers are particularly 
vulnerable and a special effort should be made to target intervention measures at this 
sub-group of the IOU population. A model that describes the flow of IOUs through 
prisons in England and Wales has been proposed and parameterisation of this model 
provides further evidence that mus are at increased risk of imprisonment and pass 
through prisons at a faster rate compared to non-IOUs. The impact of the HBV 
vaccination programme in prisons was estimated considering both the coverage of 
the IOU population with vaccination and its impact on HBV transmission within the 
IOU population. This showed that prison is a good location in which to target IOUs 
for HBV vaccination and that this may have a significant impact on the transmission 
of HBV within the IOU population. Finally the cost-effectiveness of HeV case-
finding on reception into prisons was estimated showing the importance on the cost-
effectiveness of targeting individuals that have previously injected illicit drugs and 
not received a positive HeV test in the past for testing. The work here demonstrates 
some of the applications of a fully parameterised model of the flow of the IOU 
population through prisons. However this model relies heavily on data sources that 
inform as to the rate that IOUs start and stop injecting and their offending 
characteristics. It is therefore important to the relevance of the results obtained from 
the model that data that reflects the current characteristics of the IOU population is 
available. 
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